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ABSTRACT 
 
Stroke is one of the most common causes of disability and death worldwide. The most 
commonly experienced stroke in the clinical setting is focal ischaemia in which the middle 
cerebral artery (MCA) is occluded and leads to a complex series of various 
pathophysiological pathways that ultimately lead to neuronal cell death. Several studies have 
been conducted on various therapeutic agents in the search for a neuroprotective drug and 
various animal models have been used to carry out this research. While theanine, a 
component of green tea and minocycline, a tetracycline antibiotic, have been shown to 
possess some neuroprotective properties, the mechanisms by which these two agents carry 
out these effects still remains unclear. The objectives of this study were to investigate the 
mechanisms by which these drugs carry out these neuroprotective effects and their 
neuroprotective ability in a MCA occlusion model of focal ischaemia. 
 
Ischaemia leads to oxidative stress due to the imbalance of free radicals and the endogenous 
antioxidant defence system. An antioxidant assay using the stable 2, 2-diphenyl-1-picryl-
hydrazyl (DPPH
●
) radical was used to assess the antiradical properties of each drug. It was 
found that minocycline showed superior antioxidant activity in vitro when compared to 
theanine. Further studies on the drugs‟ ability to attenuate the Fenton reaction (in which iron 
catalyses the formation of reactive species) were elucidated using electrochemical analysis, 
UV/VIS studies, ferrozine and ferritin assays. It was found that minocycline, in contrast to 
theanine, was able to bind to iron ions and thus potentially prevent the participation of iron in 
metal catalysed radical reaction. The antioxidant activity of both drugs was further 
investigated by assessing their effect on cyanide-induced superoxide generation and 
quinolinic acid (QA)-induced lipid peroxidation (LP). Experimental evidence shows that both 
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drugs had no significant effect on the generation of superoxide in vitro and that there was a 
significant decrease in LP for minocycline in vitro and theanine in vivo. The metal binding 
and antioxidant properties were postulated to be a possible mechanism through which these 
agents reduced lipid peroxidation. 
 
A study was conducted to determine the effects of the drugs on the biosynthesis of the 
neurotoxin, QA and it was found that minocycline increases the levels of holoenzyme activity 
of tryptophan-2, 3-dioxygenase (TDO) in vitro and that theanine reduces the levels of the 
same enzyme in vivo after treatment for 10 days. TDO is the enzyme that converts tryptophan 
to other products that enable enzymatic activity to change it to QA. Minocycline was thought 
to bring about this effect as it has been shown from preceding experimental studies that it is 
an effective reducing agent. Theanine on the other hand is hypothesised to bring about a 
reduction in holoenzyme activity by changing the binding of tryptophan to the enzyme or 
affecting the radicals that participate in the enzymatic degradation of tryptophan. 
 
A focal ischaemic model of stroke was induced by occluding the MCA. Histological 
examination of the hippocampus post -ischaemia shows a reduction in the size of the infarct 
after pre-treatment with minocycline only.  A further study into the effects of the drugs on the 
generation of superoxide and on the levels of the endogenous glutathione after a stroke was 
carried out. Pre-treatment of the animals with either theanine or minocycline showed no 
significant effects on the generation of the radical species or of the endogenous antioxidant 
which ruled out these as a mechanism of neuroprotection of both drugs, post-ischaemia. 
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The findings of this study provide novel information on the possible mechanisms by which 
both theanine and minocycline act to bring about neuroprotection. In particular in this study, 
pre-treatment with minocycline has shown promise in the focal ischaemic model of stroke. 
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 CHAPTER 1 
LITERATURE REVIEW 
  
1.1 STROKE 
 
1.1.1 INTRODUCTION 
 
Stroke is the most common cause of adult disability and death worldwide (Rantanen and 
Tatlisumak, 2004; Emre et al., 2007; Yasuhara et al., 2008).  In the United States of America, 
it is responsible for 9.5 % of all deaths and with over 700 000 new cases of strokes occurring 
annually (Broderick, 1998; Tuhin, 2002). Approximately 80 % of all strokes are ischaemic 
(due to a brain infarction), 10 % are caused by intracerebral haemorrhage and the rest are 
caused by subarachnoidal haemorrhages (Feigen et al., 2003; Hankey and Nelson, 2009). The 
disability after stroke, for example, paralysis, memory loss and pain and the cost of treatment 
including medication, hospitalisation and rehabilitation, causes a major socio-economic 
burden on society. 
 
1.1.2 STROKE AETIOLOGY 
 
An ischaemic stroke results from a temporary or permanent reduction or interruption in 
cerebral blood flow (Gupta and Briyal, 2004; Khatak, 2010). Obstruction to blood flow 
occurs when a major brain artery is blocked or has burst, thus depriving the brain of oxygen 
and essential nutrients such as glucose. The reduction of blood flow in most cases is caused 
by an embolism or by a thrombus obstructing the flow of blood in the artery (Dirnagl et al., 
1999; Zazulia, 2003). 
 
With a reduction in blood flow, 2 areas of neuronal damage are formed around the site of the 
thrombus or embolism, namely the ischaemic core and the penumbral zone (Hilkle and 
Bowman, 2003). The ischaemic core is where the blood flow is completely interrupted 
resulting in irreversible cell damage due to lack of glucose and oxygen (Gupta and Briyal, 
2004). The penumbra is the area surrounding the core in which ischaemia is incomplete due 
to perfusion from collateral vessels (Gupta and Briyal, 2004). If cerebral blood flow is 
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restored even at a sub-optimal level, it will provide an opportunity for the cells within the 
penumbra to recover and regain functional activity.  
 
1.1.3 PATHOPHYSIOLOGY 
 
1.1.3.1 The Cascade of Cerebral Ischaemia 
 
Cerebral ischaemia leads to pathophysiological changes which contribute to brain injury due 
to the reduced glucose and oxygen (O2) which occur collectively or individually. The 
pathophysiological changes include the increased production of free radicals, excitotoxicity, 
interruption of sodium (Na
+
) and calcium (Ca
2+
) influx, stimulation of the inflammatory 
process, endothelium (ET) release, delayed coagulation and endothelial dysfunction (Gupta 
and Briyal, 2004). The mechanisms that give rise to cell death following ischaemia are yet to 
be defined but it is clear that the 3 major factors which contribute to cell death are: acidosis; 
increased intracellular cytosolic Ca
2+
 and the production of free radicals (Gariballa, 2000; 
Pollock and Pollock, 2005). 
 
The brain consumes a large amount of O2 and glucose in order to produce energy by 
oxidative phosphorylation (Dirnagl et al., 1999). Reduced O2 and glucose to the tissues 
within the brain leads to an energy crisis and with the energy depletion comes a loss in 
membrane potential due to the interruption of ion pump activity (Dirnagl et al., 1999; Gupta 
and Briyal, 2004). As the energy levels are depleted, energy dependent processes such as the 
presynaptic uptake of excitatory neurotransmitters are blocked, leading to an increase in 
glutamic acid in the extracellular space (Dirnagl et al., 1999). Excess glutamic acid leads to 
the activation of N-methyl-D-aspartate (NMDA) receptors and metabotropic glutamate 
receptors leading to an increase in cytosolic Ca
2+
. The accumulation of Ca
2+
 in the cells plays 
a role in the propagation of the irreversible neuronal damage through various processes such 
as lipid peroxidation. The cascade of events leading to ischaemic-induced neuronal death are 
summarised in Figure 1.1. 
 
Extracellular oedema that develops in ischaemia is largely due to the activation of the Na
+
 
transport across the blood brain barrier (BBB) which reflects local brain damage caused by 
the damaged neurons, glia and endothelial cells (Lipton, 1999). 
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Figure 1.1: Summary of events that may lead to cell death after the onset of cerebral ischaemia redrawn from 
Gupta and Briyal, 2004. 
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1.1.3.2 Free radicals and oxidative stress 
 
The central nervous system (CNS) and the brain are especially vulnerable to attack by free 
radicals because their membrane lipids are rich in polyunsaturated fatty acids (PUFAs). 
Additional reasons include the limited amount of antioxidant enzymes such as superoxide 
dismutase (SOD), glutathione peroxidise and catalase (Halliwell and Gutteridge, 1989). 
Certain areas in the brain such as the globus pallidus and substantia nigra, are rich in iron 
which catalyses radical reactions (Halliwell and Gutteridge, 1989). Free radical production 
has been implicated as an important mechanism of brain injury post-ischaemia and after 
reperfusion (Gariballa, 2000). 
 
The potential mechanism for the production of free radicals during ischaemia, involves the 
limited supply of oxygen which leads to the electron transport chain of the inner 
mitochondrial membrane becoming highly reduced, resulting in oxygen radical production. 
The proposed mechanism for radical production during reperfusion may be due to the large 
quantities of superoxide radical (O2
•-
) and hydrogen peroxide being produced as a result of 
the reperfusion and thus the peroxidation of membrane lipids in the brain (Gariballa, 2000). 
 
The production of a greater number of free radicals than antioxidants within the brain leads to 
a state of oxidative stress (Bell et al., 2002; Onténiente et al., 2003). Oxidative stress may 
affect the free radical nitric oxide (NO•), which has an important role in biological processes 
in the brain such as vascular integrity (Draije et al., 1995), the control of cerebral blood flow 
(White et al., 1998), auto-regulation (White et al., 2000) and modulation of neuronal activity 
and thromobogenesis (Şeneş et al., 2007). Lipid peroxidation is a consequence of an increase 
in oxidative stress and studies have shown that there is an increase in lipid peroxidation in 
patients that have suffered an ischaemic stroke (Şeneş et al., 2007). 
 
1.1.3.3 Glutamate receptors and excitotoxicity in ischaemia 
 
During ischaemia there is an increase in the levels of intracellular Ca
2+
 and extracellular 
excitatory amino acids such as glutamic acid and aspartate. The increase in excitatory 
neurotransmitters is responsible for the death of neurons within the penumbra zone (Takagi et 
al., 1993; Lipton, 1999, Yepes et al., 2000). An inverse relationship exists between the size of 
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the infarct and the magnitude of glutamic acid release (Takagi et al., 1993). The 
excitotoxicity that arises as a result of the increase in excitatory neurotransmitters is induced 
by the overstimulation of glutamate receptors, in particular the NMDA receptors. The NMDA 
receptors are the major route of Ca
2+
 entry into the neuronal cell. Ca
2+
 is a secondary 
messenger in neurons where it plays a role in several physiological processes such as 
neurotransmitter release. However excess intracellular Ca
2+
 can lead to cell death. The 
calcium influx into cells during ischaemia is sufficient to lead to the activation of Ca
2+
 
dependent processes and enzymatic routes involved in neuronal death.   
 
There are two main energy-dependent pathways that are responsible for the elevation of 
extracellular excitatory neurotransmitter levels during ischaemia: a Ca
2+
 dependent pathway 
and the other pathway is independent of Ca
2+
 (Katayama et al., 1991). The Ca
2+
 pathway 
occurs at the onset of ischaemia when there is sufficient energy to drive the pathway whilst 
the Ca
2+
 independent pathway is a delayed pathway due to the decline in energy levels as the 
stroke progresses (Katayama et al., 1991). The increase in glutamic acid released during 
ischaemia results in a change in the glutamic acid transport system. The alteration of glutamic 
acid transportation is a consequence of 3 mechanisms namely: decreased uptake, reversed 
activation and decreased expression of protein transporters (Camacho and Massieu, 2006). 
The generation of free radicals inhibits glutamic acid uptake in the glia (Rao et al., 2003). 
Swanson et al., (1995) showed that anaerobic reactions that take place during ischaemia 
result in lactic acidosis and this may contribute to reduced glutamic acid uptake due to 
decreased functionality of glutamic acid transporters in astrocytes. Figure 1.2 summarises the 
failure of glutamic acid transportation that occurs during ischaemia.  
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Figure 1.2: Possible alterations in the activity and the expression of glutamic acid transporters during cerebral 
ischemia (Camacho and Massieu, 2006). 
 
The explanation of Figure 1.2: lack of glucose and oxygen during ischemia leads to energy 
failure and increased intracellular lactate (1), which inhibits glutamic acid uptake both in 
neurons and glial cells (2). Free radical production induced after glutamate receptor 
activation may oxidise cysteine residues on the  glutamic acid transporter, thus inhibiting 
glutamic acid uptake (3). Low energy levels promote the increase in intracellular Na
+
 (4) as 
well as the inverse functioning of glutamic acid transporters (5). Through a still unknown 
mechanism, down regulation of glutamic acid transporters at the plasma membrane occurs 
after the ischemic insult (6). The alterations shown above might be involved in the elevation 
of extracellular glutamic acid (7) and the development of neuronal death associated with 
ischemia (8) (Camacho and Massieu, 2006). 
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1.1.4 THE CURRENT THERAPEUTIC APPROACHES FOR THE 
MANAGEMENT OF STROKE 
 
A clear understanding of the pathophysiological pathways involved in ischaemia will aid the 
development of effective drugs that will be useful in the prevention and management of 
stroke and the disability that results from it. Important objectives in the treatment of stroke 
entail limiting primary and secondary neuronal death by the inhibition of apoptotic 
mechanisms, enhancing the endogenous ability of the neuronal system to restore lost function 
and replacing lost cells (Onténiente et al., 2003). An ideal drug for the management of 
ischaemia would improve blood flow, have a beneficial effect on biochemical 
pathophysiological pathways, and relieve the spasm of nutrient arteries and have antioxidant 
properties (Gariballa, 2000).  
 
Currently, the only treatment for stroke is a thrombolytic agent. However, aside from its use 
being limited to administration within 3 hours of the stroke, only 5 - 8 % of patients qualify 
for this treatment within this period (Gupta and Briyal, 2004). Thrombolytic therapy has been 
shown to reduce neuronal damage and improve recovery after a stroke (Gupta and Briyal, 
2004). However, large doses of the thrombolytic are associated with reperfusion-associated 
complications whilst low doses, although associated with lower risk have the potential of 
being less effective (Gupta and Briyal, 2004).  
 
Neuroprotective agents have been investigated for their potential as drugs that may be used in 
ischaemic injury. Amongst these are free radical scavenging drugs such as the dietary 
supplement α-tocopherol (vitamin E) (Chaudhary et al., 2003), the synthetic drug tamoxifen 
(Zhang et al., 2005) and a combination of endogenous melatonin and synthetic meloxicam 
(Gupta et al., 2002). These agents have been studied and been shown to be protective in 
animal models of ischaemia. Many drug models such as antagonists of voltage gated Ca
2+
 
channels and antagonists of the excitatory amino acid receptors have also been studied and 
although these showed promise in animal models, these were found to be ineffective in 
human subjects (Gupta and Briyal, 2004). Therefore, there is still a need to discover a drug 
that possesses the ideal characteristics stated above that would be beneficial to human 
subjects. 
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1.1.5 EXPERIMENTAL MODELS OF ISCHAEMIA 
 
1.1.5.1 Introduction 
 
Several models exist as ischaemic experimental models for the in vitro and in vivo study of 
stroke. The in vitro models include cultured neurons, glia and cultured brain slices (Gupta 
and Briyal, 2004). However these models are limited as they are only able to demonstrate the 
level of cytotoxicity of the therapy being investigated. 
 
In vivo experimental models are preferred as experimental models of ischaemia as these 
possess glia, neurons and vasculature that closely resemble the human system (Gupta and 
Briyal, 2004). A good in vivo experimental model of ischaemia will have the following 
characteristics (Gupta and Briyal, 2004; Woitzek et al., 2006): 
 
 The ischaemic process and the pathophysiological responses thereof must be 
consistent with human stroke, reproducible and reliable, 
 A standard method of vessel occlusion, 
 No barbiturates which have been shown to be neuroprotective, to be used during the 
course of the experiment, 
 The infarct produced must not be extremely big and must be of a predictable average 
size,  
 It must be a simple technique that is minimally invasive, 
 Any physiological variations are to be controllable without difficulty and 
 Economical and easy availability of animals of the same species. 
 
3 main types of animal models exist to model ischaemia and these are focal global and 
forebrain ischaemia that are discussed below. 
 
1.1.5.2 Forebrain ischaemia 
 
Forebrain ischaemia as the name implies, is an experimental model of ischaemia that is 
limited to the forebrain. This model therefore is not an accurate representation of ischaemia 
that occurs in a clinical sense. There are 4 models of this type of ischaemia that have been 
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performed on certain species of animal models: bilateral common carotid artery (CCA) 
occlusion (in Mongolian gerbils), four vessel occlusion (in rats), bilateral common carotid 
occlusion (in spontaneously hypertensive rats) and two vessel occlusion (in rats with 
hypotension) (Gupta and Briyal, 2004).  
 
1.1.5.3 Global ischaemia 
 
In this model there is complete interruption of blood supply to the brain, leading to cerebral 
necrosis in isolated regions (Lipton, 1999). There are two ways in which it can be induced: 
total body ischaemia and global cerebral ischaemia (Gupta and Briyal, 2004). Total body 
ischaemia includes decapitation and cardiac arrest without resuscitation, cardiac arrest and 
resuscitation and systemic hypotension (Gupta and Briyal, 2004). Global cerebral models of 
global ischaemia can be induced by increased intracranial pressure, cervical compression and 
a combination of occlusion of the major arteries that supply blood to the brain (Gupta and 
Briyal, 2004). 
 
1.1.5.4 Focal ischaemia 
 
Focal ischaemia is the most common type of stroke encountered by humans. This is therefore 
the most useful model for the clinical setting. Furthermore, this model may be performed to 
bring about either permanent or temporary occlusion of the middle cerebral artery (MCA). 
Inducing focal ischaemia leads to a moderate to extreme reduction in blood flow in the artery 
(Sironi et al., 2003). Temporary occlusion allows for the reperfusion of blood into the 
vasculature and in permanent occlusion there is no restoration of blood flow. The most 
commonly used models of focal ischaemia are thromboembolic, suture MCA occlusion, 
surgical MCA occlusion, photochemically-induced thrombosis and endothin-1-induced MCA 
occlusion (Gupta and Briyal, 2004; Durukan et al., 2008). 
 
This model has the advantage over global ischaemia of producing heterogeneous pathology 
which includes the core and penumbra (Section 1.1.2) (Gupta and Briyal, 2004).  Overall this 
is the most suitable model of ischaemia as it fulfils the following criteria discussed in Section 
1.1.1.1:  it is a simple technique, it is applicable to more than one animal species, the 
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ischaemic lesion size is reproducible and most importantly, it is relevant to human stroke 
(Durukan et al., 2008). 
 
1.2 NEURODEGENERATION 
 
1.2.1 NEURONAL CELL DEATH 
 
1.2.1.1  Introduction 
 
Neuronal death can occur by two distinct pathways namely: necrosis and apoptosis (Vermes 
and Haanan, 1994, Festjens et al.,2006). The mitochondria of the cell play a role in necrosis 
and apoptotic neuronal cell death (Sas et al., 2007) which implies that both processes are 
energy dependent (Love, 2003). The role of the mitochondrion in both types of neuronal 
death is dependent on the initial insult. Necrotic cell death occurs in severe and toxic insults 
whereas apoptosis occurs in mild insults (Sas et al., 2007). Differences that occur within a 
cell in both processes are shown in Figure 1.3. 
 
 
Figure 1.3: The distinguishing features of necrosis and apoptosis (Mattson, 2006). 
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1.2.1.2 Necrosis 
 
Necrosis, as previously mentioned, is a result of severe insult and occurs when cells are 
exposed to extreme conditions such as hypothermia, hypoxia and ischaemia (Wyllie et al., 
1998). It affects a number of cells and leads to swelling of the cytoplasm, mitochondria and 
other organelles within the cell and this leads to cell lysis (Sas et al., 2007). Necrosis triggers 
an inflammatory reaction where the affected cells are phagocytised by macrophages (Wyllie 
et al., 1998; Sas et al., 2007). 
 
1.2.1.3 Apoptosis 
 
Apoptosis is a form of cell death that involves scattered discrete cells rather than groups of 
contiguous cells (Kerr et al., 1972). It is a well regulated process of morphological and 
biochemical events. The following morphological changes occur in apoptosis: cell shrinkage 
as the cytoplasm shrinks and the nucleus is condensed, formation of membrane bound 
vesicles and the fragmentation of the cell into multiple small membrane-bound bodies that 
contain intact organelles (Wyllie et al., 1981; Wyllie et al., 1998). The apoptotic process is 
responsible for cell growth and development, differentiation of immune cells and the 
elimination of abnormal and unwanted cells without adversely affecting surrounding cells 
(Mattson, 2006; Sas et al., 2007). No inflammatory response accompanies this type of 
neuronal death (Fadeel and Orrenium, 2005). Apoptosis has a role in the pathogenesis of 
various diseases as its exaggeration or failure in the human body can lead to diseases such as 
cancer and neurodegenerative disorders respectively (Sas et al., 2007). 
 
Oxidative stress can lead to an excessive influx of Ca
2+
 into the cell. Ca
2+
 regulates several 
important steps in the apoptotic pathway such as in early signalling events and in chromatic 
cleavage (McConkey and Orrenius, 1997). The process of apoptosis is mediated by caspases 
(cysteine-requiring aspartate-directed proteases) that are responsible for programmed cell 
death in mammals (Love, 2003). In models of experimental stroke, the up-regulation of 
caspases (specifically of caspase-3) precedes the death of neurons (Broughton et al., 2009).  
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1.2.2 MECHANISMS OF NEURODEGENERATION 
 
1.2.2.1 Introduction 
 
Oxygen is essential to life for many living organisms and plays an important role in several 
biological processes such as the efficient production of energy. At higher levels than that 
found in air, oxygen can be poisonous. Aerobic organisms survive only because they have 
antioxidant defence systems to protect them from the damaging effects of oxygen. Cell death 
is attributed to the formation of free radicals especially superoxide anion which is a very 
toxic oxygen containing free radical (Halliwell and Gutteridge, 1984a). 
 
Oxidative stress is a state of imbalance between radical species produced in the tissues and 
the antioxidant defences (Halliwell, 2007). It is manifested by excess radical production, 
oxidation to proteins and nucleic acids, loss of reductive potential of cells and lipid 
peroxidation. The brain is particularly vulnerable to oxidative damage as it consumes about 
20 % of the oxygen inspired, it is rich in polyunsaturated fatty acids and metal ions and it has 
relatively low levels of antioxidant defences (Papa, 1996; Faraci, 2004; Butterfield, 2006). 
 
1.2.2.2 Free radicals  
 
Halliwell and Gutteridge (1989) define a free radical as „any species that is capable of 
independent existence that contains one or more unpaired electrons‟. The presence of an 
unpaired electron makes the free radical highly reactive. The reaction of a free radical with a 
non radical species leads to the generation of different radicals which may be more or less 
reactive than the original reacting radical (Halliwell and Gutteridge, 1986). When two free 
radicals react, the species generated are „neutral‟ and unreactive.  
 
The respiratory chain in the mitochondria is one of the major sources of free radicals in the 
human body (Sas et al., 2007). Other pathways responsible for the production include 
xanthine oxidase, monoamine oxidase (MAO), cytochrome P450 (CYP450), nitrous oxide 
systems (NOS) and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (Sas et 
al., 2007). Free radicals generated within the body damage lipids, proteins, deoxyribonucleic 
acid (DNA) and other biomolecules (Halliwell et al., 1995). There are different types of free 
Literature Review CHAPTER 1 
 
Page | 13  
 
radical species but these can be generally divided into oxygen and nitrogen containing 
species termed reactive oxygen species (ROS) and reactive nitrogen species (RNS) 
respectively. ROS and RNS are important in neuronal signalling and physiology but at 
elevated levels these can lead to dysfunction of neurons and death (Butterfield, 2006; Faraci, 
2006). ROS are produced inside cells and have a short life span, thus their toxic effects are 
often limited to the cell in which they were produced or cells in close proximity to the place 
of their production (Kontos, 2001). ROS are important mediators in cell death as these are 
involved in the two major causes of cell death which are apoptosis and excitotoxicity (Sas et 
al., 2007) or by acting synergisistically with pro-inflammatory mediators (Slater et al., 1987). 
 
1.2.2.3 Superoxide anion radical 
 
The superoxide anion radical (O2
•-
) is the primary product when oxygen is reduced by 
accepting an electron from a reducing agent. Of the oxygen consumed by the body, 17 % of it 
is converted into O2
•-
 (Halliwell and Gutteridge, 1986). The levels of O2
•-
 within a cell are 
determined by the rate of its production, the activity of antioxidant enzymes and the 
availability of oxygen (Kontos, 2001). The O2
•-
 is highly reactive and is able to reduce and 
oxidise other compounds whereas other reactive species such as hydrogen peroxide and the 
hydroxyl radical are only able to act as oxidising agents (Kontos, 2001). The O2
•-
 is unable to 
cross biological membranes and very few compounds and enzymes are able to react with it 
(Şenes et al., 2007).  
 
The O2
•-
 causes damage  to biomolecules by inducing the oxidation of the lipids within cell 
membranes and their interaction with hydrogen peroxide or organic peroxides can generate 
highly reactive entities that damage DNA, lipids and other essential cell components 
(Halliwell and Gutteridge, 1986). Iron (III) release from ferritin where it is stored, is 
facilitated by O2
•-
, which reduces it into iron (II). The reduced iron is then available to 
catalyse iron-dependent radical reactions and lipid peroxidation. Overgeneration of O2
•-
during an ischaemic stroke (Şenes et al., 2007) coupled with the production of O2
•-
 that 
occurs due to the accumulation of monocytes and macrophages after ischaemia (Saito et al., 
1993) results in neuronal damage. 
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Not all the effects of O2
•-
 are deleterious. During an inflammatory reaction, O2
•-
 contributes to 
the death of bacteria that has been engulfed by granulocytes (Halliwell and Gutteridge, 1986). 
The effects of O2
•- 
are more damaging in the presence of hydrogen peroxide. 
 
1.2.2.4 Hydrogen peroxide 
 
Any biological system that generates O2
•-
 will produce hydrogen peroxide (H2O2) by the 
enzymatic conversion of O2
•-
 by superoxide dismutase and other enzymatic reactions 
(Halliwell and Gutteridge, 1989). Unlike O2
•-
, H2O2 is able to cross biological membranes but 
its reactivity is limited (Halliwell et al., 1995; Kontos, 2001). H2O2 is not highly toxic after it 
diffuses across cellular membranes, but in the presence of O2
•-
 it can react with metal ions 
such as Fe
2+
 and Cu
+
 to produce the hydroxyl radical which is a highly reactive free radical 
(as explained in Section 1.2.2.5). 
 
1.2.2.5 Hydroxyl radical 
 
The hydroxyl radical (•OH) is an extremely reactive radical that is the product of the Haber-
Weiss reaction (Equation 1.3) which is the reaction between O2
•-
 and H2O2 in the presence of 
transition metal ions such as Fe 
3+
, Fe
2+
 and Cu
+
 (Halliwell and Gutteridge, 1989). The 
Fenton reactions involve the reduction of iron (III) to iron (II) in the presence of O2
•-
 
(Equation 1.1) and then oxidation of iron (II) back into iron (III) facilitated by the homolytic 
fission of H2O2 (Equation 1.2). The net reaction of the two Fenton reactions (Equations 1.1 
and 1.2) is the Haber-Weiss reaction.  
 
Beckman and colleagues (1990) reported that the protonation and decomposition of 
peroxynitrite forms a free radical that is of similar reactivity to •OH. This finding was later 
confirmed by van der Vliet and co-workers (1994a) who showed that the radical was indeed 
•OH.  
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The •OH is a very short lived radical that is limited to the site of its catalytic production 
(Valko et al., 2005) but it can initiate chain reactions that yield secondary radicals that may 
expand the range of its toxic action. The •OH reacts immediately with all molecules within its 
vicinity by hydrogen abstraction, electron transfer or by addition reactions (Slater, 1978) and 
because of its high rate constant it will react with all types of molecules within a living 
organism such as DNA, amino acids and phospholipids (Halliwell et al., 1995). 
 
1.2.2.6 Peroxyl radical 
 
The peroxyl radical (ROO•) is mainly formed as a product of the chain propagation step in 
lipid peroxidation (Halliwell and Gutteridge, 1989) and non lipid systems (Dean et al., 1993). 
The simplest ROO• that can be formed is the hydroperoxyl radical (HOO•) which can react 
with thiols to produce thiyl radicals (RS•) (Halliwell et al., 1995) and in the chain reactions in 
the oxidation of lipids. 
 
1.2.2.7 Singlet oxygen 
 
This species is mainly formed by photosensitisation reactions. The formation of singlet 
oxygen (
1
O2) can take place in the retina of the eye and certain diseases such as porphyrias 
lead to excess 
1
O2 formation (Halliwell and Gutteridge, 1989). Due to the absence of 
unpaired electrons within its structure, 
1
O2 is not regarded as a free radical but is classified as 
a powerful non-radical oxidising agent (Halliwell et al., 1995). Examples of compounds that 
readily react with 
1
O2 are DNA, tryptophan (TRP) and NADPH. The generation of 
1
O2 by 
photosensitisation reactions has been used medically (called photodynamic therapy). For 
example, photodynamic therapy is used in the treatment of genital sores caused by Herpes 
Simplex (Halliwell and Gutteridge, 1989).  
       
               Equation 1.1 Fenton reaction  
            
             Equation 1.2  
  
  
       
              
                       Equation 1.3  Haber-Weiss reaction 
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1.2.2.8 Nitric oxide radical 
 
Under normal physiological conditions, the nitric oxide free radical (NO•) serves an 
important role as a mediator in various processes such as cerebral blood flow (White et al., 
1998, Toda et al., 2009), autoregulation and cerebral vasodilation (White et al., 2000). 
However, when its concentrations are elevated during ischaemia, peroxynitrite is formed by 
the reaction of NO• and O2
•-
 (Zalba et al., 2000) and it is the peroxynitrite anion that leads to 
further oxidative damage such as oxidation of lipids.  
 
1.2.2.9 Peroxynitrite anion 
 
The reaction of NO• and O2
•-
 produces the peroxynitrite anion (ONOO
-
) (Beckman et al., 
1990) which is a powerful oxidising agent that has powerful bactericidal and parasiticidal 
properties (Beckman et al., 1990). Van der Vliet and colleagues (1994b) showed that ONOO
-
 
depleted antioxidants in the blood as it rapidly oxidised ascorbic acid, uric acid and plasma 
thiol groups. These authors also discovered that ONOO
-
 contributed to oxidative damage by 
oxidising lipids and proteins. The ONOO
-
 can further cause oxidative damage when it is 
decomposed to •OH (Beckman et al., 1990). 
  
1.2.2.10 Mitochondrial dysfunction 
 
The mitochondria are responsible for supplying cells with energy and thus it consumes most 
of the oxygen inspired. Other than supplying energy to the cell, it also plays an important role 
in other cell processes such as Ca
2+
 homeostasis, regulation of cell cycles, free radical 
generation, thermogenesis and signalling processes which are important for cell death 
(apoptotic and necrotic), aging and development processes (Sas et al., 2007). Mitochondrial 
dysfunction is thus marked by disturbances of Ca
2+
, adenosine-5‟-triphosphate (ATP) or the 
metabolism of ROS (Brookes et al., 2004). Excitotoxicity (Section 1.2.3.11) and respiratory 
toxins such as cyanide (Section 1.2.6) lead to mitochondrial dysfunction. Parkinson‟s disease 
(PD), Alzheimer‟s disease (AD) and ischaemia-reperfusion injury are diseases marked by 
oxidative stress and mitochondrial dysfunction (Simanian and Coyle, 1996). 
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When the function of one or more respiratory chain complexes within the mitochondria is 
damaged, there is enhanced free radical production. This results in oxidative damage of the 
mitochondria and opening of the mitochondrial permeability transport pores (mtPTPs) 
ultimately leading to the disruption of mitochondrial function (Sas et al., 2007). The opening 
of the mtPTPs leads to the induction of apoptosis. During normal mitochondrial function, a 
small proportion of electrons leak out during oxidative phosphorylation. When there is a 
problem with mitochondrial functioning, excess electrons leak out and thus combine with 
oxygen to generate ROS which ultimately leads to a state of oxidative stress within the cell 
(Beal, 2000). Oxidative stress then leads to the opening of the mtPTPs which results in a 
cycle of events leading to further damage of the mitochondria and ultimately to pathways that 
result in cell death (Hong et al., 2004).  
 
1.2.2.11 Excitotoxicity  
 
Glutamic acid is a major excitatory neurotransmitter that plays an important role in memory 
and learning (Kakuda, 2002). It is released from neuronal cells via an impulse and stimulates 
glutamate receptors and opens ion channels leading to permeability of sodium (Na
+
), 
potassium (K
+
) and calcium (Ca
2+
). There are three types of ionotropic glutamate receptors 
namely: N-methyl-D-aspartate (NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazole 
propionate (AMPA) and kainite receptors. When the ATP levels are depleted due to an 
injury, the mitochondria become dysfunctional and depolarisation of the neuronal membrane 
occurs (Section 1.2.3.10). This results in excess glutamic acid being released into the 
extracellular space, leading to glutamic acid binding to NMDA and non-NMDA receptors, 
increasing the cell permeability to Ca
2+ 
and Na
+
 resulting in neuronal cell death (Figure 1.4) 
(Kakuda, 2000; Kakuda et al., 2000; Arundine and Tymianski, 2004). Excitotoxicity is 
therefore neuronal death mediated by the overstimulation of the glutamate receptors. 
 
Two components make up excitotoxicity: a Na
+
 and chloride ion (Cl
-
) dependent component 
which is characterised by immediate cell swelling and the other is Ca
2+
-dependent cell 
degeneration component (Rothman and Olney, 1987; Arundine and Tymianski, 2004). An 
increase in the influx of Na
+ 
and Cl
- 
creates an osmotic imbalance between the neuron and the 
extracellular environment (Rothman and Olney, 1987). The osmotic imbalance causes water 
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to flow into the cell, causing cell swelling, damage and potential cell lysis, which are 
characteristics of cell necrosis (Epstein and Gendelman, 1993). 
 
Excessive Ca
2+ 
influx is a result of the overstimulation of glutamate receptors mediated by 
prolonged activation of the glutamate receptors or by neuronal injury inducing changes in 
receptor functioning (Arundine and Tymianski, 2004). Ca
2+
 overload ultimately leads to an 
increase in the production of ROS and RNS, activation of genetic signals, leading to 
apoptosis and mitochondrial dysfunction.  
 
Stimulation of the NMDA receptor resulting in a Ca
2+
 influx in the neuronal cell decreases 
the membrane potential of the mitochondria leading to the opening of mtPTP (Schinder et al., 
1996). This then results in the uncoupling of the electron transfer from ATP synthesis and 
this hampers energy metabolism and increases free radical production (Beatrice et al., 1980). 
 
 
 
Figure 1.4: A schematic diagram showing mechanisms of excitotoxicity. Stimulation of NMDA and non-NMDA 
receptors and cellular pathways ultimately leading to excitotoxicity (Epstein and Gendelman, 1993). 
 
Neuronal cell death is also mediated by AMPA receptor-mediated Ca
2+
 influx by the 
activation of phosphorylation of cyclic AMP response element-binding protein (CREB) via 
the stimulation of the mitogen activated protein kinase (MAPK). Thus the overstimulation of 
the glutamate receptors by glutamic acid accumulation has proven to be neurotoxic and the 
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metabolic disturbances that result from it have been implicated in many diseases such as AD 
(Hynd et al., 2004) and depression (Hayley et al., 2005; Yao and Reddy, 2005). 
 
1.2.3 OXIDATION OF MACROMOLECULES 
 
1.2.3.1 Introduction 
 
Oxidative damage is the damage that radical species cause on biomolecules such as lipids, 
DNA and proteins within living organisms (Hallliwell, 2007). The alteration of 
physiologically critical molecules such as these is associated with various pathologies 
(Laguerre et al., 2007). 
 
1.2.3.2 Oxidation of nucleic acids 
 
Free radicals can cause the damage of DNA in several ways and the damage that occurs is 
preferentially localised in certain genes (Lu et al., 2004b). Damage to DNA can also occur by 
direct damage by H2O2, decreased levels of ATP and NAD
+
; a decrease in the ratio of GSH to 
GSSH; an increase in intracellular Ca
2+
(Halliwell and Gutteridge, 1986), ROS directly 
reacting with DNA (Ames et al., 1993) or when ROS-derived lipid-hydroperoxides 
breakdown into genotoxins (Marnett, 2000). ROS such as ONOO
-
 can lead to covalent 
modifications of DNA (Lee and Blair, 2001; Sas et al., 2007). Lipid hydroperoxides are 
derived from ROS and produced enzymatically by the action of cyclo-oxygenases (COX) on 
PUFAs (Lee and Blair, 2001).  
 
The presence of oxidised DNA bases is often used as a marker for free oxidative DNA 
damage (Helbock et al., 1999). The guanine base is usually used as a biological marker for 
oxidative damage to DNA as it is particularly sensitive to oxidation and is converted to 8-
hydroxyguanine (8-OH-G) in the presence of the •OH (Figure 1.5). 
 
Under normal conditions, lesions that result from genotoxins derived from ROS and lipid 
hydroperoxides are repaired in order to maintain the integrity of DNA. If the lesions are not 
repaired, this leads to DNA replication and subsequently mutation (Marnett, 2000; Lee and 
Blair, 2001). Irreparable damage to DNA triggers apoptosis and necrosis (Sas et al., 2007). In 
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extreme oxidative stress conditions, extensive damage to DNA leads to the activation of 
apoptotic machinery and switches the mode of cell death from apoptosis to necrosis (Virág, 
2005). With age, mitochondrial DNA becomes more susceptible to oxidative stress due to a 
decrease in repair capacity and its proximity to the respiratory chain (Sas et al., 2007). 
 
Oxidation
8-hydroxyguanine
(8-OH-G)
C8-OH-adduct
radical of guanine
Guanine
HO.
 
Figure 1.5: Showing the radical attack to the guanine base (Shigenaga et al., 1989). 
 
1.2.3.3 Oxidation of proteins 
 
Oxidative stress that leads to the damage of proteins depends on many factors which include: 
the nature and location of the free radical, the proximity of the radical to the protein and the 
concentration of antioxidants (Grune et al., 1997). The most common products of protein 
oxidation are aggregates of covalently and non-covalently cross-linked proteins (Grune et al., 
1997). 
 
Oxidation of proteins is initiated in several ways: electron leakage, metal-ion dependent 
reactions, auto-oxidation of lipids (Dean et al., 1997), elevation of levels of intracellular Ca
2+
 
in response to oxidative stress (McConkey and Orrenius, 1997) and when lipid 
hydroperoxides lead to the production of bifunctional electrophiles (Lee and Blair, 2001). 
Figure 1.6 shows the postulated mechanisms of protein oxidation. Fortunately, only a small 
number of proteins are damaged in cells subjected to oxidative stress (Halliwell, 2007) but 
the damage results in the  modification of protein structure and function (Lee and Blair, 2001; 
Butterfield, 2006). Oxidised proteins are not physiologically inactive and their unfolding 
makes them susceptible to proteinases (Dean et al., 1997). Protein nitration leads to the 
modification of protein function which is thought to be important in the pathomechanism of 
several diseases such as Huntington‟s disease (HD), AD and PD. 
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Figure 1.6: Mechanisms of protein oxidation in vivo (Dean et al., 1997). 
 
1.2.3.4 Lipid peroxidation 
 
Lipid peroxidation (LP) refers to the oxidation of lipids within the body as a result of 
oxidative stress. It occurs by three reaction pathways: 
 
 Non-enzymatic chain auto-oxidation mediated by free radicals, 
 Non-enzymatic and non-radical photo-oxidation and  
 Enzymatic oxidation. 
 
Biological lipids are susceptible to LP due to the presence of double bonds within their 
structure. LP occurs in 3 stages namely chain initiation, chain propagation and chain 
termination (McBrien and Slater, 1982; Laguerre et al., 2007). Chain initiation occurs when 
the initiator such as a chemical agent or free radical, causes the homolytic fission of a 
hydrogen atom on the lipid leading to the formation of lipid and hydrogen radicals. 
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Propagation is the next step in LP that involves the conversion of lipid radicals into lipid 
peroxide radicals and the other radical species into ROS. The duration of a propagation 
reaction is dependent on the fatty acid composition, concentration of oxygen and presence of 
antioxidants within the membranes (Gutteridge and Halliwell, 1990). Termination is the final 
stage in which two radicals react or the radical species react with another species to form a 
non-reactive product. 
 
During cell injury, enzymes such as COX and lipo-oxygenases are activated and the release 
of transition metal ions from injured cells takes place. Enzymatic-induced LP takes place 
when the cell injury-induced enzymes and the released transition metal stimulate the 
production of fatty acid peroxides (Gutteridge and Halliwell, 1990). LP is often a late event 
of cell injury that accompanies rather than causes final cell death (Smith et al., 1983; 
Gutteridge and Halliwell, 1990). 
 
LP causes physical and chemical changes within the membrane which alter the integrity of 
the membrane (Ottino and Duncan, 1997), impair membrane function, decrease fluidity, 
increase non-specificity in permeability to ions such as Ca
2+
 and the inactivation of 
membrane-bound receptors and enzymes (Gutteridge and Halliwell, 1990). An increase in 
intracellular Ca
2+ 
due to oxidative stress increases the availability of transition metals which 
initiate LP and thus increases LP especially in injured tissue (Halliwell and Gutteridge, 
1986). The degree of oxidative stress in lipids is assessed by determining the concentration of 
lipid oxidation products in the body fluids or by the susceptibility of lipids to peroxidation 
induced ex vivo (Dotan et al., 2004) 
 
Many studies have shown that damage to cells caused by ROS and LP play a crucial role in 
ageing and in the pathogenesis of several chronic and acute diseases such as PD, cancer and 
lupus (Halliwell and Gutteridge, 1984a; Esterbauer, 1993). There are several health risks that 
are associated with consumption of the products of LP (Esterbauer, 1993).The body can be 
protected from the harmful effects of LP by antioxidants, low oxygen tension and metal 
chelators (Barber and Bernheim, 1967). 
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1.2.4 METAL IONS 
 
Transition metal ions are able to participate in radical reactions that lead to the generation of 
ROS (Halliwell and Gutteridge, 1989). Injury induced increases in intracellular Ca
2+
 lead to 
the increase in availability of transition metals within the cell (Halliwell and Gutteridge, 
1986). Iron is responsible for the Fenton reaction that generates the toxic •OH radical 
(Section 1.2.3.5). Cu
+
 also reacts with H2O2 to generate the •OH but with a much greater rate 
constant than Fe
2+
 does (Halliwell and Gutteridge, 1984a). Cu
+
 in the blood does not generate 
“free” •OH because any Cu+ is bound to proteins in the blood and is thus made unavailable to 
react with H2O2 (Rowley and Halliwell, 1983). Of all transitional metals ions, Fe
2+
 is the 
most powerful pro-oxidant (Shimada et al., 1992). 
 
Transition metals are found at the active site of many enzymes and because these are able to 
accept and donate single electrons by overcoming spin restriction (Hill, 1981). These are 
efficient in the catalysis of the oxidation of biomolecules as they simultaneously bind to 
biomolecules and dioxygen, thus effectively serve as a bridge between the oxygen and the 
biomolecule (Miller et al., 1990).  
 
Transition metal ions have the ability to stimulate the oxidation of lipids by decomposing 
lipid peroxides (LOOH) into radicals that continue the chain propagation step of LP 
(Equation 1.4) (Halliwell and Gutteridge, 1984b; Gutteridge and Halliwell, 1990). The 
alkoxyl and peroxyl radicals lead to further LP by abstracting hydrogen atoms from 
neighbouring lipids. In general, metals such as cobalt (Co), copper (Cu) and iron (Fe) with 2 
valency states and suitable redox potentials increase the rate of LP (Barber and Berheim, 
1967). 
 
  
Excessive amounts of transition metals, as well as deficiencies in them, have been implicated 
in several diseases. For example, excess copper in certain parts of the brain have been shown 
    
         
                               Equation 1.4 
  (alkoxyl        (peroxyl 
  radical)           radical) 
Literature Review CHAPTER 1 
 
Page | 24  
 
to contribute to the initiation and/or the progression of several neurodegenerative diseases 
such as AD, whilst copper deficiency leads to an alteration of glucose metabolism (Uriu-
Adams and Keen, 2005). 
 
1.2.5 CYNANIDE 
 
Cyanide is a very potent respiratory toxin (Yen et al., 1995). The main mechanism in which 
cyanide acts involves the inhibition of cytochrome oxidase aa3 which is a terminal oxidative 
enzyme of the electron transport chain (Johnson et al., 1987). The cyanide-induced histotoxic 
hypoxia that occurs, results in elevated levels of brain Ca
2+
 (Johnson et al., 1986) which is an 
important mediator in neuronal death and changes in intracellular ionic regulation (Johnson et 
al., 1986). Johnson and colleagues (1987) showed that a single dose of cyanide causes 
significant LP in the brain and this leads to both functional and morphological manifestations 
of neurotoxicity. Cyanide also causes DNA fragmentation leading to cell death that resembles 
apoptosis (Mills et al., 1996; Mills et al., 1999). An agent that will attenuate the toxic effects 
of cyanide would have to prevent such reactions from occurring. Chlorpromazine has been 
shown by Moduh and colleagues (1988) to be an effective antidote for cyanide poisoning by 
its ability to prevent Ca
2+
 influx and LP.  
 
1.2.6 QUINOLINIC ACID 
 
1.2.6.1 Introduction 
 
Quinolinic acid (2, 3-pyridine dicarboxylic acid; QA) is an endogenous amino acid that is a 
metabolite of the tryptophan-kynurenine pathway that is usually present in nanomolar 
concentrations in the human brain (Moroni, 1999). QA unlike its bioprecursors TRP and 
kynurenine (KYN) is unable to cross the BBB and it may be thus assumed that it is 
synthesised within the brain (Foster et al., 1984). QA production is regulated by the 
bioavailability of the iron (II) ion, the compartmentation of metabolic enzymes and the 
presence of 3-hydroxyanthranilic acid oxygenase (3-HAO) (Foster et al., 1986). Substantial 
increases in QA level have been found in infections and inflammatory neurological disorders 
(Heyes et al., 1996) as it is produced by immune activated macrophages (Heyes et al., 1998). 
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1.2.6.2 Biosynthesis of quinolinic acid 
 
1.2.6.2.1 Introduction 
 
TRP is one of the twenty standard amino acids in the human body.  The largest proportion of 
TRP within the central nervous system (CNS) is converted to indoleamines (indoles or indole 
derivatives containing amine groups) or used in protein synthesis (Saito et al., 1993). The 
majority of TRP is metabolised by the kynurenine pathway (KP) (Figure 1.7) which 
represents the major catabolic route for TRP in the brain and in the periphery (Sas et al., 
2007). The conversion of TRP to L-kynurenine (L-KYN) is initiated by the oxidation of the 
indole ring of TRP under aerobic conditions (Knox and Mehler, 1950). 
 
The major metabolites of KP are kynurenic acid (KYNA), QA and 3-hydroxy-kynurenine (3-
OH-KYN) (Sas et al., 2007), all of which are neuroactive. KYNA is a non-competitive α-7-
nicotinic acetylcholine receptor blocker (Hilmas et al., 2001) and has affinity for the NMDA 
receptor and α-amino-3-hydroxy-5 methyl-4-isoxazole propionate (AMPA) receptor (Sas et 
al., 2007). QA, a potent neurotoxin, is an N-methyl-D-aspartate (NMDA) excitotoxic 
receptor agonist (Saito et al., 1993; Št‟astný et al., 2004). Whereas QA is neurotoxic, KYNA 
is neuroprotective. Rios and Santamaria (1991) reported that KYNA blocks QA-induced LP. 
 
Some TRP metabolites of KP are powerful antioxidants. Christen et al., (1990) reported that 
TRP metabolites such as 3-hydroxyanthranilic acid (3-HAA) and 3-OH-KYN have been 
shown to possess free radical scavenging properties by the scavenging of the peroxyl radical. 
Imbalances in KP metabolites (particularly KYNA, QA and 3-OH-KYN) may lead to 
disturbances in normal brain functioning and this may play a role in the pathology of some 
brain disorders (Sas et al., 2007). 
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Figure 1.7: Graphical representation of the KP. Tryptophan 2, 3-dioxygenase (TDO) or indoleamine 2, 3-
dioxygenase (IDO) catalyse the formation of kynurenine (Sas et al., 2007) 
 
Some neurological diseases and pathological states occur when there is a change to KP 
metabolites (Sas et al., 2007). Increases in the toxic metabolite 3-OH-KYN imply low levels 
of KYN which contributes to the susceptibility of neurons to damage. Elevated levels of 
KYNA exert an inhibitory effect on NMDA receptors and this may explain the cognitive 
deficits in patients with Down‟s syndrome (Baran et al., 1996) and the cognitive deterioration 
that occurs in AD.  
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1.2.6.2.2 Enzymes regulating the Kynurenine Pathway 
 
1.2.6.2.2.1 Tryptophan-2, 3-dioxygenase 
 
This enzyme is also known as tryptophan pyrrolase or L-tryptophan-oxygen  
2, 3-oxidoreductase. In humans it is expressed in the liver and not in other tissues (Takikawa, 
2005). Tryptophan-2, 3-dioxygenase (TDO) is specific for L-TRP and is responsible for the 
conversion of L-TRP to L-KYN. TDO exists in two forms namely the already active 
holoenzyme and the apoenzyme form which requires haeme and haematin for its activation in 
vivo and in vitro respectively (Badawy and Evans, 1975). Haeme is a co-factor of TDO and 
regulates the activity of TDO (Badawy and Evans, 1975).  
 
Haeme is required for activity of TDO and reversibly binds the inactive apoenzyme to form 
the oxidised and inactive holoenzyme containing ferrihaeme (Equation 1.5) (Knox and Piras, 
1966). TRP then binds to the inactive holoenzyme reducing it to the fully active form which 
contains haeme in the ferrous form which results in TRP becoming a free radical (Equation 
1.6). Oxygen that is present then binds to the TRP radical complex and O2
•- 
is generated. The 
O2
•- 
produced results in the oxidation of the ferric ion in the haeme to the ferrous form 
(Equation 1.7). 
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1.2.6.2.2.2 Indoleamine-2, 3-dioxygenase 
 
Indoleamine-2, 3-dioxygenase (IDO) is a haeme containing dioxygenase similar to TDO. 
Human IDO has a number of substrates it oxidises which include D- and L-TRP (Yamamoto 
and Hayaishi, 1967), D- and L-5-hydroxy KYN and TRP (Shimizu et al., 1978) unlike TDO 
which has only one substrate L-TRP. IDO acts on its indoleamine substrates by cleaving the 
pyrrole ring by utilising oxygen and O2
•-
 as a cofactor (Hayaishi et al., 1957).  The KYN 
produced by IDO can be further metabolised by KP into various phenolic compounds 
(Christen et al., 1990). 
 
IDO is expressed in a number of peripheral organs such as the brain, colon, kidney, large and 
small intestines, spleen and stomach whereas TDO synthesis is limited to the liver. IDO 
activity is induced by the activation of dendritic cells such as macrophages and astrocytes and 
                                                   Equation 1.5 
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this results in the decline of TRP levels systemically and locally (Takikawa, 2005). 
Interferons, which are soluble proteins that are released by cells in the immune system, 
appear to use the mechanism of TDO induction which ultimately leads to lower TRP to 
inhibit growth of bacteria (Takikawa, 2005). Interferon-γ, which has been used to treat renal 
tumours (Dermott and Atkins, 2005), causes IDO-induced TRP depletion which in turn 
causes a decrease in serotonin (5HT) synthesis and thus accounts for interferon-γ side effects 
such as depression, diarrhoea and anxiety (Ebbinghaus et al., 2005).  Other than the 
catabolism of TRP, other physiological functions of IDO include the suppression of various 
intracellular pathogens and viral infections (Takikawa, 2005). 
 
1.2.6.2.2.3 Formamidase 
 
TRP is converted by either IDO or TDO to N-formyl-KYN which is degraded by 
formamidase to L-KYN. The KYN produced is further metabolised in three ways, by 
kynurenine amino transferase (KAT), KYN 3-hydroxylase and kynureninase. 
 
1.2.6.2.2.4 Kynurenine 3-hydroxylase 
 
KYN 3-hydroxylase is a flavin adenine dinucleotide (FAD)-dependent monooxygenase, 
which is responsible for the hydroxylation of L-KYN to 3-OH-KYN (Schwarcz and 
Pellicciari, 2002). Astrocytes generally lack KYN 3-hydroxylase and thus favour the 
synthesis of KYNA (Guillemin et al., 2001). Thus astrocytes are neuroprotective in terms of 
maximising the production of KYNA and minimising QA synthesis (Stone, 2001b). 
 
1.2.6.2.2.5 Kynureninase 
 
Kynureninase is a pyridoxal phosphate-dependent enzyme (Schwarcz and Pellicciari, 2002). 
It catalyses the hydrolysis L-KYN and 3-OH-KYN to 3HAA.  
 
1.2.6.2.2.6 Kynurenine amino transferase 
 
Kynurenine amino transferase (KAT) is responsible for the conversion of KYN to KYNA 
and the conversion of 3-OH-KYN to xanthurenic acid. There are two types of KATs in the 
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brain and distributed mainly in astrocytes but also in the hippocampus and striatum (Okuno et 
al., 1991). Microglial cells contain little KAT and thus produce intermediates that favour the 
QA branch of KP (Guillemin et al., 2001). 
 
1.2.6.2.2.7 3-Hydroxyanthranilic acid oxygenase 
 
3-Hydroxyanthranilic acid oxygenase (3-HAO) is produced in peripheral organs although 
higher concentrations of it are found in the liver and kidney. 3-HAO catalyses the conversion 
of 3-HAA to an unstable intermediate α-amino-β-carboxymuconoic acid semialdehyde, 
which rearranges itself non-enzymatically to QA by cyclisation and dehydration or is 
enzymatically converted to picolinic acid (Decker et al., 1961). Neuroprotection shown by 3-
HAO inhibitors has been attributed to the prevention of QA formation and thus decrease in 
brain levels of QA (Sas et al., 2007). 3-HAO is sometimes responsible for regulating the rate 
of substrate influx through KP (Saito et al., 1993). 
 
1.2.6.3 The neurotoxicity of QA 
 
QA is a weak but specific competitive agonist of the NMDA receptor.  When it binds to 
NMDA receptors, it leads to an increase in intracellular calcium and this leads to the 
initiation of many reactions that contribute to cell death and the promotion of LP (Štipek et 
al., 1997; Iwahashi et al., 1999; Št‟astny et al., 2004). LP is involved in the neurotoxic effects 
of QA (Santamaria and Rios, 1993). By the activation of the NMDA receptor and induction of 
LP, QA leads to changes in the permeability of the BBB (Št‟astný et al., 2004). 
 
QA has the ability to generate free radicals such as reactive oxygen species (ROS). The 
increase in intracellular Ca
2+
 caused by QA stimulating NMDA receptors leads to a cascade 
of events that lead to the generation of free radicals. Beal et al., (1986) discovered that when 
QA is injected intracerebrally, it causes a decrease in γ-aminobutyric acid (GABA) which 
leads to the generation of •OH. There is no effective removal mechanism for QA in the 
extracellular space, the outcome of which contributes to QA has long lasting effects and high 
in vivo potency (Foster et al., 1984).  
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QA has been implicated in the aetiology or pathology of various neurological diseases 
especially those that involve inflammatory reactions (Sas et al., 2007) such as ischaemia 
brought on by strokes (Stone, 2001a). 
 
1.3 NEUROPROTECTION 
 
1.3.1 INTRODUCTION 
 
Neuroprotection occurs when neuroprotective agents are able to prevent the effects of toxins 
to neuronal cells. Free radicals have a role in the pathology of several human conditions such 
as cerebral ischaemia and AD and thus agents that effectively inhibit radical formation or 
reactions will be found to be protective (Gutteridge and Smith, 1988). 
 
1.3.2 ANTIOXIDANT THERAPY 
 
1.3.2.1 Introduction 
 
An antioxidant is defined by Halliwell et al., (1995) as a substance that when present at lower 
concentrations compared to those of an oxidisable substrate significantly delays or prevents 
the oxidation of that substrate.  Antioxidants are either synthesised in the body e.g. enzymes, 
or are taken in as part of the diet (Halliwell, 2007).  It is possible that an antioxidant may 
effectively protect one system from oxidative stress but fail to protect or even lead to the 
damage of another system (Halliwell et al., 1995). The antioxidants are categorised according 
to their mechanism: preventing the formation of active oxidants; scavenging (donation of 
electrons to reactive species); transforming reactive species into inert compounds; stabilising 
biological membranes; removal of substances that catalyse free radical-induced damage; 
quenching and removal of active oxidants and repair of damage caused by oxidation products 
and adaptive responses (Gutteridge et al., 1983; Etsuo et al., 2005; Ligumsky et al., 2005). 
Antioxidants work in controlling the levels of oxidative species rather than completely 
eliminating them because it is energetically cheaper to repair or replace damaged 
biomolecules rather than maintaining excess antioxidant defence levels (Halliwell, 2007). 
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1.3.2.2 Enzymatic antioxidant systems 
 
There are many enzymes that exist in the mammalian body that protect the body from the 
deleterious effects of free radicals and these are shown in Tables 1.1 and 1.2 according to the 
body compartment in which they are found. These enzymatic antioxidants are classified as 
preventative antioxidants as they prevent the reactive species from initiating toxic reactions. 
 
Table 1.1: Intracellular antioxidant defence systems in mammals (Halliwell and Gutteridge, 1986). 
Intracellular Antioxidants Function 
Superoxide dismutase Removal of O2
•- 
Catalase Removal of  H2O2 
Glutathione peroxidise 
Glutathione-S-transferase 
Related GSH-requiring enzymes 
Removal of H2O2 and lipid peroxides  
(without reactive aldehyde formation) 
 
Table 1.2: Extracellular antioxidant defence systems in mammals (Halliwell and Gutteridge, 1986). 
Extracellular Antioxidants           Function 
Extracellular superoxide dismutase 
Removal of O2
•-
 (but present in very low 
concentrations) 
Uric acid 
Scavenging of •OH and 1O2. Binds to iron and 
copper ions in forms that are poorly reactive in 
radical reactions 
Caeruloplasmin 
Inhibition of LP; quickly oxidises Fe
2+
 and Fe
3+
  
that can bind to transferrins 
Albumin 
Binds metals (especially to copper but, also, 
weakly, iron). Inhibits copper-dependent 
radical reactions 
Haptoglobin/ Haemopexin Bind free haemoglobin/haem 
 
H2O2 is a non-radical oxidising species that can give rise to the formation of the highly 
reactive radical •OH (Section 1.2.3.4). There are 2 types of enzymes that are responsible for 
the removal of H2O2 from cells and these are catalases and peroxidases. Catalase (CAT) 
enzymes contain either iron or manganese (Mn) within their structure and convert H2O2 into 
water and O2 (Halliwell and Gutteridge, 1989). Glutathione (GSH) peroxidase catalytically 
converts 2 GSH which contains a thiol (-SH) group and a H2O2 into oxidised glutathione 
(GSSG) and water respectively (Equation 1.8). GSSH is the oxidised form of GSH and 
consists of 2 GSH molecules joined together. GSH peroxidise is specific for GSH and it 
donates a hydrogen to GSH. 
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GSH peroxidase has other substrates other than H2O2 and these include hydroperoxides and 
peroxynitrite. Other enzymes exist that protect the body from the harmful effects of H2O2, 
these include cytochrome c peroxidise and NADH peroxidise among others (Halliwell ad 
Gutteridge, 1989). 
 
Superoxide dismutase (SOD) is the enzyme that catalyses the dismutation of O2
•-
 to form 
H2O2 (Halliwell et al., 1995; Didion et al., 2002).  SOD is able to react with O2
•-
 at a very 
rapid rate. Its levels in the plasma and synovial fluid are very low (Halliwell and Gutteridge, 
1986). Uric acid is the end product of purine metabolism; it is present in the serum and 
scavenges O2
•, ROO• and •OH radicals. Besides being an effective radical scavenger, it is a 
good chelator of metal ions (Davies et al., 1986). 
 
1.3.2.3 Metal chelators 
 
Metal chelators form complexes with metal ions and are classified as preventative 
antioxidants as these prevent metal ion-catalysed generation of reactive species (Benzie and 
Szeto, 1999; Laguerre et al., 2007). Chelators of metal ions include ethylene diamine tetra-
acetic acid (EDTA), albumin which forms complexes with copper ions, ferritin which 
complexes with iron ions and haemopexin and haptoglobin which form complexes with haem 
and haem proteins respectively (Gutteridge and Halliwell, 1990). 
 
Iron storage and transport proteins such as ferritin and transferrin are regarded as part of the 
antioxidant defence systems in the body as they store iron within their structure and prevent it 
from otherwise participating in the Fenton reaction (Section 1.2.2.5) if it was in the “free 
form” (Halliwell and Gutteridge, 1989). Metallothioneins are proteins that are present in the 
liver and kidney which are able to enter the nucleus of the cell and bind to zinc, copper and 
mercury ions, thus preventing them from participating in harmful reactions that transition 
metals would otherwise participate in (Section 1.2.5) (Halliwell and Gutteridge, 1989). 
Haeme is an iron containing molecule that is able to participate in radical reactions that can 
                                         Equation 1.8 
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lead to oxidation of lipids, proteins and DNA. Haemopoxin is able to remove it from the 
circulatory system of the body and it is in this manner that it can be termed a preventative 
antioxidant (Gutteridge and Smith, 1988). 
 
1.3.2.4 Free radical scavengers 
 
1.3.2.4.1 Introduction 
 
Free radical scavengers are antioxidants that are preferentially oxidised in place of 
biomolecules (Halliwell and Gutteridge, 1989). Free radical scavengers act by donating an 
electron to reactive radical species. In so doing, these prevent the progression of radical-
mediated oxidative damage (Halliwell and Gutteridge, 1989).  
 
1.3.2.4.2 Endogenous scavengers of free radicals 
 
Endogenous antioxidants are localised in either the lipophilic or hydrophilic compartments of 
the body. Lipophilic compartments such as membranes and lipoproteins have lipophilic 
antioxidants such as vitamin E distributed within their structure (Etsuo et al., 2005) and the 
antioxidant is able to scavenge radicals that arise from within them. For example, during LP, 
radicals such as ROO• and chain initiating species are scavenged by lipophilic radicals. The 
hydrophilic antioxidants such as vitamin C are distributed in the aqueous compartments of 
the body and are able to scavenge radicals that arise there (Etsuo et al., 2005). Vitamin C is 
able to directly scavenge •OH even at millimolar concentrations (Halliwell and Gutteridge, 
1989). LP of low density lipids is effectively inhibited by the combination of vitamins C and 
E (Etsuo et al., 2005).   
 
1.3.2.4.2.1 Melatonin 
 
Melatonin (5-methoxy-N-acetyl-tryptamine) a product of tryptophan metabolism, is an 
endogenous neurotransmitter that is produced in the pineal gland (Reiter, 1991) and is 
responsible for the regulation of circadian rhythms (Cagnacci, 1996). It has several 
neuroprotective properties (summarised in Figure 1.8), including the ability to significantly 
reduce LP induced by several methods (Sewerynek et al., 1995; Daniels et al., 1998; 
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Southgate and Daya, 1999). A study by Limson and colleagues (1998) showed that melatonin 
is able to bind to aluminium, cadmium, lead and zinc. This could mean that melatonin could 
potentially inhibit metal ion-induced oxidative reactions. In addition to this, exogenously 
administered melatonin is able to reduce the degree of tissue and neurovascular damage and 
behavioural deficits associated with strokes (Reiter et al., 2003; Macleod et al., 2005; Reiter 
et al., 2005; Chen et al., 2006). Melatonin has been shown to be neuroprotective in several 
neurodegenerative disorders such as AD and HD (Tunez and Montilla, 2007). 
 
 
 
 
Figure 1.8: Mechanisms of the neuroprotective properties of melatonin (Reiter et al., 2002). 
 
Melatonin is a potent antioxidant, because it is able to donate electrons to toxic radicals 
(Reiter, 1998) and is able to scavenge up to 4 or more reactive species per molecule (Tan et 
al., 2002). It has been shown to scavenge •OH (Tan et al., 1993) and stimulate the CAT 
enzyme that is responsible for the removal of H2O2 (Montula et al., 1997). Its anti-
inflammatory property is attributed to melatonin‟s ability to scavenge NOO- and to reduce the 
formation of NO• (Cuzzocrea et al., 1998) as these 2 species are believed to have a role in 
mediating the inflammatory process (Beckman and Koppenol, 1996). The metabolites of 
melatonin also possess antioxidant properties (Maharaj et al., 2007). 
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1.3.2.5 Green tea  
 
1.3.2.5.1 Introduction 
 
Tea is a common beverage and of the total tea consumed worldwide, 20 % of it is green tea 
(Jankun et al., 1997). Green tea (Camilla sinesis) has many components that have 
physiological and pharmacological actions. These include catechins, flavonoids, caffeine and 
GABA. Catechins possess antioxidant, anti-obesity and anticancer properties; caffeine 
processes neuroactive properties as it affects the autonomic and dopaminergic nervous 
systems and GABA is an inhibitory neurotransmitter (Kakuda, 2001; Kakuda, 2002; Yamada 
et al., 2005). Theanine is a non-proteinous amino acid that is also found in green tea that 
produces the taste in it. 
 
1.3.2.5.2 Theanine 
 
1.3.2.5.2.1 Introduction 
 
Theanine (L-theanine; γ-glutamylethylamide or γ-ethylamino- L-glutamic acid) (Figure1.9) 
reportedly accounts for 50 % of all the amino acids in green tea leaves and comprises 
between 1-2 % of the total dry weight of green tea leaves (Goto et al., 1996). It is synthesised 
from ethylamine and glutamic acid (also known as glutamate) in the roots of tea plants and 
from there it is transported to the leaves of the plant (Buckowski et al., 1999) where it may be 
converted by the plant to catechins (Eschenauer and Sweet, 2006). It is an analogue of the 
excitotoxic neurotransmitter glutamic acid (Figure 1.8) and it is because of this that 
theanine‟s potential neuroprotective properties have been widely studied.  
 
As a glutamic acid analogue, theanine is able to bind to glutamate receptors such as NMDA, 
kainate and AMPA receptors as an antagonist. Theanine reduces neuronal death after 
ischaemia by binding to the above mentioned glutamate receptors (Kakuda, 2002; Egashira et 
al., 2007). Kakuda et al. (2008) showed that theanine inhibits glutamine transport in neurons 
in the brain. At a concentration of 500 µM, theanine suppresses glutamic acid-induced 
neuronal toxicity (Kakuda, 2002). The effect of theanine on neurotransmitters has also been 
studied. It has been shown to reduce the levels of brain 5-hydroxyindoles (Yokogoshi et al., 
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1995), decrease overall 5HT levels in the brain (Yokogoshi et al., 1997) and increase the 
release of dopamine (Yokogoshi et al., 1998). Theanine possesses anxiolytic and cognitive 
enhancing properties (Nathan et al., 2006) and has a hypotensive effect in spontaneously 
hypertensive rats (Yokogoshi and Kobayashi, 1997). 
 
 
 
Figure 1.9: Chemical structure of theanine and glutamic acid (Yamada et al., 2005). 
 
1.3.2.5.2.2 Pharmacology 
 
1.3.2.5.2.2.1 Dosing 
 
Approximately 4 cups of green tea is equivalent to between 50-200 mg of theanine 
(Eschenauer and Sweet, 2006).  Doses of up to 4000 mg/kg of theanine were tested in rats 
and were found to have no adverse effects (Borzelleca et al., 2006).  
 
1.3.2.5.2.2.2 Adverse effects 
 
A 13 week study on theanine to assess the toxicokinetic and toxicity was carried out by 
Borzelleca and colleagues (2006) on rats using doses of theanine of 0, 1500, 3000 and 4000 
mg/kg. The blood and urine samples were collected, body weights and food consumption and 
behavioural observations were made to assess the effects of theanine. No adverse effects and 
treatment-related deaths were observed. This study and the fact that theanine has been widely 
consumed for several decades implies that theanine is a safe drug.  
 
  
Theanine Glutamic acid 
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1.3.2.5.2.2.3 Drug interactions  
 
Theanine has been shown to have a positive interaction when administered with the 
chemotherapeutic agent doxorubicin. Sadzuka et al., (1996) reported that theanine enhances 
the efficacy of doxorubicin. It does this by inhibiting the efflux mechanism from tumour cells 
thereby increasing the inhibitory effect of the anticancer drug on tumour growth (Eschenauer 
and Sweet, 2006). Theanine also reduced the adverse reactions of doxorubicin such as the 
induction of lipid peroxide level and the reduction of glutathione peroxidase activity 
(Sugiyama and Sadzuka, 2004). Other potential drug interactions with theanine are with 
antihypertensives and with lipid lowering agents which result in an additive decline in blood 
pressure and lipid levels respectively (Eschenauer and Sweet, 2006). 
 
1.3.2.5.2.3 Pharmacokinetics 
 
1.3.2.5.2.3.1 Absorption 
 
The absorption of theanine occurs via a common Na
+ 
coupled co-transporter in the brush 
border membrane in the intestinal tract (Kitaoka et al., 1996). Its levels in the blood and liver 
rapidly increased an hour after administration and thereafter were sharply decreased. 
Theanine is taken up by the brain by a leucine-preferred transport system (Yokogoshi et al., 
1995). After intraperitoneal (i.p.) admission, it takes 30 minutes for theanine to be taken up 
by the brain (Kimura and Murata, 1971) and it reaches peak concentrations within 5 hours in 
the brain (Terashima et al., 1999). Serum concentrations of theanine were reached 0.5-2 
hours after the administration of a 200 mg dose in rats (Unno et al., 1999). 
 
1.3.2.5.2.3.2 Distribution 
 
Theanine levels in tissues such as blood, liver and the brain were detected as early as an hour 
after administration (Terashima et al., 1999). 
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1.3.2.5.2.3.3 Metabolism 
 
Orally administered theanine is metabolised to glutamic acid and ethylamine in the rat kidney 
(Unno et al., 1999; Terashima et al., 2003). The enzyme responsible for its degradation is a 
phosphate-independent glutaminase (Tsuge et al., 2003). 
 
1.3.2.5.2.3.4 Excretion 
 
As theanine is metabolised mainly by the kidney, a large percentage of theanine is 
immediately excreted through urine (Tsuge et al., 2003). Theanine was detected in the urine 5 
hours after administration and its concentration in the urine continued to increase during the 
next 24 hours (Terashima et al., 2003). 
 
1.3.2.6 Tetracyclines  
 
1.3.2.6.1 Introduction 
 
Tetracyclines are a class of broad spectrum antibacterials. The first tetracycline to be isolated 
and used in the clinical setting in 1948 was chlortetracycline (Duggar, 1948). These agents 
are divided into two classes according to their mechanism of action namely typical and 
atypical tetracyclines. Typical tetracyclines act by binding to the 30S ribosomal subunit of 
bacteria and inhibit protein synthesis (Dormercq and Matute, 2004; Bryskier, 2005) and the 
atypical tetracyclines act by interfering with the electrochemical gradient of the bacterial cell 
membrane which subsequently promotes cell lysis and thus cell death (Bryskier, 2005).  
 
The use of tetracyclines became popular but their use has recently been limited due to the 
emergence of bacterial resistance to these agents (Byskier, 2005). The manner in which 
bacteria develop resistance to antibacterial agents is by developing an efflux mechanism, 
protecting their ribosomal units, mutations in the 30S ribosomal unit and by enzymatically 
inactivating the antibiotic (Byskier, 2005). Semisynthetic tetracycline analogs doxycycline 
and minocycline have been used more frequently clinically due to their efficacy and the 
susceptibility of many bacterial infections to them. The tetracyclines remain the treatment of 
choice for Lyme disease, several sexually transmitted diseases and cholera. The combination 
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of tetracyclines with other drugs has also formed effective therapeutic agents in the treatment 
of diseases such as amyloidosis (when combined with chloramphenicol) (Bryskier, 2005).  
 
1.3.2.6.2 Minocycline 
 
1.3.2.6.2.1 Introduction 
 
Minocycline (7-dimethyl-amino-6-demethyl-deoxytetracycline hydrochloride) (Figure 1.10) 
is a second generation semi-synthetic tetracycline that belongs in the “typical” class of 
tetracyclines. Its superiority to most tetracyclines is due to the fact that it is a long acting 
antibiotic that readily crosses the BBB as it has enhanced lipophilicity at physiological pH 
(Barringer et al., 1974). Both gram negative and gram positive bacteria are susceptible to 
minocycline because it resistant to the efflux mechanisms in both these types of bacteria 
(Bryskier, 2005).  
 
Minocycline is effective in treating upper and lower respiratory infections with several strains 
of bacteria such as Staphylococcus aureus (S. aureus) and Streptococcus pneumoniae being 
susceptible to it (Steigbigel et al., 1968). Being lipophilic in nature, minocycline readily 
accumulates in sebaceous follicles in the skin and can thus be used to treat skin and soft 
tissue infections especially acne vulgaris (Eady et al., 1990; Freeman et al., 1994). Organisms 
such as Neisseria gonorrhoea and Chlamydia trachomatis are susceptible to minocycline in 
vitro. Minocycline may be used as a prophylaxis against gonorrhoea. However, the 
tetracycline doxycycline and other antibiotics are clinically superior to minocycline 
(Herfindal et al., 1992). Minocycline is useful in the treatment of non-gonoccocal urethritis 
(Romanowski et al., 1993). S. aureus infections particularly methicillin resistant S. aureus 
(MRSA) have been shown to be sensitive to minocycline (in vitro). No clinical studies have 
been carried out to evaluate the clinical use of minocycline in the treatment of MRSA but 
minocycline‟s inhibition of beta-lactamase production and its penetrability into tissues has 
made it effective in S. aureus infections of the bone, lungs and heart valves (Freeman et al., 
1994). Although rifampicin is the first choice in the prophylaxis of meningococcal 
meningitis, minocycline may be used as an alternative to it (Bryskier, 2005). 
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Figure1.10: Chemical structure of minocycline   
(http://www.medicinescomplete.com/mc/martindale/2009/images/CLK1103C001.gif) 
 
1.3.2.6.2.2 Pharmacology 
 
1.3.2.6.2.2.1 Dosing 
 
Due to its long half life, minocycline is usually orally administered at a dose of 200 mg once 
on the first day then 100 mg twice daily (Bryskier, 2005) and it is better adsorbed with food 
(Herfindal et al., 1992). Minocycline can also be administered by intravenous infusion with a 
200 mg dose being administered over a period of 30-60 minutes (Bryskier, 2005). 
 
1.3.2.6.2.2.2 Adverse effects 
 
Most adverse effects of minocycline (and other tetracyclines) are caused by their toxic 
degradation products (Bryskier, 2005). The adverse effects associated with the use of 
minocycline are: photosensitivity reactions in which a rash appears on the regions on skin 
exposed to sunlight, hypersensitivity reactions which rarely occur but include oedema and 
rashes, hyperpigmentation associated with prolonged use of minocycline and permanent 
discolouration of bones and teeth. Gastrointestinal side effects such as oesophageal ulcers 
which develop mainly when minocycline is taken with little or no fluid, dizziness and ataxia 
have also been reported with the use of minocycline in therapeutic doses (Herfindal et al., 
1992; Bryskier, 2005). Minocycline is able to cross the placenta and distribute in the foetus 
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and thus interfere with bone and tooth development. It is also secreted in breast milk. It is 
because of these reasons that the use of minocycline in pregnant and lactating women is 
prohibited.  
 
1.3.2.6.2.2.3 Drug interactions 
 
In general tetracyclines are not to be administered with antacids, dairy products and other 
preparations containing calcium, magnesium, zinc and iron as chelation with the drug will 
occur and thus reduce the oral bioavailability of the drug (Herfindal et al., 1992; Bryskier, 
2005). Combination with diuretic agents may cause an increase in serum levels of 
minocycline and with oral contraceptives may reduce the efficacy of the contraceptives 
(Bryskier, 2005). Minocycline also interacts with warfarin (Gasse et al., 2005). 
 
1.3.2.6.2.3 Pharmacokinetics 
 
1.3.2.6.2.3.1 Absorption 
 
Minocycline is well absorbed orally with approximately 95 % of the concentration being 
reached in the plasma within less than an hour (MacDonald et al., 1973) and bioavailability is 
improved when it is taken on an empty stomach or at least 1 hour before a meal (Bryskier, 
2005). Time-to-peak (Tmax) is reached approximately 2-3 hours after administration and its 
serum half life was found to be approximately 16 hours (MacDonald et al., 1973). 
Minocycline is highly protein-bound (76 %). 
 
1.3.2.6.2.3.2 Distribution 
 
Findings by MacDonald et al. (1973) showed that due to minocycline‟s lipophilicity, it is 
widely distributed with its concentrations in tissues being higher than serum concentrations. 
This characteristic makes it therapeutically effective, as its penetration into and around 
tissues combined with its long half-life support the clinical recommendation to reduce the 
dose frequency of minocycline (Freeman et al., 1994). Minocycline has the highest partition 
coefficient of the tetracyclines and this characteristic makes it a superior drug within its class. 
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1.3.2.6.2.3.3 Metabolism 
 
Nelis and De Leenheer (1981) showed that the major pathways of minocycline metabolism 
occur mainly by hydroxylation and N-demethylation with its principle metabolite being 9-
hydroxyminocycline by a microsomal biotransformation that is yet to be elucidated. 
 
1.3.2.6.2.3.4 Excretion 
 
Minocycline is minimally excreted in the urine (6-19 %) with most of it being eliminated in 
bile. It is for this reason that it is recommended that a daily dose of 200 mg not to be 
exceeded (Freeman et al., 1994). 4-epiminocycline, which is considered the degradation 
product of minocycline, is formed by the epimerisation of minocycline in the acidic 
environment of the kidneys (Nelis and De Leenheer, 1981). Faecal and urinal examination 
show that minocycline is partially metabolised to inactive substances (MacDonald et al., 
1973). 
 
1.4   RESEARCH OBJECTIVES 
 
Stroke evokes several toxic pathways that lead to a state of oxidative stress. The toxic events 
that occur as a result of stroke include an increase in free radical production, LP, an increase 
in the activity of neutrophils and macrophages which eventually lead to neurodegeneration 
and cell death (Gariballa, 2000). These processes lead to the biosynthesis of toxic 
endogenous toxins such as QA, which further contribute to ischaemic-induced injury. 
Exogenous substances that are taken therapeutically or as part of the diet (Yasuhara et al., 
2008) have a role in potentiating or preventing the damage that may result after ischaemic 
insult. Recent studies have shown that theanine (Kakuda, 2002) and minocycline 
(Yrjänheikki et al., 1999) have neuroprotective properties in a stroke. 
 
This study was undertaken to elucidate the potential neuroprotective mechanism of theanine 
and minocycline using various inorganic studies and biological assays. These included: 
 
 Measuring the potential free radical and antioxidant of the above-mentioned agents 
in the presence of neurotoxins in rat brain homogenate, 
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 An electrochemical and UV/Vis analysis and iron binding assays to investigate the 
metal binding properties of the drugs, 
 Establish the effects of the agents on the liver enzyme TDO and thus its effect on the 
biosynthesis of the neurotoxin QA, 
 Examination of the effect that the drugs have on the brain post-ischaemia and 
 The influence on the generation of O2
•- 
and the endogenous levels of GSH after 
ischaemic insult. 
 
The results of this study will contribute to the understanding of the mechanisms by which 
these drugs act and to determine whether the drugs are useful in preventing neuronal 
damage that occurs after a stroke.   
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 CHAPTER 2 
ANTIRADICAL AND ANTIOXIDANT ACTIVITY 
 
2.1 INTRODUCTION 
 
Free radicals that are generated in vivo result in damage of DNA, small molecules and lipids 
(Halliwell et al, 1995). Lipid peroxidation results from free radicals attacking membrane 
lipids which lead to the destruction of the cell membrane, cell integrity and the proper 
functioning of membrane bound enzymes and receptors as illustrated in Figure 2.1. Free 
radicals have also been shown to play a role in cardiovascular diseases (Dorman et al., 2003). 
Reactive oxygen species (ROS) are oxygen containing free radicals produced by the 
sequential univalent reduction of oxygen (Fridovich, 1978). The most commonly formed 
ROS are the superoxide anion radical (O
•
2
- 
), hydroxyl radical (HO
•
) and hydrogen peroxide 
(H2O2) a non radical ROS.  
 
An antioxidant has been defined by Halliwell et al., (2007) as any substance that delays, 
prevents or removes oxidative damage to a target molecule.  The importance of an 
antioxidant in vivo cannot be emphasised enough as these agents protect the human body 
against damage by ROS. An antioxidant may carry out its antioxidant activity in four ways: it 
may prevent the formation of active oxidants; scavenge the free radicals or quench and 
remove active oxidants and repair damage done by oxidants (Halliwell et al., 1995). 
 
The free radical scavenging activity of a potential antioxidant is evaluated in vitro by its 
ability to scavenge the stable 2, 2-diphenyl-1-picryl-hydrazyl (DPPH
●
) radical. This radical is 
stable due to the delocalisation of the spare electron over the whole molecule which gives rise 
to its characteristic deep violet colour in an alcoholic solution with an absorption band at 
517nm (Molyneux, 2004).  
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Figure 2.1: Illustration of free radicals attacking the cell membrane and proteins within the membrane 
(www.nia.hih.gove/Alzheimers/Resources/HighRes.htm). 
 
The DPPH radical scavenging activity is influenced by the structure of the radical scavenger 
and its ability to donate hydrogen atoms as shown in equations 2.1 and 2.2 (Saito and 
Kawabata, 2005). In the presence of a hydrogen atom donor (RH) or a radical species (R
●
) 
(Figure 2.2), the violet colour of the DPPH
●
 solution changes to a pale yellow. 
 
 
 
The DPPH thus acts as both an oxidisable substrate and as a reaction indicator molecule 
(Dorman et al, 2003).  
  
 
 
 
                              Equation 2.1 
 
                          Equation 2.2 
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Figure 2.2: Showing the manner in which DPPH reacts with a radical substance. 
(http://upload.wikimedia.org/wikipedia/commons/4/4d/DPPHInhibition.png) 
 
A substance that is able to scavenge DPPH radicals will be able to prevent abstraction of 
hydrogen from susceptible polyunsaturated fatty acids (PUFAs) (Dorman et al., 2003).  
 
Antioxidants derived from natural products such as plants have generated much interest 
globally. Green tea which is a popular herbal tea has been shown to have many naturally 
occurring antioxidants which include ascorbic acid, phenols and flavonoids (Sang et al., 
2002; Lin et al., 2008). It has also been shown to have the highest hydrogen atom donating 
ability when compared to other teas (Gadow et al., 1997; Benzie and Szeto, 1999; Atoui et 
al., 2005) and that regular intake increases antioxidant status in vivo and the plasma 
antioxidant capacity (du Toit et al., 2001) and thus reduces coronary heart disease (Benzie 
and Szeto 1999). Whether theanine exhibits free radical scavenging activity in a dose 
dependent manner needs to be established. Theanine is a glutamic acid analogue and glutamic 
acid causes significant cell death in rat neurons. However, it has been shown that 
simultaneous exposure of the rats neurons to theanine and glutamic acid resulted in the 
suppression of cell death due to the presence of theanine (Kakuda, 2002). Theanine has 
shown to prevent lipid peroxidation (Tsuge et al., 2003). Investigation of the antibiotic 
minocycline, as a neuroprotective agent has shown promising results (Ravina et al., 2003).  
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2.2 ANALYSIS OF THE FREE RADICAL AND ANTIOXIDANT ACTIVITY 
IN VITRO 
 
2.2.1 INTRODUCTION 
 
The brain is susceptible to damage by free radicals as it is rich in PUFAs and its high 
utilisation of oxygen (Şenes et al., 2007). Free radical related damage to DNA, proteins and 
lipids (such as the PUFAs in the brain), has been proposed to play an important role in the 
development of several neurodegenerative disorders (Halliwell et al., 1989). It is therefore 
important to search for agents that have antioxidant properties and thus potentially delay the 
rate at which neurodegeneration can occur. The antioxidant properties of theanine and 
minocycline were investigated using increasing concentrations of the drugs and these were 
compared to a known antioxidant vitamin C. 
 
2.3 MATERIALS AND METHODS 
 
2.3.1.1 Chemicals and reagents 
 
Theanine, minocycline and 2, 2-diphenyl-1-picryl-hydrazyl (DPPH) were purchased from 
Sigma Chemical Corporation, St Louis, Missouri, United States of America. The above 
chemicals were dissolved in methanol. Methanol and ascorbic acid (vitamin C) were 
purchased from Saarchem, Wadeville, Gauteng, South Africa. 
 
2.3.1.2 Determination of antioxidant activity using the DPPH radical scavenging 
method 
 
A modified method of free radical scavenging of Brand-Williams et al., (1995) described 
below, was used to measure the free radical scavenging ability of theanine and minocycline.  
 
DPPH (2 ml, 0.1 mM) was dissolved in methanol and incubated for 30 minutes with 2 ml 
theanine or minocycline at final concentrations of 50, 100, 200, 300, 400, 450 and 500 µg/ml. 
The maximum effective working volume for this experiment is recommended to be 4 ml with 
equivalent volumes of DPPH and reductant for optimum analytical accuracy (Molyneux, 
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2004). The test compounds were not dissolved in water as water gives rise to poor absorption 
readings (Molyneux, 2004) but rather in methanol as it gives rise to more sensitive absorption 
profiles of DPPH with no interference with the reaction (Molyneux, 2004; Sharma and Bhat, 
2009). Vitamin C was used as a positive control to check if the procedures were working 
correctly (Brand-Williams et al., 1995; du Toit et al., 2001). Due to the photosensitivity of 
both DPPH and minocycline, all operations were done under dim light (Ozcelik et al., 2003; 
Sharma and Bhat, 2009). After incubation, the absorbance was then read at 517 nm using a 
Shimadzu UV mini 1240 UV/VIS spectrophotometer. The absorbance of the samples using 
methanol as the blank was recorded.   
 
As previously mentioned, in the presence of a hydrogen ion donor, there is a change in colour 
of the DPPH solution from violet to yellow as well as a decrease in absorbance. After the 
absorbance values were recorded, the DPPH radical scavenging activity was calculated using 
the following equation: 
 
 
 
 
 
Where,  
   = the absorbance of control reaction which was made up of DPPH in the absence  
of the test compound and 
   = the absorbance of DPPH in the presence of the test compound.  
 
This equation shows that the higher the percentage inhibition, the higher the hydrogen atom 
donating ability and thus the more efficient the test compound is as an antioxidant. 
 
2.3.1.3  Statistical Analysis 
 
The results were analysed using a one-way Analysis of variance (ANOVA) followed by the 
Student Newman-Keuls Multiple Range Test using the Graph Pad 4 ® program. The level of 
significance used was p < 0.05 (Zar, 1974). 
  
 
                         
       
  
                 Equation 2.3 
 
Antioxidant and Antiradical Activity CHAPTER 2 
 
Page | 50  
 
2.4 RESULTS  
 
The free radical scavenging activity of the theanine, minocycline and vitamin C analysed 
over a concentration range is shown in Figure 2.3. The results illustrate that an increase in the 
percentage of DPPH radical scavenged correlates with an increase in the hydrogen donating 
ability and thus an increase in antioxidant activity. 
 
Figure 2.3 shows that although there is a change in the percentage of DPPH radical 
scavenged at different concentrations, there is no statistically significant change in percentage 
of free radical scavenging when the concentration is increased from 50µg/ml for all drugs. 
There is a statistically significant difference (p < 0.001) between the free radical scavenging 
properties of theanine in comparison to minocycline and vitamin C and no statistically 
significant difference between the free radical scavenging properties of minocycline and 
vitamin C.  
 
The colour changes of the solutions when the test compounds were added to DPPH were 
noted. The violet colour of the DPPH solution immediately changed to yellow on adding 
vitamin C and changed to yellow after 18 minutes on adding minocycline. With theanine 
however, the violet coloured solution only changed to a yellow solution after more than 6 
hours. 
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Figure 2.3: DPPH
● 
scavenging activity of theanine, minocycline and vitamin C at increasing concentrations. 
Each point represents the mean ± SD (n=3).      (p<0.001) in comparison to theanine (ANOVA followed by 
Student Newman-Keuls Multiple Range Test).                    
 
2.5 DISCUSSION 
 
The DPPH
●
 scavenging activity is influenced by the chemical structure of the radical 
scavenger (Sharma and Bhat, 2009). On a visual level, a slow colour change from the violet 
coloured DPPH radical solution to yellow implies that the reductant has poor hydrogen 
donating ability (Shimada et al., 1992). 
 
Vitamin C is a highly effective scavenger of the DPPH radical as evidenced by the violet 
coloured DPPH solution immediately changing colour to yellow on addition of vitamin C. 
Vitamin C has two sites for H abstraction thus two molecules of DPPH
●
 are scavenged per 
molecule of vitamin C (Figure 2.4) rendering it a very effective scavenger of DPPH and thus 
has been described as having rapid reaction kinetics with steady state being reached in less 
than 1 minute (Shimada et al., 1992; Brand-Williams et al, 1995; Molyneux, 2004). 
 
 
 
 
 
Antioxidant and Antiradical Activity CHAPTER 2 
 
Page | 52  
 
 
 
Figure 2.4: Structure of vitamin C 
(http://www/upload.wikimedia.org/wikipedia/commons/8/81/Ascorbic_acid_structure.png). 
 
Brand-Williams et al., (1995) have shown that certain compounds reactivity with DPPH 
corresponds to the number of available hydroxyl groups, where the number of available 
hydroxyl (OH) groups is related to the number of DPPH molecules scavenged. A proposed 
mechanism of DPPH
●
 scavenging activity by minocycline could be that the hydrogen is 
abstracted from a phenolic OH group and this leads to the formation of the diphenyl picryl 
hydrazine radical a phenol-derived radical (Lebeau et al., 2000; Saito and Kawabata, 2005) 
(Figure 2.5). Within its structure, minocycline has a dimethylamino substituent which 
provides for increased resonance stabilisation of the phenol-derived radical and increases 
steric stabilisation of the phenol-derived radical produced by the reaction (Kraus et al., 2005). 
The violet colour of the DPPH solution changes to yellow after 18 minutes incubation when 
minocycline is added, this indicates intermediate reaction kinetics when steady state is 
reached between 5-30 minutes (Brand-Williams et al, 1995).  
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Figure 2.5: Mechanism of radical scavenging by minocycline (Kraus et al., 2005). 
 
It has been shown in a previous study that radical scavenging capacity of half a cup of green 
tea is equivalent to 200 mg of vitamin C and that green tea has the greatest antioxidant power 
when compared to oolong and black teas (Miller et al., 2000; Gadow et al., 1997). Flavonoids 
in tea account for most of the antioxidant activity in tea (du Toit et al., 2001). Therefore, the 
presence of theanine in green tea also contributes to the antioxidant capacity of tea.  Although 
theanine possesses free radial scavenging properties, it has very slow reaction kinetics with 
steady state being reached in more than 6 hours. The colour change of the violet coloured 
DPPH radical solution is hardly changed when it is added. 
 
Free radicals are involved in lipid peroxidation and play a role in cardiovascular diseases 
(Dorman et al., 2003). Effective free radical scavengers must also be investigated for 
potential lipid peroxidation inhibitors as these may prevent the abstraction of hydrogen from 
susceptible PUFAs (Dorman et al., 2003) as well as cardiovascular protective properties. 
Minocycline has shown more promising results in vitro than theanine and its free radial 
scavenging properties are comparable to naturally occurring vitamin C.  
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 CHAPTER 3 
IRON CHELATION STUDIES 
 
3.1 INTRODUCTION 
 
Iron (Fe) is an essential element for all forms of life. Two thirds of body Iron is found in 
haemoglobin and transferrin (a transport protein) and the remaining iron is stored in ferritin 
and haemosiderin (Halliwell and Gutteridge, 1985). In the mammalian body, iron is used for 
the utilisation of oxygen and is a component of numerous oxidases and oxygenases 
(Puntarulo, 2005). Iron‟s bioavailability is hindered by its tendency to become oxidised, 
hydrolysed and polymerised into insoluble ferric hydroxide (Boyer et al., 1988a). 
 
Iron is a catalyst for the Haber-Weiss reaction (Section 1.2.2.5) by facilitating the conversion 
of superoxide anion radicals (O2•
-
)
 
and hydrogen peroxide (H2O2) to hydroxyl radicals (•OH) 
(Halliwell and Gutteridge, 1986). •OH is highly reactive and the damage it can do to the body 
is site specific depending on the location of the iron, which does not exist in a “free form” but 
is bound to proteinous membranes, nucleic acids and low molecular weight chelating agents 
(Halliwell and Gutteridge, 1986). For example, if the iron catalyst is attached to DNA, the 
Haber-Weiss reaction will lead to •OH dependent base modification and if the metal catalyst 
is attached to cell membranes, this will lead to lipid peroxidation (LP) (Halliwell and 
Gutteridge, 1986). Iron dependent LP requires chelated ferric ion (Fe
3+
) and ferrous-
dioxygen-ferric chelate complex as initiating species (Bucher et al., 1983; Decker and Welch, 
1990). There is no obvious physiological mechanism of disposing excess iron (other than 
menstrual periods), thus in a case of iron overload, the excess iron will lead to the generation 
of free radicals which will lead to harmful effects on cells (Halliwell and Gutteridge, 1986). 
Iron has been shown to play a role in neurodegenerative diseases such as Parkinson‟s disease 
(Babincová and Babinec, 2005) and an increase in iron in the substantia nigra is associated 
with oxidative stress due to the presence of free, redox active iron (Boyer et al., 1988b). 
Damaged to tissue by injury, infection makes it particularly vulnerable to radical reactions.  
 
Ferritin is the major storage protein for iron in bacteria, plants and mammals (Figure 3.1). It 
maintains iron in a soluble, non toxic form in which it may be easily mobilised (Boyer and 
McCleary, 1987; Babincová and Babinec, 2005). Ferritin is synthesised in response to iron 
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and acts as an iron “sink” (Halliwell and Gutteridge, 1985). Ferritin is composed of 24 tightly 
packed subunits and each molecule may store up to 4500 iron atoms as hydrous ferric oxide. 
It has narrow channels within it that lead to a central core (Funk et al., 1985). It is through 
these pores that Fe
2+
 moves during its mobilisation and deposition into the core in its oxidised 
form as Fe
3+
 (Gutteridge et al., 1983; Funk et al., 1985). A strong external chelator and 
reducing agent
 
is required for the removal of iron from ferritin (Jameson et al., 2004). 
However, it is still unclear which agents are responsible for the removal of iron in vivo. 
Ferritin iron has been shown to participate in the initiation of LP by the reduction of Fe
3+
 
within the core by reductants such as O2•
-
 (Gutteridge et al., 1983; Puntarulo, 2005). 
Puntarulo (2005) has observed that elevated levels of ferritin are associated with the severity 
of a stroke as well as elevated levels of O2•
-
 and H2O2. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Ferritin molecule showing where iron is stored within its structure  
(http://www.javeriana.edu.co/Facultades/Ciencias/neurobioquimica/libros/perinatal/ferritin1.jpg). 
  
Antioxidants are useful in scavenging free radicals and can thus prevent cell damage and 
there is a place for their use therapeutically in degenerative diseases. In plasma, antioxidants 
play a role in removing free radicals as well as preventing iron-mediated catalysis of free 
radical reactions (Halliwell and Gutteridge, 1986). In this way, antioxidants prevent or delay 
the primary and secondary effects of iron. The use of ferritin has been suggested as another 
therapeutic means of ridding the body of excess iron. Metal chelators have a therapeutic role 
Iron Chelation Studies CHAPTER 3 
 
Page | 56  
 
in cases of iron overload and these rid the body of potentially toxic iron by binding to iron 
compartmentalised metal ions (Halliwell and Gutteridge, 1986; Puntarulo, 2005). Nitric oxide 
is effective as an antioxidant as it chelates and scavenges free radicals (Puntarulo, 2005). 
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3.2 ULTRAVIOLET AND VISIBLE SPECTROSCOPIC ANALYSIS OF 
THEANINE AND MINOCYLCINE ALONE AND IN COMBINATION 
WITH      IRON (II) AND IRON (III) 
 
3.2.1 INTRODUCTION 
 
The fundamental principle that underlies spectrophotometric techniques is that all chemicals 
to some extent absorb electromagnetic radiation of specific wavelengths (Newman, 1965).  
This allows for the qualitative and quantitative determination of chemicals according to the 
extent to which they absorb electromagnetic radiation. Ultraviolet and visible (UV/VIS) 
spectroscopy is a spectrophotometric technique that measures the absorbance of 
electromagnetic radiation in the UV/VIS range in the electromagnetic spectrum which 
extends from 200 nm to 800 nm. 
 
When a chemical absorbs UV or VIS radiation, this causes the molecules within the solution 
to become “excited”, that is to say, the molecules assume a higher energy state (Silverstein et 
al., 1981). The electrons in the molecule are promoted from a bonding or non-bonding orbital 
into an empty anti-bonding orbital (Silverstein et al., 1981). Within the UV/VIS spectra, the 
electron is promoted from either a non bonding or pi (π) orbital to a pi anti-bonding (π*) 
orbital. This causes a release of energy in the form of heat or fluorescence (Newman, 1964).  
 
The chemical groups that absorb light in the UV/VIS range are those that possess atoms with 
non-bonding orbitals (in other words a lone pair of electrons) or π bonds (Silverstein et al., 
1981). Molecules such as unsaturated organic compounds, compounds with atoms such as 
oxygen (O) and nitrogen (N) which posses a lone pair of electrons and conjugated double 
bonds are most likely to have π bonding orbitals (Silverstein et al., 1981). 
 
Different molecules absorb light in different wavelengths so a qualitative analysis of an 
unknown chemical is possible from the absorption spectrum it produces (Newman, 1964). 
The wavelength of the light absorbed depends on the energy required for the electrons within 
its structure to make a transition to a higher energy state. An absorption band is defined by its 
intensity and position (Silverstein et al., 1981). The position of the absorption band 
corresponds to the wavelength of radiation and the intensity of the absorption band depends 
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on two factors namely, the probability of interaction between radiant energy and the 
electronic system and the difference between the ground and excited state of the electron 
(Silverstein et al., 1981).  
 
Any change in the structure or composition of a known system will result in a change in the 
spectrum in wavelength or intensity (Newman, 1965). It is on this principle that the 
interaction of theanine and minocycline with iron (II) and iron (III) will be investigated. 
 
3.2.2 MATERIALS AND METHODS 
 
3.2.2.1 Chemicals and reagents 
 
Theanine and minocycline were purchased from Sigma Chemical Corporation, St Louis, 
Missouri, United States of America. Hydrated ferrous sulphate (Fe
2+
SO4.7H20) and ferric 
chloride (Fe
3+
Cl3) were purchased from Saarchem, Wadeville, Gauteng, South Africa. All 
solutions were prepared using deaerated milli Q water to prevent auto oxidation of the iron. 
 
3.2.2.2 UV/VIS Spectroscopy 
 
The interaction between theanine and minocycline with iron (II) (Fe
2+
) and iron (III) (Fe
3+
) 
was studied by comparing the absorption spectra of the test compound alone and in 
combination with the iron solutions in equimolar concentrations of 0.1 mM to 1 mM. The 
absorption spectra were determined using a GBC UV/VIS 916 spectrophotometer using 
quartz cuvettes with a path length of 1 cm.   
 
3.2.3 RESULTS 
 
No peaks corresponding to an absorption band were observed for theanine in the ultraviolet 
and visible range of the spectra.  
 
Minocycline produces a yellow coloured aqueous solution. Figures 3.2 and 3.3 show that the 
absorption bands of 1mM minocycline occur between 308 nm and 343 nm and between 343 
nm and 395 nm with λmax values of 349 nm and 359 nm. The figures also show that a 
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decrease in absorptive intensity occurs when Fe
2+
 and Fe
3+ 
respectively were added to 
minocycline. A concentration of 0.1mM of minocycline produced the same results shown 
below. 
 
 
 
Figure 3.2: UV spectroscopic analysis of minocycline alone and in the presence of an equimolar concentration 
1mM of Fe
2+
. 
 
 
 
Figure 3.3: UV spectroscopic analysis of minocycline alone and in the presence of an equimolar concentration 
1mM of Fe
3+
. 
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3.2.4 DISCUSSION 
 
It was expected that theanine would not produce a spectrum due to the fact that although 
theanine does possess atoms with lone pairs such as nitrogen (N) and oxygen (O), it is not 
highly delocalised which makes it more likely to produce a spectrum in the UV/VIS range. A 
study by Fu et al. (2007) shows that theanine can be detected in tea samples but with an 
indirect method of UV analysis. 
 
Minocycline on the other hand, is a molecule with several types of delocalised systems within 
its structure. It contains benzene rings, carbon-oxygen double bonds and the lone pairs of 
electrons on the N and O within its structure (Figure 3.4). This makes it possible for the 
electrons in this structure to be excited to a π* orbital.  The minocycline is a yellow coloured 
solution. Yellow coloured solutions have wavelengths in the range 435 nm to 500 nm 
associated with them and the λmax values of 349 nm and 359 nm obtained for minocycline 
correspond with this. 
 
 
 
Figure 3.4: Chemical structure of minocycline (http://www.pharmgkb.org/images/drugs/PA450519-1.gif). 
 
As previously mentioned, any change in the structure or composition of a known system will 
result in a change in the spectrum in terms of wavelength or intensity (Section 3.2.1). There 
was a decrease in the intensity of the minocycline absorption spectra on addition of Fe
2+
 and 
Fe
3+
. This may be attributed to the fact that on mixing two compounds, there is a change in 
the intensity of the wavelength that may be attributed to the fact that there was interaction 
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between the minocycline and iron atoms or that the iron interferes with the absorption of 
minocycline.  
 
The results then indicate that there is interaction between minocycline and iron. However, 
UV/VIS spectroscopy alone does not identify definite interactions therefore, electrochemistry 
and other experiments would have to be conducted to determine the nature of interaction if 
any, between the minocycline, theanine and iron. 
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3.3 ELECTROCHEMICAL ANALYSIS OF IRON (III) ALONE AND IN THE 
PRESENCE OF THEANINE OR MINOCYCLINE 
 
3.3.1 INTRODUCTION 
 
Electrochemistry is described as a scientific field that deals with the relation between 
electrical current or potential and a chemical system (Rubinstein, 1995). Cyclic voltammetry 
and adsorptive stripping voltammetry (AdSV) are interfacial electrochemical techniques that 
are classified as controlled potential techniques (Limson, 1998). Both methods make use of 
an electrical cell which consists of working, reference and auxiliary electrodes (Figure 3.5) 
(Bard and Faulkner, 1980; Limson, 1998).   
 
 
 
Figure 3.5: An electrochemical cell showing the three electrode system 
(http://www.cce.paisley.ac.uk/marco/Enzyme_Electrode/Chapter1/Ferrocene_animated_CV1.htm). 
 
The chemical reactions take place on the surface of the electrode and involves the transfer of 
electrons, known as redox reactions (Rubinstein, 1995), where redox stands for reduction and 
oxidation. The current (i), that passes through the electrode is directly proportional to the flux 
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of redox active material on the surface of the electrode, which in turn is proportional to the 
concentration of the species at the electrolyte-electrode interface (Bard and Faulkner, 1980), 
thus, current is a direct measurement of the reaction rate (Rubinstein, 1995). Electron transfer 
that occurs at the electrolyte-electrode interface is observed as the current (Bard and 
Faulkner, 1980). 
 
The working electrode imparts information such as a change in potential which may indicate 
a variation in electrode reaction (Bard and Faulkner, 1980). It is at this electrode that the 
analyte is either oxidised or reduced. The reference electrode maintains a constant potential 
and is isolated from the solution (Bard and Faulkner, 1980). The auxiliary electrode is in 
direct contact with the reaction solution and allows for the passage of electrons through it 
which results in a current through the cell that may be picked up externally (Bard and 
Faulkner, 1980). 
 
Cyclic voltammetry and AdSV were the 2 electrochemical methods chosen to analyse the 
ability of theanine and minocycline to bind to Fe
3+
 under deaerated conditions. These studies 
were conducted in aqueous media and under biological pH conditions. 
 
3.3.1.1 Cyclic voltammetry 
 
Cyclic voltammetry is an electrochemical technique used to characterise the redox properties 
of organic compounds (Bard and Stratman, 1954; Limson, 1998). The technique of cyclic 
voltammetry involves the application of a linear electrical potential gradient (relative to the 
reference electrode) across the electrode–solution interface (at the working electrode) to 
oxidise or reduce the species in solution (Ligumsky et al., 2005). The cyclic voltammogram 
produced of current versus potential where the current produced results from the applied 
potential and depends on a number of parameters such as the area of the electrode and the 
rate at which the potential is applied (Bard and Faulkner, 1980; Wang, 1994).  The potential 
and current will give information about whether the molecules are able to donate electrons 
(Wang, 1994).  The lower the current, the lower the reducing potential of the substrate. The 
voltammetric waves produced are in a peak-shaped or sigmoidal form (Wang, 1994). The 
voltammogram that is produced with this technique consists of a forward and reverse scan. 
The forward scan or positive potential show the oxidised species and the reverse scan or 
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negative potential show the reduced species (Limson, 1998).  Peaks formed in the scan are 
caused by the formation of the diffusion layer near the electrode surface (Bard and Faulkner, 
1980). 
 
The shape of the current wave is determined by several factors and it will give information 
concerning the analyte. The interpretation of the cyclic voltammogram can be made based of 
the peak location on the current axis, the size of the anodic current and the peak potential 
(Ligumsky et al., 2005). The peak location on the current axis reflects the ability of the 
compound to donate electrons, the size of the anodic current is proportional to the 
concentration of the substrate in the bulk solution and thus can be used to monitor the 
concentration and the peak potential is defined as the reducing power of the substrate 
(Ligumsky et al., 2005). 
 
Cyclic voltammetry is used to determine the reducing power of the substrate under 
investigation and is often conducted first in an electroanalytical study (Bard and Faulkner, 
1980; Ligumsky et al., 2005).  Theanine and minocycline were analysed with this method to 
access their reducing power and AdSV was then carried out to access the interaction with 
Fe
3+
 with theanine and minocycline. 
 
3.3.1.2 Adsorptive stripping voltammetry 
 
This is a sensitive electrochemical technique that is employed in the measurement of trace 
metals (Limson, 1998). AdSV involves continuous stirring of the solution at a fixed rate 
allowing the convention of the analyte to the electrode and allows the metal to bind to the 
ligand (Limson, 1998).  The metal-ligand complex is then adsorbed onto the electrode surface 
(adsorption or electrodeposition) and thereafter the stripping step takes place where the 
metal-ligand complex is released back into solution (Limson, 1998). This technique therefore 
relies on the formation of surface active complexes of the target metal in the presence of a 
complexing agent followed by the accumulation of the complex onto a film electrode (Bard 
and Stratman, 1954). This method is useful for the analysis of very dilute solutions down to 
concentrations of 10
-10
 to 10
-11
 molar solutions, as well as for trace metals that exhibit surface 
active properties (Wang, 1994). 
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3.3.2 MATERIALS AND METHODS 
 
3.3.2.1 Chemicals and reagents 
 
As described in section 3.2.2.1. Tris hydroxymethyl amino methane (tris-HCl) was purchased 
from Merck, Darmstadt, Germany. 
 
3.3.2.2 Apparatus 
 
Cyclic and adsorptive stripping voltammograms were recorded on an Autolab PGSTAT 30 
voltammeter (Netherlands) equipped with a Metrohm VGA cell stand (Sweden). A 3mm 
glassy carbon electrode (GCE) was employed as the working electrode for the voltammetric 
experiments. A silver/silver chloride (Ag/AgCl) [(KCl = 3 M)] and a platinum wire were 
used as the reference and auxiliary electrodes respectively, in all the voltammetric 
experiments. Prior to use and between the scans, the GCE was cleaned by polishing with 
alumina on a Buehler pad,  followed by immersion in dilute nitric acid solution and rinsing in 
milli Q water. 
 
3.3.2.3 Cyclic voltammetry 
 
For the cyclic voltammetry experiments, appropriate concentrations of theanine or 
minocycline were added to the electrochemical cell containing the electrolyte 0.2 M tris-HCl 
buffer, pH 7.4 which was then deaerated for 5 minutes. A potential window was then scanned 
to characterise and provide a fingerprint of the species in solution. The GCE was then cleaned 
and polished as described in section 3.3.2.2. 
 
Changes in the current response and potential were observed in order to investigate whether 
theanine and minocycline were electrochemically active. 
 
3.3.2.4 Adsorptive stripping voltammetry 
 
An appropriate concentration of Fe
3+
SO4 was introduced into an electrochemical cell 
containing the electrolyte, 0.2 M tris-HCl buffer (pH 7.4) which was then deaerated for 5 
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minutes. Thereafter, an optimum deposition of potential for Fe
3+
 was identified and applied 
for 60 seconds to effect the formation and adsorption of the meat lino onto the GCE. A 
potential scan in the negative direction from the deposition potential to at least 0.20 V beyond 
the reduction of the metal was applied, at a scan rate of 0.10 Vs
-1
, to strip the adsorbed metal 
species from the GCE.  
 
During the stripping step, current responses due to the reduction of the metal species were 
measured as a function of potential to generate voltammograms. The GCE was then cleaned 
and polished as described in section 3.3.2.2. The procedure was then repeated between 
successive additions of appropriate concentrations of either theanine or minocycline (0-0.06 
mM) to the electrolyte containing Fe
3+
 in the electrochemical cell. All reported potential 
values are referenced against the Ag/AgCl reference electrode. Current versus concentration 
plots were constructed to measure the extent of shifts in current response and reduction 
potential of metal with increasing concentrations of the ligand (either theanine or 
minocycline). Green tea is rich in polyphenols which have been shown to interfere with iron 
metabolism due to the formation of strong complexes (Hynes and Coinceanainn, 2002). This 
method of electrochemical analysis will help to determine if theanine, which is a component 
of green tea, has the potential to form complexes with iron. 
 
3.3.3 RESULTS 
 
The voltammograms have the current axis labelled i/A which represents recorded current (i) 
in amperes (A) and the potential axis labelled E/V which represents the potential (E) in volts 
(V). Figures 3.6 and 3.7 show the cyclic voltammograms obtained for theanine and 
minocycline respectively.  A smooth shaped of the voltammogram for theanine was obtained 
(Figure 3.6). A voltammogram with peaks (shown by the arrows) was obtained for 
minocycline (Figure 3.7) with peaks at 0.4105 V, 0.1495 V and -0.1441V. 
 
The adsorptive stripping voltammogram for Fe
3+
 (0.01 mM) alone and in the presence of 
increasing concentrations of theanine shown in Figure 3.7. There is a peak current response at 
-8.33 x 10
-6
 A at a reduction potential of -0.3603 V for Fe
3+
 in solution and a concentration 
dependent reduction shift in the reduction potential of Fe
3+
 towards less negative potentials. 
A similar voltammogram was obtained for minocycline. 
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Figure 3.6: Cyclic voltammogram of theanine alone. 
 
 
 
Figure 3.7: Cyclic voltammogram of minocycline alone. 
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Figure 3.8: Adsorptive stripping voltammogram for Fe
3+
 (0.01 mM) alone and in the presence of increasing 
concentrations of theanine, abbreviated to thea (0.01 - 0.03 mM).  
 
The percentage changes of increasing concentrations of theanine and minocycline on the peak 
current response of Fe
3+
 were calculated and presented in graphical means (Figures 3.9 and 
3.10).  A comparison of the ratio of added test compound to iron and the percentage increase 
in peak current response is represented in Table 3.1 in order to compare the relative 
difference in iron binding of both drugs as the concentrations of Fe
3+
 used to calculate the 
percentage increase in peak current response were 0.01 mM and 0.03 mM of Fe
3+
 for 
theanine and minocycline respectively. 
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Figure 3.9: The percentage increase in the current of increasing concentrations of theanine on the peak current 
of 0.01 mM Fe
3+
 
 
 
Figure 3.10: The percentage increase in the current of increasing concentrations of minocycline on the peak 
current of 0.03 mM Fe
3+
. 
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Table 3.1: The ratios of the Fe
3+
 to test compound and the corresponding percentage increase in the current. 
Ratio of Fe
3+
 to test compound 
% Increase in current 
Minocycline Theanine 
0:1 0 0 
1:1 38 40 
1:2 46 56 
 
 
3.3.4 DISCUSSION 
 
The smooth shape of the cyclic voltammogram for theanine implies that it may not be 
electrochemically active. This may be due to the fact that within the theanine molecule, there 
are very few electrons that could take part in an electrochemical reaction. The peaks (shown 
by the arrows) on the cyclic voltammogram for minocycline, indicate that it is 
electrochemically active due to the numerous electrons it contains within the benzene rings, 
carbon-oxygen double bonds and the lone pairs of electrons on the N and O within its 
structure.  
 
Chelators affect the reduction potential of iron (the ease with which it is reduced) and thus its 
effectiveness as a catalyst (Winterbourn, 1995). In the Fenton reaction, Fe
3+
 is reduced to 
Fe
2+
 and it is the reduced form of iron that catalyses the Haber-Weiss reaction in which toxic 
hydroxyl radicals (•OH) are formed. Thus in the presence of a chelator, Fe3+ will either be 
reduced to form the ferrous ion or the oxidation of the Fe
2+
 iron to form the ferric ion. In this 
experiment, the formation of complexes of the test drug with Fe
3+
 was investigated because it 
is the ferric ion that is reduced in the Fenton reaction whose product (Fe
2+
) ultimately 
catalyses the formation of •OH from the superoxide anion and hydrogen peroxide. 
 
The increase in the reduction potential of iron when both theanine and minocycline is added 
to it shows that complexes are formed with the iron (Figure 3.8). Figure 3.9 further confirms 
this showing a concentration dependent formation of the theanine-Fe
3+ 
and minocycline-Fe
3+ 
complexes. In the UV/VIS study it was concluded that there was a reduction in the intensity 
of the wavelength that may be attributed to the fact that there was interaction between the 
minocycline and iron atoms or that the iron interferes with the absorption of minocycline 
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(section 3.2.4). The AdSV results indicate that there is definitely interaction between the 
minocycline and iron in terms of the formation of a complex.  
 
The gradients of the percentage changes in current (Figures 3.9 and 3.10) are 2439.8 and 
871.79 for theanine and minocycline respectively. The steeper gradient and higher value for 
the gradient of theanine implies that the complexes that it forms with iron are formed at a 
faster rate than the minocycline-iron complexes. However such a conclusion cannot be drawn 
due to the different concentrations of Fe
3+
 that were used to generate the respective AdSV 
voltammograms. Thus a comparison of the ratios of added test compound to iron and the 
percentage increase in peak current response was calculated and represented in Table 3.1 
which shows that theanine has a higher percentage increase than minocycline in peak current 
response as there is an increase in theanine.  
 
These results can be used to deduce that theanine produces complexes with ferric ions that 
are stronger than the complexes formed between minocycline and the ferric ions. The fact 
that both test compounds form complexes also implies that the complexes formed are strong 
enough to hinder the reduction of Fe
3+
 at the electrode and thus slow the cathodic current 
flow.  However from the results above, it cannot be concluded how many ligands are required 
to completely hinder the iron from being reduced and how strong the chelating activity of the 
test compounds is. A further study will be carried out with ferrozine to determine strength of 
theanine and minocycline in inhibiting the formation of the iron (II)-ferrozine complex in the 
presence of ferritin. 
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3.4 THE COMPARATIVE EFFECTS OF THEANINE AND MINOCYCLINE 
ON THE INHIBITION OF THE IRON (II)-FERROZINE COMPLEX 
 
3.4.1 INTRODUCTION 
 
Ferrozine whose chemical name is 3-(2-Pyridyl)-5, 6-diphenyl-1, 2, 4 triazine 4‟4‟‟disulfonic 
acid sodium (Figure 3.11), is an effective chelator of Fe
2+
 and forms a magenta coloured 
solution. The Fe
2+
-ferrozine complex (Figure 3.12) is made up of the metal and ligand in the 
ratio of 1 to 3, it has a λmax of 562 nm and the Beer-Lambert law is obeyed up to 4 mg/L of 
iron (Stookey, 1970).  
 
 
 
Figure 3.11: Illustration of the ferrozine ligand. The left figure is a stick representation of the indicator ligand 
ferrozine and the right figure is a ChemDraw representation of the ligand. The nitrogen atoms on ferrozine form 
a coordinate bond with Fe (II). In this illustration, the colours of the carbon atoms are green, the hydrogens are 
white, the nitrogen atoms are blue, the oxygen atoms are red, and the sulphur atoms are yellow in this stick 
representation. (http://www.chemistry.wustl.edu/~edudev/LabTutorials/Ferritin/ferrozine.html). 
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Figure 3.12: A stick representation of the complex ferrozine forms with iron. In this illustration, Fe (II) is 
complexed with three (3) ferrozine ligands. The colours of the carbon atoms are green, the hydrogens are white, 
the iron atoms are magenta, the nitrogen atoms are blue, the oxygen atoms are red, and the sulphur atoms are 
yellow in this stick representation. (http://www.chemistry.wustl.edu/~edudev/LabTutorials/Ferritin/feferr.html). 
 
Ferrozine may be used for the direct determination of iron in aqueous solutions. The 
advantages of using ferrozine for the quantitative determination of iron are that it has 
minimum interferences, low cost and the high sensitivity of the experiment. In the presence 
of other chelating agents, the formation of the Fe
2+
-ferrozine complex is inhibited or reduced 
depending on the other chelator‟s effectiveness and this results in a decrease in the colour of 
the complex. EDTA has been shown to be an effective inhibitor of the formation of the Fe
2+
-
ferrozine complex (Boyer and McCleary, 1987).  
 
The measurement of the inhibition of the Fe
2+
-ferrozine complex is important in determining 
whether a drug will have an affinity for Fe
2+
and thus whether the drug will enhance or inhibit 
the Fenton reaction which involves the reduction of Fe
3+ 
to Fe
2+
. The purpose of this 
experiment is to investigate if theanine and minocycline inhibit the formation of  
Fe
2+
-ferrozine complex and thus their potential as therapeutic agents in neurodegenerative 
diseases.  
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3.4.2 MATERIALS AND METHODS 
 
3.4.2.1 Chemicals and reagents 
 
Theanine, minocycline and ferrozine were purchased from Sigma Chemical Corporation, St 
Louis, Missouri, United States of America. EDTA and ferrous sulphate (Fe
2+
SO4) were 
purchased from Saarchem, Wadeville, Gauteng, South Africa. It is suggested that glassware 
is soaked in concentrated acid to ensure satisfactory and reproducible results (Stookey, 1970). 
 
3.4.2.2 Chelating activity of theanine and minocycline  
 
The chelating activity of theanine and minocycline was assessed by using a modified method 
of Decker and Welch (1990) is outlined below: 
 
A 1 ml solution of the test compound (theanine or minocycline) in increasing volumes (0-100 
µg/ml) was added to 3.7 ml milli-Q water. To this, 0.1 ml of Fe
2+
SO4 (2 mM) and 0.2 ml of 
ferrozine (5 mM) were added. The reaction mixture was then incubated at room temperature 
for 20 minutes. The absorbance of the reaction mixture was then measured at 562 nm using a 
Shimadzu UV mini 1240 UV/VIS spectrophotometer. A low absorbance value indicated a 
higher chelating activity of the test compound being analysed. 
 
The percentage of the Fe-ferrozine complex formation was calculated using the following 
equation: 
 
 
 
Where, 
     = absorbance of the control (reaction mixture without the test compound)  
  = absorbance of the reaction mixture in containing the different concentrations of 
the test compound.  
 
                                             
     
  
            Equation 3.1 
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In this reaction, EDTA is at the same concentrations as the test compounds and was used as a 
positive control. 
 
3.4.2.3 Statistical Analysis 
 
The results were analysed using a one-way ANOVA followed by the Student Newman-Keuls 
Multiple Range Test using the Graph Pad 4 ® program. The level of significance used was p 
< 0.05 (Zar, 1974). 
 
3.4.3 RESULTS 
 
Figure 3.13 shows that both theanine and minocycline are ineffective in the chelation Fe
2+
 
and the inhibition of the formation of Fe
2+
-ferrozine complex despite an increase in 
concentration. There is a statistically significant difference between the percentage inhibition 
to the formation of the complex by EDTA in comparison to both theanine and minocycline.  
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Figure 3.13: Percentage inhibition of the Fe
2+
-ferrozine complex by theanine, minocycline and EDTA. Each 
point represents the mean ± SD (n=5).   (p < 0.001) in comparison to EDTA (ANOVA followed Student 
Newman-Keuls Multiple Range Test).    
                 
3.4.4 DISCUSSION 
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As previously mentioned, ferrozine is a very strong iron chelator (section 3.4.1) and it forms 
a stable complex with iron that has a high extinction coefficient (Boyer et al., 1988). Thus, 
addition of the Fe
2+
SO4 to the reaction mixture before adding the ferrozine would give the 
test compounds the opportunity to chelate with the ferrous sulphate before the stronger 
chelating agent ferrozine was added and once added there would be competition for the 
chelation of the iron. There would be evidence of this as there would most probably be a 
gradual colour change as the ferrozine binds to the iron during the incubation period. 
However, theanine and minocycline show very poor inhibition to the formation of the 
magenta coloured Fe
2+
-ferrozine complex even at high concentrations of 100 µg/ml. There is 
a statistically significant difference between both theanine and minocycline‟s percentage 
inhibition of the Fe
2+
-ferrozine complex and that of EDTA. EDTA has been shown to be an 
effective inhibitor of the formation of the Fe
2+
-ferrozine complex (Boyer and McCleary, 
1987) and the hyperbolic curve that is produced suggests that the concentration range results 
in saturation kinetics, implying that at concentrations greater than 100 µg/ml, it  may be  
100 % effective in inhibiting the formation of the complex. 
 
Theanine and minocycline have exhibited poor iron (II) binding which would initiate even 
weaker iron (III) binding as the ferrous ion is more liable than the ferric ion. 
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3.5 THE COMPARATIVE EFFECTS OF THEANINE AND MINOCYCLINE 
ON THE RELEASE OF IRON (II) FROM FERRITIN 
 
3.5.1 INTRODUCTION 
 
Ferritin, as previously mentioned (Section 3.1) is the storage form of iron. In vitro, iron can 
be mobilised from ferritin by direct chelation of the ferric ion or by the presence of a 
chelating agent (Funk et al., 1985). The channels within the ferritin molecule are narrow and 
are mechanically involved in the deposition and mobilisation of iron (Jameson et al., 2004). 
A potential reductant must be able to penetrate the shell of the ferritin molecule in order to 
access the Fe
3+
 within its core and protonate the hydroxide ions that are coordinated to the 
surface of the ferric ion in hydrous ferric oxide (Funk et al., 1985). Both a chelator and 
reductant are required for the effective release of ferrous iron from ferritin, the iron is 
released very slowly or ineffectively when only one is present (Jameson et al., 2004). Ferritin 
has been shown to stimulate LP which leads to cell damage (Puntarulo, 2005). Green tea has 
been shown to lead to a decrease in ferritin concentrations in the plasma (Hynes and 
Coinceanainn, 2002) and as theanine is a component of green tea it could potentially 
contribute to this effect.  
 
Ferrozine is an effective chelator, however, when mixed with ferritin, it forms the  
Fe
2+
-ferrozine complex at a very slow rate. Ferrozine is unable to enter the ferritin protein 
shell due to its large size and its overall charge of -1 at physiological pH (Jameson et al., 
2004). Although reducing agents such as O2•
-
 are effective in the removal of ferritin bound 
Fe, ferrozine is superior to these as a chelator (Boyer et al., 1988). 
 
Ferritin is principally found in the spleen, liver and bone marrow (Aisen, 1980), hence the use 
of horse spleen ferritin. In this experiment, the amount of iron released from ferritin will be 
measured as a percentage of control values. The iron released from ferritin will form a 
complex with ferrozine which will be detectable spectrophotometrically. 
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3.5.2 MATERIALS AND METHODS 
 
3.5.2.1 Chemicals and reagents 
 
Theanine, minocycline, ferrozine and horse spleen ferritin were purchased from Sigma 
Chemical Corporation, St Louis, Missouri, United States of America. 
 
3.5.2.2 Iron release from ferritin assay  
 
Iron release from ferritin was determined by the spectrophotometric measurement of the   
Fe
2+
-ferrozine complex by a modified method of Babincová and Babinec (2005) described 
below: 
 
In order to prevent auto oxidation from dissolved gases and any free metals that may be 
within the glassware, the milli Q water was deaerated with nitrogen gas (N2) and all 
glassware was soaked in hydrochloric acid (Stookey, 1970). The reaction mixture containing 
200 µg/ml of ferritin, 0.2 mM of ferrozine and the test compound in increasing 
concentrations (0.025, 0.050, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 and 1 mM) was 
incubated at 37 
o
C in phosphate buffered saline (PBS) (pH 7.4) for 20 minutes. The 
absorbance of the reaction mixture was then measured at 562 nm using a Shimadzu UV mini 
1240 UV/VIS spectrophotometer.  
 
The control mixtures contained no test compound.  The amount of iron released from ferritin 
by the test compounds theanine and minocycline was expressed as a percentage of the control 
values and compared to EDTA a known inhibitor of the Fe
2+
-ferrozine complex. 
 
3.5.2.3 Statistical analysis 
 
This was performed as described in Section 2.2.2.3. 
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3.5.3 RESULTS 
 
Figure 3.14 illustrates the concentration dependent release of iron as Fe
2+
 from horse spleen 
ferritin. Theanine at a concentration of 0.8mM increases the release of iron by a mere 11 % in 
comparison to minocycline which increases the release of iron by 61 % in comparison to 
control values. There was a significant difference between all the compounds. 
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Figure 3.14: Release of iron from ferritin by theanine and minocycline expressed as a percentage of control 
values. Each point represents the mean ± SD (n=5).     (p < 0.001) in comparison to other compounds (ANOVA 
followed by Student Newman-Keuls Multiple Range Test).                    
 
3.5.4 DISCUSSION 
 
The ferritin assay is useful for testing the effectiveness of various reductants as ferritin iron 
releasing agents (Boyer et al., 1987). The iron release is trapped and chelated by the 
ferrozine. The equations below (modified from Boyer et al., 1987) explain how a drug 
participates in the mobilisation of ferritin iron: 
 
 
                 
 
                       
   
                Equation 3.2 
 
                                     
               Equation 3.3 
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An increase in percentage of iron release indicates that theanine and minocycline are able to 
mobilise Fe
2+ 
from the ferritin core and make it available for the catalysis of the Haber-Weiss 
reaction (although theanine will do so to a lesser extent). Theanine only exhibits an increase 
of greater than 100 % in iron release at concentrations 0.3, 04 and 0.5mM releasing 120 %, 
107 % and 115 % respectively.  This implies that theanine is inefficient in reducing Fe
3+
 and 
is thus a poor reductant. However theanine is indeed statistically significantly more efficient 
than EDTA as a reductant. This is because EDTA is an efficient inhibitor of the iron (II)-
ferrozine complex and thus causes a reduction in percentage iron released that is less than 
control conditions.  
 
Fe
3+
 chelators have been shown to cause ferritin iron removal although the rates are very 
slow (Boyer et al., 1987). Minocycline has been shown to form complexes with Fe
3+
 
(Sections 3.2.4 and 3.3.3) and is most likely to bring about the reduction of iron (III) from 
within the ferritin core. It has shown to bring about a statistically significant increase in the 
iron mobilised from ferritin than theanine and EDTA. Because minocycline can complex 
with the Fe
2+, it will prevent it from participating in the formation of toxic •OH. 
 
In oxidative stress conditions, the iron is made available for initiation of LP by two 
mechanisms: the release of iron from the ferritin core by theanine and minocycline and by the 
mobilisation of iron by O2•
-. This will lead to the synthesis of •OH which will ultimately lead 
to lipid peroxidation. 
 
The brain is rich in PUFAs which make it particularly susceptible to attack by free radicals 
and it has the ability to readily accumulate iron. Zaleska and Floyd (1985) found that a linear 
relationship exists between the susceptibility of various rat brain regions to undergo LP in 
vitro and their content of endogenous iron. An agent that can prevent iron from catalysing the 
formation of free radicals and bind to iron and prevent it from accumulating in the brain will 
prove to be neuroprotective to a certain extent. Although both test compounds are poor 
inhibitors of the iron-ferrozine complex and thus prove to at least prevent iron chelate-
mediated LP, these can promote the release of iron from ferritin thus making it available to 
take part as a catalyst in free radical reactions. 
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Effective and potential drug agents will be those that are able to form complexes with Fe
2+
 
and react with bound Fe
3+
. Overall, minocycline has been shown to be more effective than 
theanine in both these aspects. It will however need to be assessed in its role in other 
reactions such as lipid peroxidation to show its effectiveness as a potential neuroprotective 
agent.  
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 CHAPTER 4 
 
    LIPID PEROXIDATION  
 
4.1 INTRODUCTION 
 
The major constituents of biological membranes are proteins and lipids. PUFAs are lipids that 
contain more than 2 carbon-carbon double covalent bonds. PUFAs are essential for normal 
cell functioning as these confer properties such as fluidity and permeability to the membrane 
that surrounds a cellular structure. Examples of PUFAs include arachidonic, docosaetraenoic 
and docosahexanoic acids. LP is an irreversible radical reaction that occurs when hydrogen is 
abstracted from PUFAs. PUFAs are especially vulnerable to attack by free radicals since the 
double bond within the fatty acid weakens the carbon-hydrogen bonds on the carbon adjacent 
to the double bond (Halliwell and Gutteridge, 1989). Saturated fatty acids do not have these 
double bonds and are therefore less susceptible to oxidation by free radicals (Etsuo et al., 
2005). LP results in the impairment of membrane function, decrease in fluidity, increase in 
non-specificity in permeability to ions such as calcium (Ca
2+
) and the inactivation of 
membrane-bound receptors and enzymes (Gutteridge and Halliwell, 1990). 
 
Endogenous LP occurs in response to oxidative stress. The LP radical chain reaction takes 
place in three stages: chain initiation, propagation and termination. The overall reaction is 
illustrated by the scheme shown in Figure 4.1. LP is initiated by the attack of the lipid by a 
chemical species that has sufficient reactivity to abstract a hydrogen from the lipid (LH) and 
thus cause the formation of a hydrogen radical (H•) and a carbon centred radical (L•). The 
latter which is highly reactive, becomes stable by the abstraction of hydrogen from another 
chemical species (Laguerre et al., 2007). The propagation step takes place in aerobic 
conditions, during which the L• is converted into a lipid peroxyl radical (LOO•) (Equation 
4.1) and this radical reacts in a „self-sustained‟ reaction to form hydroperoxide (LOOH) and 
another L• radical (Equation 4.2).  
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The final step of chain termination occurs when LOOH is converted into secondary 
nonradical oxidation compounds (Halliwell and Gutteridge, 1999; Laguerre et al., 2007). A 
single initiation could lead to the conversion of several fatty acid chains into LOOH 
(Gutteridge and Halliwell, 1990). 
 
 
 
Figure 4.1: Mechanisms involved in LP (Gutteridge and Halliwell, 1990) 
 
LH 
 
 
 
 
 
 
 
 
 
Chain Propagation 
O2  (Aerobic conditions) 
Chain Termination 
L  
 
LOO         (Peroxyl radical) 
 
LOOH      (Lipid hydroperoxide) 
 
Non-radical compounds 
H• abstraction that occurs  
on several places on the lipid Chain Initiation 
H• abstraction from adjacent  
membrane lipid 
                     Equation 4.1 
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LOOHs are the primary product of LP and decompose rapidly in the presence of iron or 
copper ions, iron proteins such as haemoglobin and simple chelates of these ions (Gutteridge 
and Halliwell, 1990; Moore and Jackson-Roberts, 1998). The quantity of LOOHs produced 
depends on the number of double bonds present in the lipid molecule (Esterbauer, 1993). The 
mechanisms of the secondary and tertiary reaction of the LOOHs include chain cleavage, 
rearrangement and di- and polymerisation reactions (Esterbauer, 1993). Tissue or cell death 
leads to more LP due to the release of metal ions that are released by damaged cells and 
antioxidants within the tissue being diluted out (Gutteridge and Halliwell, 1990). LP is often 
a late event that accompanies rather than causes final cell death (Smith et al., 1983; 
Gutteridge and Halliwell, 1990). 
 
Transition metals such as copper and iron and their chelates are known to initiate LP by 
decomposing peroxides to radicals that are capable of abstracting hydrogen from the lipid and 
continuing the chain reaction (Bucher et al., 1983; Gutteridge and Halliwell, 1990). Iron is 
the most important catalyst of LP as it takes part in electron transfer reaction with oxygen 
(Halliwell and Gutteridge, 1989). Iron catalyses the Haber-Weiss reaction (Equation 1.3) 
where O2
•-
 is converted to •OH as well as the Fenton reaction (Equation 1.2) where H2O2 is 
also converted to •OH. In vivo animal studies have shown that treatment with iron complexes 
results in a significant increase in LP (Winterbourn et al., 1991). The •OH does not to initiate 
LP as concomitant addition of •OH scavengers does not inhibit LP (Bucher et al., 1983). 
Copper catalyses the formation of •OH from H2O2 (Halliwell and Gutteridge, 1984a) and 
decomposes lipid peroxides to form cytotoxic carbonyl compounds, hydrocarbon gases and 
free radicals that can continue the chain initiation reaction in LP (Gutteridge and Halliwell, 
1990). Cells that have been injured by heat, mechanical trauma, infections and oxygen 
deprivation in the case of ischaemia, release metal ions which lead to a significant increase in 
LP in surrounding tissues (Gutteridge and Halliwell, 1990). Iron and copper also cause the 
acceleration of the decomposition of lipid peroxides by causing the fission of the O-O bond 
to form an alkoxyl radical (LO•) (Halliwell and Gutteridge, 1999). Heavy metals such as 
cadmium, cobalt, lead and nickel have been shown to increase the rate of lipid peroxidation 
(Kappus, 1987). 
 
Antioxidant defences that protect the body from radical damage are divided into 4 categories 
according to their mechanism of action: antioxidants that prevent the formation of active 
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oxidants, free radical scavengers, those that quench and remove active oxidants and those that 
repair damage and excrete toxic oxidation products (Etsuo et al., 2005). The inhibition of LP 
occurs by the action of low molecular weight antioxidants, protective enzymes and low 
oxygen tension (which is protective) and by chelation of metal ions (Barber and Bernhein, 
1967; Esterbauer, 1993). Antioxidants act by providing hydrogen that can easily be abstracted 
by peroxyl radicals (Gutteridge and Halliwell, 1990). Intracellular antioxidants such as SOD 
and GSH peroxidise act by removing reactive oxygen species before they react with iron 
(Gutteridge and Smith, 1988). There are however no antioxidant enzymes in the extracellular 
fluid and the antioxidant mechanism employed is to limit radical reaction by converting pro-
oxidant forms of iron and copper into less reactive forms by binding such ions to proteins 
(Gutteridge and Smith, 1988). The binding of metal ions to proteins prevents these from 
accelerating LP and other free radical reactions. Chelators such as EDTA inhibit both 
enzymatic and non enzymatic reactions that catalyse LP. 
 
Cell damage by ROS and LP plays a crucial role in the pathogenesis of several chronic and 
acute diseases such as cancer, inflammation and ischaemia (Sies, 1991). Levels of 
malondialdehyde (MDA) which is an aldehyde formed from the decomposition of LOOH, or 
MDA-like products have been shown to be significantly higher in human serum in certain 
pathological conditions such as cardiovascular disorders, reperfusion injury and diabetes 
(Esterbauer, 1993). The extent of LP as a result of pathological conditions is considered an 
important parameter for oxidative stress.  Reperfusion of ischaemic tissue causes the 
production of oxygen derived free radicals which in turn attack PUFAs and thus lead to LP 
(Cordis and Maulik, 1993). 
 
The oxidation of lipids can be measured at the different stages of the LP reaction and the 
following can be measured to determine the extent of LP: the loss of PUFAs, the primary 
peroxidation products or the secondary carbonyls and hydrocarbon gases produced 
(Gutteridge and Halliwell, 1990). The most common assay used to assess the extent of LP is 
the thiobarbituric acid (TBA) assay which measures the secondary oxidation products of LP. 
In this assay the lipid sample and TBA are heated at low pH and this leads to the formation of 
a pink chromogen with a λmax of 532 nm. The pink chromogen is formed by the reaction of 1 
MDA molecule with 2 TBA molecules (Figure 4.2) (Laguerre et al., 2007). MDA is a 
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recognisable marker for LP (Ottino and Duncan, 1997) and the TBA assay is suitable for both 
in vivo and in vitro assessments of LP. 
   
  
 
Figure 4.2: The formation of MDA (circled) from a peroxyl radical of tri-unsaturated fatty acid and the 
formation of TBA chromophore from TBA and MDA (Laguerre et al., 2007) 
 
The disadvantage of the TBA assay is that several other aldehydes are formed during the LP 
reaction to give other chromogens that are also detectable at a wavelength of 532 nm 
(Gutteridge and Halliwell, 1990). Despite this, the TBA assay may be employed to assess LP 
or the susceptibility of the tissues to peroxidation with some degree of reliability. 
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4.2 THE COMPARATIVE EFFECTS OF THEANINE AND MINOCYCLINE 
ON QA-INDUCED LIPID PEROXIDATION IN RAT BRAIN 
HOMOGENATE IN VITRO 
 
4.2.1 INTRODUCTION 
 
Certain tissue homogenates such as rat brain and liver undergo LP more readily whereas 
others, such as intestinal homogenates, do not (Barber and Bernheim, 1967). The brain was 
homogenised as it has a high concentration of PUFAs and is easily oxidised during LP. LP 
can be induced in tissues by iron, organic hydroperoxides and the metabolism of carbon 
tetrachloride (CCl4) which results in the production of free radicals among other chemicals 
(Kappus, 1987). Although LP may be induced by different chemicals, the degradation 
products are still the same. 
 
QA which is a metabolite of the tryptophan-kynurenine pathway can be used to induce LP 
(Rios and Santamaria, 1991). It is released by activated microglia and macrophages in 
response to a variety of pathological diseases (Št‟astný et al., 2004) and its levels increase in 
inflammatory neurological diseases such as ischemia brought on by stroke (Halliwell and 
Gutteridge, 1989). QA changes the permeability of the BBB by activating the NMDA 
receptors and by inducing LP (Št‟astný et al., 2004). The average concentration of QA in the 
human brain is between 0.5 and 2 pmol/mg tissue (Wolfensberger et al., 1983). QA is a 
useful toxin to study in systems that mimic what happens in vivo as it has been found that a 
mid to high micromolar concentration of QA could develop under pathological conditions 
owing to discrete subpopulations of QA producing cells secreting QA directly onto specific 
target sites that could potentially generate high local concentrations of QA (Št‟astný et al., 
2004). 
 
The brain is susceptible to LP because it is rich in PUFAs and relatively deficient in 
antioxidant protective mechanisms. Minocycline has shown more promising results as a 
neuroprotective agent than theanine as it is a potent free radical scavenger (Section 2.3.4) and 
is efficient in binding with both iron (III) (Fe
3+
) and iron (II) (Fe
2+
) ions. Their potential 
neuroprotective properties were further assessed by investigating their effects on QA-induced 
LP. 
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4.2.2   MATERIALS AND METHODS 
 
4.2.2.1 Chemicals and reagents 
 
Theanine, minocycline, 2, 3-pyridine dicarboxylic acid (QA), butylated hydroxytoluene 
(BHT), 2-thiobarbituric acid (TBA) and 1, 1, 3, 3-tetramethoxypropane (99 %) were 
purchased from Sigma Chemical Corporation, St Louis, Missouri, United States of America 
Trichloracetic acid (TCA), ethanol and butanol were purchased from Saarchem, 
Johannesburg, South Africa.  
 
4.2.2.2 Animals 
 
Adult male Wistar rats purchased from the South African Vaccine Producers, Johannesburg, 
South Africa were used throughout the study. The animals were housed under artificial 
illumination with a daily photoperiod of 12 hours (lights were switched on at 0600 hours and 
switched off at 1800 hours). The animal-house temperature was maintained at a temperature 
range of between 20 ºC to 24 ºC, while an extractor fan ensured the constant removal of stale 
air. The rats that were between 200 g and 250 g were housed 5 per cage with food and water 
ad libitum. The Rhodes University Animal Ethics Committee approved all the protocols for 
the experiments that were conducted. 
 
4.2.2.3  Brain removal 
 
The rats were sacrificed by cervical dislocation followed by decapitation. The brain was 
exposed by making an incision through the bone on either side of the parietal structure, from 
the foramen magnum to near the orbit. The calvarium was removed, exposing the brain which 
was them removed and either used immediately or frozen in liquid nitrogen and stored at  
-70ºC for future use. 
 
4.2.2.4  Homogenate preparation 
 
Once the brain was removed it was weighed and homogenised in a glass Teflon hand held 
homogeniser in ice cold 0.1 M phosphate buffered saline (PBS), at pH 7.4 to yield a 10 % 
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w/v homogenate. This is necessary to prevent lyosomal damage of the tissue. The 
homogenate was then used immediately for the assay. 
 
4.2.2.5  Preparation of MDA standard curve 
 
The construction of a calibration curve for the TBA assay is complicated by the fact that 
MDA is very unstable thus, one of its derivatives, either 1, 1, 3, 3-tetramethoxypropane or  
1, 1, 3, 3-tetraethoxypropane is used instead (Halliwell and Gutteridge, 1989). 1, 1, 3, 3-
Tetramethoxypropane was used in the preparation of the standard curve. A series of reaction 
tubes, each containing varying concentrations of 1, 1, 3, 3-tetramethoxypropane standards (in 
the range 0-50 nmoles/ml) diluted in 0.1 M PBS was prepared to give a total volume of 1 ml. 
To these tubes, 0.5 ml of BHT (0.5 % in ethanol) and 1 ml of TCA (15 % in milli-Q water) 
were added, the reaction tubes were vortexed. A 2 ml aliquot was removed and to this 0.5ml 
of TBA (0.33 % in milli-Q) was added. This mixture was vortexed and incubated at 95 ºC for 
an hour. A standard curve was generated by measuring the absorbance at 532 nm using a 
Shimadzu UV mini 1240 UV/VIS spectrophotometer and plotting these against the molar 
equivalent of MDA in the complexes formed (Appendix III).  
 
4.2.2.6  Lipid peroxidation assay 
 
A modification of the TBA assay as described by Placer et al., (1966) was used in this 
experiment and is described below: 
 
Triplicate samples of rat brain homogenate (1 ml) contained 1mM QA (100 µl) in the absence 
and presence of increasing concentrations (0-2 mM) of theanine and minocycline (100 µl). 
The samples were incubated in an oscillating water bath for an hour at 37 ºC. Control samples 
did not contain QA or drugs. The reaction was terminated at the end of the incubation period 
by the addition of 1 ml TCA (15 % in milli-Q water) and 0.5 ml BHT (0.5 % in ethanol) to 
each sample. The samples were vortexed and heated at 95 ºC for 15 minutes in an oscillating 
water bath to release protein-bound MDA. Following this, samples were cooled and 
centrifuged at 2000 x g for 20 minutes to yield a protein-free supernatant. The supernatant  
(2 ml) was transferred to a clean set of test tubes and 0.5 ml TBA (0.33 % in milli-Q water) 
was added. All samples were vortexed and heated at 95 ºC for an hour in an oscillating water 
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bath to allow for the formation of the MDA-TBA complex. After rapidly cooling the test 
tubes in ice, 2 ml of butanol was added to the samples to extract the pink complex. The 
samples were then vortexed and centrifuged at 2000 x g for 15 minutes. An aliquot of the 
extracted complex in butanol (the top layer) was read at 532 nm using a Shimadzu UV mini 
1240 UV/VIS spectrophotometer. MDA levels were then determined from a standard curve 
generated from 1, 1, 3, 3-tetramethoxypropane as described in Section 4.2.2.5. Final results 
were expressed as MDA (nmoles/mg tissue).  
 
4.2.2.7  Statistical analysis 
 
This was performed as described in Section 2.2.2.3. 
 
4.2.3   RESULTS 
 
As shown in Figure 4.3, 1 mM QA increases the amount of MDA in comparison to control  
(p < 0.05). Minocycline reduces the QA-induced LP in a concentration dependent manner. 
The suppression of MDA is highly significant for each concentration used (p < 0.01) in 
comparison to samples containing QA alone. In contrast there is no significant difference 
between samples with QA alone and any of those containing QA and theanine. 
 
A comparison between the two drugs at the same concentration shows that minocycline 
decreased QA-induced LP significantly (p < 0.01) for 0.5, 1 and 2 mM and  
(p < 0.05) for 0.25 mM when compared to theanine. 
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Figure 4.3: Effect of 1 mM QA alone and in combination with either theanine or minocycline on LP in rat brain 
homogenate in vitro. Each bar represents the mean ± SD; (n=5).      (p < 0.01) in comparison to QA and      
     (p < 0.05) in comparison to QA (ANOVA followed by Student Newman-Keuls Multiple Range Test).                    
 
4.2.4   DISCUSSION 
 
Štípek et al. (1997) reported that the oxidising activity of QA on LP in the rat brain in vitro as 
investigated by Rios and Santamaria (1991) requires the presence of Fe
2+
 ions and that the 
mechanism is likely to involve Fe
2+
 chelation by QA. Homogenising tissue results in the 
release of metal ions especially iron from storage sites within cells (Barber, 1963; Gutteridge 
and Stocks, 1976).  In the TBA assay, QA was added to the homogenised tissue and thus was 
able to form a complex with Fe
2+
. UV absorption spectra have shown that 2-
pyridinecarboxylic acid containing compounds such as QA are able to chelate Fe
2+
 ions 
(Figure 4.4) and that a UV spectral wave generated disappeared on addition of hydrogen 
peroxide (H202) indicating that the complex may have been oxidised by H202 to Fe
3+
 with the 
subsequent formation of the potent •OH radical by the Fenton reaction (Iwahashi et al., 
1999). Furthermore, on addition of the iron chelator, desferoxamine, the increase in QA-
induced LP was abolished (Štípek et al., 1997).  
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Figure 4.4: Binding of Fe
2+
 by the 2-pyridine carboxylic acid moiety (Iwahashi et al., 1999) 
 
Metals with two valency states with suitable redox potential generally cause an increase in LP 
rate (Barber and Bernheim, 1967) by the decomposition of LOOH into the alkoxyl (LO•) and 
peroxyl (LOO•) radicals as shown in Equation 4.3 (Gutteridge and Smith, 1988). The radicals 
produced from this reaction can continue the LP reaction within the lipid. Iron exists in two 
valency states and can thus cause an increase in the LP rate. 
 
 
 
Antioxidants are categorised according to their mechanism of action in protecting the body 
from damage by free radicals (Section 1.3.2.1). Minocycline has shown to be a highly 
effective free radical scavenger (Section 2.3.4) and a strong chelator of Fe
2+
 and Fe
3+
 (Section 
3.5.4). From the results above (Section 4.2.3), minocycline has been shown to statistically 
significantly inhibit QA-induced LP in comparison to QA alone samples. The mechanism 
that could be proposed for such a reduction in LP could be that it acts as chelator of the Fe
2+
 
ions and thus prevent the formation of the Fe
2+
-QA complex which is required for the 
oxidising activity of QA in LP.  Theanine is a weak chelator of iron and thus it does not 
prevent the QA from chelating the Fe
2+
 that is in the homogenate and thus allows for the 
progression of QA-induced LP.  
    
    
                                  Equation 4.3 
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The TBA assay relies on the formation the TBA-MDA chromophore, therefore it follows that 
less MDA was produced in the presence of minocycline and hence, less LOOH decomposed 
to MDA. Minocycline prevents the decomposition of LOOH into other radical forms 
(minocycline exhibited antioxidant activity that was shown in Section 2.3.4) and can be 
categorised into the group of antioxidants that act by preventing the formation of active 
oxidants by donating a hydrogen to LOO• and thus prevent the chain propagation reactions of 
LP from continuing the generation of free radicals. Phenol compounds such as minocycline 
are able donate to a hydrogen as it has the capacity to stabilise unpaired electrons by 
delocalisation within its aromatic structure and the presence of other cyclic structures within 
it lead to the extension of the delocalisation and thus increase the stability of the phenol 
radical formed when the hydrogen is abstracted by the LOO• (Laguerre et al., 2007). 
 
Iron chelates have been shown to induce LP in vitro by catalysing the conversion of 
superoxide O2
•- 
and H2O2 into •OH radicals. Fe
2+
 chelates are more effective at promoting the 
formation of MDA from LOOH than free Fe
3+
 ions (Bucher et al., 1983).  Although LP may 
be induced by different toxins, the degradation products are still the same. The effects of the 
iron-minocycline chelates are less effective than the iron-QA chelates in causing lipid 
peroxidation. This is evidenced by the fact that there is a statistically significant difference in 
the MDA produced in the presence of QA and in the presence of minocycline in 
concentrations even as low as 0.25 mM. Minocycline also exhibits a concentration dependent 
decrease in the formation of MDA. However as stated in Section 4.2.3, above the 
concentration of 0.5 mM, there is no statistically significant change in the inhibition of LP. 
Kraus and colleagues (2005) reported a decrease in iron-induced LP in vitro and that this 
effect was due to minocycline‟s radical scavenging activity.  
 
Minocycline could also prove to be superior to theanine as it is lipophilic and theanine is not 
which could increase its effectiveness in inhibiting QA from interacting with iron in lipid 
homogenates. Minocycline has been proven to be an effective chelator of Fe
2+
 (Section 3.5.4) 
and this physiochemical property allows it to be an effective inhibitor of QA-induced LP and 
can thus be further investigated for more potentially neuroprotective properties.  
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4.3 THE EFFECT OF THEANINE ON QA-INDUCED LIPID 
PEROXIDATION IN RAT BRAIN HOMOGENATE IN VIVO 
 
4.3.1   INTRODUCTION 
 
Theanine showed very poor inhibition of QA-induced LP in vitro (Section 4.2.4).  It was 
however decided to explore its potential as a neuroprotectant in rats that had been 
administered a daily dose of theanine for 5 and 10 days.  
 
4.3.2   MATERIALS AND METHODS 
 
4.3.2.1  Chemicals and reagents 
 
The drugs used and purchased are the same as those described in Section 4.2.2.1. 
 
4.3.2.2  Animals 
 
Adult male Wistar rats were purchased from the South African Vaccine Producers, 
Johannesburg, South Africa and cared for as described in Section 4.2.2.2. 
 
4.3.2.3  Drug treatment 
 
The rats were divided into 2 groups: control and theanine. Each group consisted of 5 rats. The 
control groups were administered daily doses of normal saline and the remaining groups of 
rats were administered 5 mg/kg/day (0.5 ml) theanine i.p for 5 and 10 days.  
 
4.3.2.4  Brain removal 
 
The brain was removed as described in Section 4.2.2.3 
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4.3.2.5  Homogenate preparation 
 
The homogenate was prepared as described as in Section 4.2.2.4. 
 
4.3.2.6  Lipid peroxidation assay 
 
The LP assay was performed as described in Section 4.2.2.6. However, no exogenous 
theanine was added. The assay resumed after 1 ml QA (100 µM) was added to the 
homogenate and the samples were incubated. 
 
4.3.2.7  Statistical analysis  
 
This was performed as described in Section 2.2.2.3. 
 
4.3.3   RESULTS 
 
Figure 4.4 illustrates that treatment with theanine over a period of 5 and 10 days resulted in a 
statistically significant decrease (p < 0.01) in QA-induced LP in comparison with brains 
treated with QA only. Treatment with theanine also reduced the MDA produced in the 
control. However there is no statistically significant difference treating the rats for 5 or 10 
days. 
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Figure 4.5: Effect of 1 mM QA alone and in combination with either theanine on LP in rat brain homogenate in 
vivo. Each bar represents the mean ± SD; (n=5).      (p < 0.01) in comparison to QA (ANOVA followed by 
Student Newman-Keuls Multiple Range Test).                    
 
4.3.4   DISCUSSION 
 
There is a significant change in theanine‟s ability to prevent QA-induced LP in pre-treated 
brains in comparison to the in vitro results (Section 4.2.3) where theanine displayed no 
statistically significant change in QA-induced LP. This suggests that treatment with theanine 
results in some form of neuroprotection against QA-induced LP. 
 
Alpha-tocopherol (vitamin E), a major antioxidant found in all membranes (Parker, 1991) 
inhibits lipid peroxidation both in vivo and in vitro (Burton and Ingold, 1989; Murphy et al., 
1989). Pre-treatment of animals with vitamin E has been found to reduce secondary damage 
in several models of ischaemic traumatic injury to the CNS (Halliwell and Gutteridge, 1989). 
This suggests that pre-treatment may have a degree of neuroprotection depending on the drug 
analysed. 
 
Long term supplementation (of about 50 days) with green tea has been shown to decrease LP 
in the rat liver (Sano et al., 1995) and decrease lipid peroxide levels in hamsters (Vinson and 
Dabbash, 1998). Green tea was found to be efficient in trapping radicals after a single dose 
(Serafini et al., 1996). These findings suggest that pre-incubation with green tea has desirable 
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effects in the mammalian body. As a component of green tea, theanine may be better as a free 
radical scavenger and iron chelator after pre-treatment. 
 
The results (Section 4.3.3) suggest that pre-treating the brain with theanine improved its 
ability to protect it from LP induced by QA. In homogenising the tissue, antioxidants present 
in the tissue are diluted thus rendering these less effective than when these are at normal 
intracellular concentration. Both theanine‟s free radical scavenging ability (Section 2.3.4) and 
its ability to chelate iron (Section 3.5.4) in vitro are both shown to be poor. The observed 
reduction in MDA levels in theanine-treated brains implies that these characteristics must 
have improved when theanine was administered over 5 days or more. 
  
Theanine may be one of the components which contribute to the lowering of LP and lipid 
peroxide levels and free radical scavenging properties exhibited by green tea. A study in rats 
with ischaemic brain injury by Wang et al. (2008), showed that rats treated with theanine 
exhibited significantly higher levels of SOD activity and decreased levels of MDA contents 
as compared to the ischaemia-reperfusion group. These findings were attributed to theanine‟s 
regulatory effect on the imbalance of free radical metabolism due to ischaemia. The findings 
by Wang et al. (2008) as well as those that have been investigated in this in vivo study, imply 
that dosing with theanine improves its QA-induced LP lowering and antiradical properties. 
The mechanism in which theanine lowers LP could be by increasing the SOD activity and 
thus reducing the amount of O2
•-
 that can participate in the progression of LP. Theanine thus 
significantly reduces QA-induced LP. The effect of theanine on QA biosynthesis will be 
investigated in Chapter 5. If theanine is shown to reduce QA biosynthesis this could 
contribute to the ways in which theanine is neuroprotective. 
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 CHAPTER 5 
 
THE BIOSYNTHESIS OF QUINOLINIC ACID 
 
5.1    INTRODUCTION 
 
TRP is an essential amino acid that is required for physiological processes such as the 
synthesis of proteins and as a biochemical precursor of 5HT, melatonin and niacin (Saito et 
al., 1993a). It is metabolised by the KP into 3 main neuroactive chemicals namely QA, 
KYNA and 3-OH-KYN. The KP is the predominant route by which TRP is metabolised in 
the brain and in the periphery (Bender, 1983) (Figure 5.1). Along the KP, TRP is oxidised to 
N-formylkynurenine and rapidly catabolised by the action of TDO or IDO to KYN 
(Schwarcz and Pellicciari, 2002). There is a functional connection between the KP and 
cholinergic system (Sas et al., 2007).  
 
An imbalance in the KP metabolites may interfere with the normal functioning of the brain 
that may lead to the pathology of some brain disorders (Sas et al., 2007a). After transient 
cerebral ischaemia, there is a delayed increase in KP metabolism and an increase in the 
concentration of L-KYN, L-TRP and neurotoxic QA in the forebrain (Saito et al., 1993b). 
QA leads to excitotoxic neuronal death. In HD there is an increase in  
3-OH-KYN levels in the brain (Reynold and Pearson, 1989). QA an excitotoxin produced in 
the KP, is involved in the pathology of AD. QA-induced LP and the ultimate generation of 
free radicals and its agonistic effect on NMDA receptors have a significant impact on the 
pathogenesis of AD (Guillemin and Braw, 2002). In addition to this, the KP is upregulated in 
the AD brain (Sas et al., 2007). 
 
The Biosynthesis of QuinolinicAcid CHAPTER 5 
 
Page | 99  
 
 
Figure 5.1: Dynamics of kynurenine pathway metabolism in the CNS and periphery. The abbreviations in the 
illustration above in brackets are: L-tryptophan (L-TRP); L-kynurenine (L-KYN); kynurenic acid (KYNA); 3-
hydroxy kynurenine (3-HK); 3-hydroxyanthranilic acid (3-HANA), Quinolinic acid (QUIN); NMDA receptor 
(NMDA-R); 7-nicotinic acetylcholine receptor (7-nACh-R). Broken arrows: brain entry/cellular uptake (red), 
release (blue). Solid arrows: enzymatic conversion (black), receptor agonist (red), receptor antagonist (blue) 
(Schwarcz and Pellicciari, 2002), 
 
TDO is the hepatic enzyme that converts TRP to N-formylkynurenine by irreversibly 
inserting oxygen into the pyrrole portion of TRP (Hayaishi et al., 1957). In the liver, TDO is 
associated with a “free” haeme pool, which usually provides sufficient haeme to saturate half 
the available TDO. As a result, TDO exists in two forms, namely, the already active 
holoenzyme form and the apoenzyme form which requires haeme or haematin for its 
activation in vivo and in vitro respectively (Badawy and Evans, 1975). Chapter 4 has shown 
the deleterious effects of QA-induced LP on the rat brain and the neuroprotective effect of 
minocycline in vitro and that of theanine in vivo. Thus, the aim of this chapter is to assess the 
effect of theanine and minocycline on the activity of TDO which catalyses the conversion of 
TRP to QA. 
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5.2 THE COMPARATIVE EFFECT OF THEANINE AND MINOCYCLINE 
ON TDO ACTIVITY IN RAT LIVER HOMOGENATE IN VITRO 
 
5.2.1   INTRODUCTION 
 
Changes in the KP have been shown to play a role in the pathology of various diseases. TRP, 
a substrate of TDO and IDO, is required for the synthesis proteins and 5HT. Metabolites of 
the KP that are of interest are QA, which is neurotoxic and KYNA, which is neuroprotective. 
The changes in KP metabolite levels may be attributed to changes in the TRP levels and in 
enzymes that participate in the KP.  
 
Serum levels of TRP may be attributed to dietary TRP levels or changes in KP enzymatic 
activity. TRP plasma levels are lower in AD and in HD. This is due to the up-regulation of 
the KP in these disease states (Sas et al., 2007). Saito et al., (1993) reported an increase in 
kynureninase, IDO and 3-hydroxylase activity after 10 minutes of ischaemia and that there 
was an increase in the concentration of QA associated with the increase in enzymatic activity. 
Macrophages infiltrate regions of neuronal necrosis after ischaemia in the rat (Smith et al., 
1983) and this causes an increase in the production of O2
•-
 (Saito et al., 1993b). 
 
TDO exists as the active holoenzyme and inactive apoenzyme and its activity in the liver is 
responsible for the conversion of TRP to N-formylkynurenine (Section 1.2.6.2.2.1).  Haeme 
is a cofactor that plays a role in rat liver TDO and increases the activity of hepatic TDO as it 
activates the inactive apoenzyme (Badawy and Evans, 1975). The ability of haeme to saturate 
the apoenzyme is decreased by agents that destroy haeme or inhibit haeme synthesis and 
increase by agents that increase the utilisation or synthesis of haeme (Badawy and Evans, 
1975). The effect of theanine and minocycline on TDO activity will be assessed in the TDO 
assay (Section 5.2.2.5) where their effects on the active holoenzyme and apoenzyme will be 
determined.  
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5.2.2   MATERIALS AND METHODS 
 
5.2.2.1  Chemicals and reagents 
 
Theanine, minocycline, haematin, L-TRP, Bradford‟s reagent and bovine serum albumin 
(BSA) were purchased from Sigma Chemical Corporation, St Louis, Missouri, United States 
of America. Trichloracetic acid (TCA), sodium hydroxide (NaOH) and sodium chloride 
(NaCl) were purchased from Saarchem, Johannesburg, South Africa. 
 
5.2.2.2  Animals 
 
Adult male Wistar rats were purchased from the South African Vaccine Producers,   
Johannesburg, South Africa and cared for as described in Section 4.2.2.2. 
 
5.2.2.3  Removal of the liver 
 
The rats were sacrificed by cervical dislocation followed by decapitation. To remove the 
liver, a mid-ventrial incision was made through the abdominal musculature from the pelvic 
region to the posterior edge of the sternum. A transverse cut was made anteriorly to expose 
the liver which was then removed. The liver was immediately perfused with ice cold 0.9 % 
NaCl to remove all endogenous haeme and either used immediately or frozen in liquid 
nitrogen and stored at -70 ºC for future use. 
 
5.2.2.4  Preparation of the tissue 
 
The livers were thawed, weighed and chopped into fine pieces and rapidly homogenised with 
a glass-teflon hand held homogeniser in 0.01 M PBS (pH 7.4), to give a final concentration of 
10 % w/v. The homogenate was then sonicated for a period of 2 minutes at 30 second 
intervals for complete removal of the enzyme from the cells. The entire procedure where 
possible, was conducted in ice. 
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5.2.2.5  Determination of TDO activity 
 
A modification of the method described by Badawy and Evans (1975) was used and is 
outlined below: 
 
An aliquot of 15 ml of homogenate was added to 2 flasks containing 12.5 ml water and 
vortexed. To one of the 2 flasks, haematin (100 µl) was added to make a final concentration 
of 2 µM. This flask was then stirred and allowed to stand for 1 minute to allow for the 
activation of the enzyme by haematin. Thereafter, 2.5 ml of 0.03 M L-TRP was added to each 
flask. The flasks were stirred before aliquots of 2 ml were transferred to test tubes in 
triplicate. Thereafter, either theanine or minocycline was added to each of the test tubes such 
that incubation concentrations of 10 µM and 100 µM of each drug was achieved. Neither 
theanine nor minocycline was added to the control samples. The test tubes were then 
stoppered with carbogen and incubated for 60 minutes at 37ºC in an oscillating water bath. 
To stop the reaction, 0.9 M TCA (2 ml) was added to each test tube. The resulting precipitate 
was then centrifuged at 4500 x g for 15 minutes. The supernatant (2.5 ml) was transferred to 
a new set of test tubes and 0.6 M NaOH (1.5 ml) was added to each test tube. An aliquot from 
each test tube was removed for analysis. The blank consisted of 2 ml of TCA and 1.5 ml of 
NaOH. The absorbance was read at 365 nm using a Shimadzu UV mini 1240 UV/VIS 
spectrophotometer. 365 nm is the λmax of N-formylkynurenine. The extinction coefficient of 
N-formylkynurenine, ε = 4540 M-1.cm-1 was used to determine the concentration of N-
formylkynurenine. Activity of TDO was expressed as nmol N-formylkynurenine/mg of 
protein/min. The results from test tubes that did not contain haematin represented total 
holoenzyme activity. Apoenzyme activity was calculated as the difference between the total 
enzyme activity and holoenzyme activity. 
 
5.2.2.6  Protein assay 
  
Protein estimation was performed using the principles described by Bradford (1976). 
 
A calibration curve was generated using BSA which was prepared in 0.01 M PBS within a 
concentration range of 0.1 to 1.4 mg/ml. The assay was performed in test tubes. Protein 
samples (0.1 ml) of each concentration was added to the test tubes. To each test tube, 
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Bradford reagent (3 ml) was added and gently vortexed. The total liquid volume in each tube 
was 3.1 ml. The samples were left at room temperature to incubate for a period of 15 minutes. 
The absorbance was then read at 595 nm using a Shimadzu UV mini 1240 UV/VIS 
spectrophotometer. The test tube of zero concentration of protein consisted of the PBS only. 
The protein-dye complex is stable for up to 60 minutes and care was taken to record the 
absorbance of the samples before the 60 minute time limit and within 10 minutes of each 
other. A standard curve was generated by plotting concentration of protein against net 
absorbance (Appendix IV). 
 
The concentration of the protein was determined in each of the liver samples by using the 
standard curve generated.   
 
5.2.2.7  Statistical analysis  
 
This was performed as described in Section 2.2.2.3. 
 
5.2.3  RESULTS  
 
As shown in Figure 5.2, it is evident that at a concentration of 100 µM, minocycline 
significantly increases the total enzyme and holoenzyme activity of TDO (p < 0.001), whilst 
10 µM minocycline and both concentrations of theanine had no significant effect on either 
form of the enzyme.  
 
There is also a statistically significant concentration dependent increase in the activity of both 
total and holoenzyme activity of TDO with minocycline at 10 µM and 100 µM  
(p < 0.001). As evidenced by the results, minocycline only has an effect on the holoenzyme 
of TDO and not on apoenzyme. The difference between the effect on the holoenzyme 
between minocycline and theanine when both are used at a concentration of 100 µM is also 
statistically significant (p < 0.001). 
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Figure 5.2: Effect of theanine and minocycline on TDO enzyme activity in rat liver in vitro. T 10 and T 100 
represent theanine at concentrations of 10 µM and 100 µM respectively; M 10 and M 100 represent 
minocycline at concentrations of 10 µM and 100 µM respectively.  Each bar represents the mean ± SD (n=5).   
      (p < 0.001) in comparison to controls (ANOVA followed by Student Newman-Keuls Multiple Range Test).    
 
5.2.4 DISCUSSION 
 
TDO exists in two forms: the active holoenzyme that does not require the addition of 
exogenous haematin for demonstration of its activity in vitro and the inactive apoenzyme that 
requires exogenous haematin to activate its activity (Greengard, 1964; Badawy and Evans, 
1975). TDO activity is stimulated by the presence of TRP. The manner in which TRP reacts 
with TDO has been discussed (Section 1.2.6.2.2.1) and Equation 5.1 adapted from Knox 
(1966) will be used to briefly describe the reaction between TDO and TRP: 
 
 
 
        
 
 
         
              
                                   
                       
                                        
 
                                                                                                                                              Equation 5.1 
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The equation above shows that the activation of TDO occurs in a series of steps starting with 
the inactive apoenzyme which is conjugated with haematin and requires small concentrations 
of L-TRP. The oxidised ferric form of the holoenzyme is then reduced to the ferrous form in 
the presence of L-TRP and a reducing agent such as vitamin C. The reduced holoenzyme is 
fully active and can participate in the conversion of L-TRP to  
N-formylkynurenine in aerobic conditions. Oxygen has a role in the reaction of the active 
holoenzyme and L-TRP (not shown in the equation). It is responsible for the oxidation of the 
ferrous form of the holoenzyme into the ferric form resulting in it being reduced to O2
•- 
and 
the formation of a TRP peroxide (Equation 1.7) which will undergo further reaction 
independent of TDO to form N-formylkynureine. It is apparent therefore that TRP brings 
about its own oxidative removal by activating TDO which is responsible for its metabolism 
(Knox, 1966). 
 
From Figure 5.2 it is apparent that theanine has no significant effect on TDO activity in vitro 
and that minocycline does. Addition of haematin to the minocycline treated livers does not 
bring about a significant change in the activity of the apoenzyme activity in vitro and the fact 
that there is only a significant change in holoenzyme activity, shows that minocycline affects 
only the activity of the holoenzyme and that it does not require the presence of haematin in its 
mechanism of increasing total TDO activity. 
 
There are two mechanisms by which minocycline may bring about the increase in TDO 
activity and TRP metabolism and these are: 
 
 Minocycline can act as a reducing agent and facilitate the conversion of oxidised 
holoenzyme into the reduced holoenzyme or 
 Minocycline can facilitate the reduction of oxygen to O2
•-
 thereby facilitating the 
formation of the TRP peroxide which will undergo further reactions independent of 
TDO to form N-formylkynureine. 
 
Minocycline has been shown to form complexes with Fe
3+
 (Sections 3.2.4 and 3.3.3) and to 
bring about the reduction of ferric iron to the ferrous ion (Section 3.5.4). Knox (1966) 
demonstrated that for maximal TDO enzyme activity, the enzyme preparation requires the 
addition of a reducing agent such as vitamin C. Minocycline reducing ability in vitro is 
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comparable to that of vitamin C (Section 2.3.4) and thus it is able to reduce the oxidised 
ferric holoenzyme TDO to the active ferrous holoenzyme. This means that more holoenzyme 
is available for the metabolism of L-TRP.  
 
The other possible mechanism for its increase in the levels of holoenzyme levels could be 
attributed to the possibility that minocycline is able to increase the levels of O2
•-
 by the 
reduction of oxygen. Its potential as a generator of O2
•-
 will be further investigated in Chapter 
7. If minocycline is proved to be a generator of O2
•-
, this could explain the drastic increase in 
TDO activity when compared to control liver samples as the increase in the TDO activity is 
approximately 400 % that of the control. 
 
The Biosynthesis of QuinolinicAcid CHAPTER 5 
 
Page | 107  
 
5.3 THE COMPARATIVE EFFECT OF THEANINE ON TDO ACTIVITY IN 
RAT LIVER HOMOGENATE IN VIVO 
 
5.3.1   INTRODUCTION 
 
The concentration of hepatic TDO changes according to the dietary and hormonal state of the 
mammal (Muñoz-Clares et al., 1980).  Theanine showed no significant change in TDO 
activity (Section 5.2.4).  It was decided to explore its effect on TDO in rats that had been 
administered a daily dose of theanine for 5 and 10 days. 
 
5.3.2   MATERIALS AND METHODS 
 
5.3.2.1   Chemicals and reagents 
 
The drugs used were the same as those described in Section 5.2.2.1. 
 
5.3.2.2   Animals 
 
Adult male Wistar rats were purchased from the South African Vaccine Producers, 
Johannesburg, South Africa and cared for as described in Section 4.2.2.2. 
 
5.3.2.3   Drug treatment 
 
The rats were treated in a same manner as described in Section 4.3.2.3.  
 
5.3.2.4   Removal of the liver  
 
The animals were sacrificed and the liver was removed as described in Section 5.2.2.3. 
 
5.3.2.5   Preparation of the tissue 
 
The liver homogenate was prepared as described in Section 5.2.2.4. 
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5.3.2.6   Determination of TDO activity 
 
This was conducted as described in Section 5.2.2.5. However, after the addition of 0.03 M  
L-TRP (2.5 ml) to each flask, aliquots of 3 ml instead of 2 ml were transferred in triplicate to 
test tubes. Theanine was not added to any of the test tubes. 
 
5.3.2.7   Protein assay 
 
The determination of protein was performed as described in section 5.2.2.6. 
 
5.3.2.8   Statistical analysis  
 
This was performed as described in Section 2.2.2.3. 
 
5.3.3   RESULTS 
 
The experimental results obtained indicate a reduction in total TDO activity on treatment 
with theanine for 10 days however the only significant decrease of total TDO enzyme activity 
occurs when theanine was administered for 10 days (p < 0.05). There is however no 
significant change in the apoenzyme and holoenzyme activities after treatment with theanine 
for 10 days although there is an increase in total enzyme activity. There is a statistically 
significant decrease in the total TDO activity between treating the rats for 5 and 10 days (p < 
0.01). There is an increase in the total and holoenzyme TDO after a 5 day treatment with 
theanine however this is not statistically significant. 
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Figure 5.3: Effect of theanine on TDO enzyme activity in rat liver in vivo. Each bar represents the mean ± SD 
(n=5).       (p < 0.05) in comparison to control,    (p < 0.01) and @ (p < 0.05) in comparison to theanine (10 
days) (ANOVA followed by Student Newman-Keuls Multiple Range Test).     
 
5.3.4   DISCUSSION 
 
TRP catabolism is facilitated by 2 enzymes, TDO and IDO, which oxidise TRP (Knox and 
Mehler, 1950). The KP occurs differently in the brain and in the periphery organs, as TDO is 
limited to the liver and IDO to various organs for example, the small and large intestines, 
kidney spleen and brain (Takikawa, 2005).  
 
Research has been conducted on the relationship between KP metabolites in the periphery 
and in the brain. Badawy et al., (1981) reported that liver TDO plays a role in determining the 
levels of circulating TRP in the blood. For instance, Weekley et al., (1985) discovered that 
the levels of KP metabolites 5HT and 5-hydroxyindole-3-acetic acid (5HIAA) were reduced 
in the pineal, pituitary, various brain regions and duodenum of aflatoxin-treated rats.  The 
authors concluded that the decreased levels of 5HT and 5HIAA in all tissues may be 
attributed to decrease in free tryptophan or alterations in 5-hydroxyindole biosynthesis.  
 
A decrease in the levels of TRP corresponds to lower levels of KP metabolite formation. 
However, because the level of TRP remains constant in this experiment (Section 5.3.2.6), the 
theanine-induced decrease in TDO activity could be attributed to changes in the enzyme 
environment. There is no significant change in TDO activity on addition of haematin which 
@ 
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suggests that the apoenzyme activity is not affected by the administration of theanine. The 
variability in the holoenzyme activity for both treatment with theanine of 5 days and 10 days 
suggests that the holoenzyme activity is affected by theanine administration.  
 
The theanine-induced decrease in holoenzyme activity may be attributed to the following: 
 
 Changes in the manner in which it binds to TRP or 
 Scavenging O2
•-
 or inhibition of the reduction of oxygen to O2
•-
. 
 
A chemical that can bind at the TDO catalytic site is required to have an indole-NH group 
within its structure (Uchida et al., 1992). A chemical that possesses this indole-NH group will 
act as a competitive inhibitor to the binding of TRP to the inactive form of the holoenzyme, 
thereby inhibiting the activity of the holoenzyme (Uchida et al., 1992).  Chemicals that do not 
possess the indole-NH group but still inhibit holoenzyme activity are non-competitive 
inhibitors of the reaction between TRP and the holoenzyme (Uchida et al., 1992). Theanine 
does not possess an indole-NH group and can thus be termed a non-competitive inhibitor of 
TDO by interfering with the binding of TRP to TDO, resulting in a decrease in TDO activity. 
The mechanism by which theanine may do this is yet to be investigated. As previously 
mentioned another way in which theanine may inhibit holoenzyme activity is by preventing 
the reduction of oxygen to O2
•-
 or by scavenging the O2
•-
 produced. The effect of theanine on 
O2
•-
 generation will be investigated in Chapter 7.  
 
Yokogoshi et al. (1998) reported that administration of theanine resulted in an increase in 
TRP concentration in the rat brain. This may mean that theanine reduces TDO activity in the 
liver in order to increase the brain levels of TRP which is a precursor of 5HT. Administration 
of theanine significantly increases 5HT levels in the hippocampus, striatum and 
hypothalamus (Yokogoshi et al., 1998) and this contributes to its anxiolytic effect (Lu et al., 
2004a). The decrease in the TDO enzymatic activity and the inhibition of QA-induced LP in 
vivo (Section 4.3.4) prove that theanine possesses neuroprotective properties as it inhibits the 
synthesis and effects of the neurotoxin QA in vivo. 
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 CHAPTER 6 
 
STROKE STUDIES 
 
6.1 INTRODUCTION 
 
Several animal models of ischaemia exist (Section 1.1.5). The animal model chosen in any 
particular study must be relevant to the human and closely resemble what happens in the 
human body during ischaemia. The findings of the experiment should be useful in 
understanding the pathophysiological consequences of ischaemia and drug development 
studies of stroke (Durukan and Tatlisumak, 2007). The focal ischaemic model is superior to 
the other models of ischaemic insult (Section 1.1.1.4).  
 
The focal ischaemic model is more widely studied than global ischaemic models for 2 
important reasons. Firstly, even at the core of the lesion formed during the stroke, the blood 
flow is usually higher than that in global ischaemia (Lipton, 1999). Secondly, the significant 
progression of ischaemia from the core of the lesion to the boundary of the lesion produce 
different metabolic conditions within the affected site which makes the focal ischaemic 
model more complex than global ischaemia (Lipton, 1999). 
 
The most common stroke experienced by humans is caused by the obstruction of the MCA or 
one of its branches (Durukan et al., 2008). Thus the focal ischaemic model involving the 
occlusion of the MCA is an appropriate model for investigating the potential neuroprotective 
properties of certain drugs. The occlusion of the MCA can be performed surgically or by 
introducing a suture into the MCA.  
 
Surgical MCA occlusion includes direct surgical occlusion of the MCA or combining the 
occlusion of the MCA and other vessels. The disadvantage of surgical models are that these 
are invasive, excellent surgical skills are required for optimum induction of ischaemia and the 
technique requires a craniotomy which affects BBB function due to the exposure of the brain 
to the atmosphere (Durukan et al.,  2008). The main advantage of surgical occlusion of the 
MCA is that the site of occlusion and size of the infarct can be controlled (Durukan et al., 
2008). 
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The most widely used approach to MCA occlusion is to insert a suture into the CCA past the 
point at which the MCA branches so that the MCA is occluded at its origin (Figure 6.1) 
(Lipton, 1999). The size of the lesion in the thread occlusion technique depends on the size 
and shape of the thread as well as the site of thread occlusion (Woizik et al., 2006). The 
advantages of this method are that it is relatively simple to perform and that there is a large 
and reproducible lesion size (Durukan et al., 2008). 
 
 
 
Figure 6.1: Intraluminal occlusion of the MCA via the external carotid artery. 
Showing the suture (b); 1: Common carotid artery, 2: external carotid artery; 3: occipital artery, 4: internal 
carotid artery; 5: pterygopalatine artery; 6: posterior communicating artery; 7: Middle cerebral artery; 8: 
anterior cerebral artery (rostral cerebral artery); 10 Basilar artery; 11 Posterior cerebral artery (Durukan et 
al., 2008).  
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6.2 THE COMPARATIVE EFFECT OF THEANINE AND MINOCYCLINE 
ON A MCA MODEL OF CEREBRAL ISCHAEMIA 
 
6.2.1 INTRODUCTION 
 
The chosen method to induce focal ischaemia involved the introduction of a suture 
intravascularly to occlude the MCA as this type of stroke model represents the most common 
type of stroke experienced clinically.  Rats were the animals chosen to model the stroke. Rats 
are suitable for such a model as their anatomy, physiology and intracranial vasculature is well 
known and is similar to that of humans and they are easy to breed, maintain and handle 
especially when it comes to anaesthetising  and operating on them (Gupta and Briyal, 2004; 
Durukan et al., 2008). It is recommended by Gupta and Briyal (2004) that anaesthetics such 
as barbiturates that have proven to be neuroprotective, should not to be used during any 
course of the procedure. 
 
The length of the suture affects the size of the lesion and deeper suture insertion is associated 
with an increase in lesion size. The suture inserted from the bifurcation of the CCA is usually 
between 17 and 22 mm depending on the size of the rat (Shimamura et al., 2006) as shorter 
insertion distances from the CCA have been shown to produce small subcortical infarcts (He 
et al., 1999). The hippocampus was chosen as the area of the brain to study after ischaemia as 
it is rich in NMDA receptors and thus vulnerable to ischaemia (Kakuda, 2002). 
 
6.2.2 MATERIALS AND METHODS 
 
6.2.2.1 Chemicals and reagents 
 
Theanine and minocycline were purchased from Sigma Chemical Corporation, St Louis, 
Missouri, United States of America. Sodium chloride (NaCl) was purchased from Saarchem, 
Johannesburg, South Africa. Chloral hydrate was purchased from Farmitalia Carlo Erba, 
Milan, Italy.  
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6.2.2.2 Animals 
 
Adult male Wistar rats were purchased from the South African Vaccine Producers,   
Johannesburg, South Africa and cared for as described in Section 4.2.2.2. 
 
6.2.2.3 Drug treatment 
 
The rats were divided into 4 groups: control, stroke alone, theanine and minocycline. Each 
group consisted of 1 rat. The control and stroke alone groups were administered a dose of 
normal saline and the remaining groups of rats were administered 5 mg/kg (0.5 ml) drug i.p. 
an hour before the MCA occlusion was performed. The rat in the control group was not 
subjected to MCA occlusion. 
 
6.2.2.4 Stroke study 
 
A modification of the MCA occlusion as described by Longa et al., (1989) was used in this 
experiment and is outlined below: 
 
An hour after the rat was administered the drug (5 mg/kg) or normal saline, the rat was 
administered with chloral hydrate (450 mg/kg) to anaesthetise it for the procedure. A midline 
incision was made on the rat and by careful dissection from the surrounding tissue, both the 
left and right CCA were exposed. After CCA exposure, the bifurcation of the CCA was 
located and the blood flow into the MCA was blocked by introducing a 4-0 nylon 
intraluminal suture through the right extracranial internal carotid artery (ICA). The left ICA 
and the right external carotid artery (ECA) were temporarily clipped. The suture was gently 
advanced approximately 20 mm until resistance was felt. The suture was left in place for 3 
minutes and then withdrawn and the brain was immediately formalinised.  
 
6.2.2.5 Removal of brain 
 
After the procedure the rats were decapitated. The brain was exposed by making an incision 
through the bone on either side of the parietal structure, from the foramen magnum to near 
the orbit. The calvarium was removed, exposing the brain which was then removed.  
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6.2.2.6 Histological Technique  
 
The brain was cut transversely into slices and mounted onto glass slides. The brains were 
then photographed under high magnification (10 X). The areas of the hippocampus on both 
the ischaemic and non-ischaemic side were measured in mm
2
. Figure 6.2 illustrates the 
position of the hippocampus on such a brain slice. Infarct areas for each slice were calculated 
by summing the total area on the non-ischaemic side and subtracting them from the total area 
on the ischaemic side. The difference in the area was then calculated as a percentage of the 
area of the non-ischaemic side of the hippocampus. 
 
 
 
Figure 6.2: A Nissl-stained section of rat brain, showing the hippocampus 
(http://www.instruct1.cit.cornell.edu/courses/bionb424/students/cth5/images/brain_cross_section_showing_hipp
.jpg.). 
 
6.2.3 RESULTS 
 
The image Figure 6.3 is a photograph of the control brain in which no MCA occlusion was 
performed. Both sides of the hippocampus are the same size as no stroke was induced. The 
images (Figures 6.4 to 6.6) below are the photographs of all the brains post-ischaemia at a 
final magnification of 10 X. The arrow shows the hippocampus on the side in which the 
ischaemia was induced (on the image it is on the right hand side but it is on the animals left 
side). On the side on which the MCA was blocked, the infarct on the affected side of the 
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hippocampus, is visible and the vasculature was more visible in than the rest of the brain 
tissue. Due to the lack of suitable morphologic assessment equipment, it was not possible to 
evaluate the extent of necrosis despite the fact that this was observed. However, this can be 
assessed in an extension of the present study. 
 
 
 
Figure 6.3: Image of the control brain in which no stroke was induced. 
 
 
 
 
Figure 6.4: Image of a brain in which the stroke was performed but no drug was administered. 
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Figure 6.5: Image of the minocycline-treated post ischaemic brain. 
 
 
 
 
Figure 6.6: Image of the theanine-treated post ischaemic brain. 
 
The potential of the drug in reducing the size of the infarct produced in the MCA occlusion 
was assessed by calculating the difference in size between the ischaemic side of the 
hippocampus from the non-ischaemic side and calculating as it as percentage growth of the 
non-ischaemic side of the hippocampus. Table 6.1 shows the percentage growth of the 
hippocampus of the control brain, the post ischaemic brain that had not been treated and each 
of the treated post-ischaemic brains. Minocycline showed least growth in the hippocampus 
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post-ischaemia which implies that it is more neuroprotective of the effects of the stroke than 
theanine. 
 
Table 6.1: Showing the percentage growth of the hippocampus in each of the experimental groups.  
 
 
 
 
 
 
 
 
 
6.2.4 DISCUSSION 
 
Rats between 2-3 years old are reported to be clinically ideal as this age range would mimic 
that of humans above the age of 50 years in which stroke usually occurs (Gupta and Briyal, 
2004). The rats used in this focal ischaemic model were 4 weeks old at the time of the 
experiment. Although not clinically relevant with regard to age, this model still serves to 
compare the potential neuroprotection shown of each drug in a model of ischaemia.  
 
Comparison of the control brain to the post-ischaemic brains shows that ischaemia produces 
an infarct in the hippocampus. This infarct is due to blockage of the MCA which causes 
oxygen and nutrient deprivation to the side of the hippocampus on which the MCA was 
blocked. The hippocampus is rich in NMDA receptors as it has an important function in the 
glutamatergic system (Cotman et al., 1987). There is a significant increase in the levels of 
QA in the hippocampus after ischaemia secondary to the induction of IDO and other enzymes 
in the KP (Saito et al., 1993b). It is for these reasons it was the main part of the brain 
examined after ischaemia as it is the most vulnerable to oxidative stress leading to activation 
of the glutamate receptors such as the NMDA receptors. 
 
Currently, thrombolytics are used to reduce neuronal damage and improve recovery post-
ischaemia (Gupta and Briyal, 2004). A tissue plasminogen activator which is a type of 
Treatment Percentage Growth in Hippocampus 
Control  0 
Stroke only 39 
Stroke & Theanine 44 
Stroke & Minocycline 7 
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thrombolytic, is an agent used for the treatment of stroke. However, its main limitation is that 
only a small percentage (5-8 %) of patients benefit from treatment with it as its 
administration is restricted to 3 hours after stroke (Yrjänheikki et al., 1999; Gupta and Briyal, 
2004). The mechanism responsible for cell death in ischaemic stroke is yet to be determined 
but it is however known that 3 major factors contribute to cell death and these are acidosis, 
the production of free radicals and a significant increase in intracellular concentrations of 
Ca
2+
 (Siesjo, 1992). Various experimental stroke studies using  glutamic acid and Ca
2+
 
antagonists in rodents have shown promise in reducing the size of infarcts resulting from 
MCA occlusion  (Deshpande and Wieloch, 1986; Nuglisch et al., 1990; Hoffman and Boast, 
1995) but have failed in the clinical setting (Onténiente et al., 2003). Failure of clinical trials 
is due to either toxic side effects or lack of efficacy in the clinical setting. Therefore there is a 
need to search for neuroprotective agents that will prove to be effective in the clinical setting. 
Both theanine and minocycline readily cross the BBB and can thus be used as test 
compounds for an ischaemic model (Kakuda, 2002; Dormercq and Matute, 2004). 
 
Pre-treatment with theanine has a neuroprotective effect in ischaemia-induced hippocampal 
neuronal death by reducing its occurrence in a dose-dependent manner (Kakuda et al., 2000) 
and it  significantly decreased the contents of water, Ca
2+ 
and MDA in cerebral tissues after 
ischaemia (Wang et al, 2008). Administration of theanine decreases the size of infarcts in a 
MCA occlusion model in mice (Egashira et al., 2004). The proposed mechanism of theanine 
was due to its regulatory effect on the imbalance of free radicals generated during ischaemia 
as it increases SOD enzyme activity in the brain (Wang et al., 2008). Theanine is an 
antagonist at AMPA and NMDA receptors (Kakuda et al., 2002) and thus provides 
neuroprotection. AMPA receptor antagonists provide protection against ischaemia induced by 
MCA occlusion (Umemura et al., 1997). GABA, an inhibitory neurotransmitter plays a role 
in ischaemia as the levels of its synthesis and receptor expression decrease following MCA 
occlusion (Sieghart, 1995). Egashira et al., (2007) showed that the neuroprotective effect of 
theanine involves its binding to GABA receptors.  
 
Although the dose of theanine administered before inducing the stroke was in a similar range 
to other studies which showed theanine as a neuroprotective in focal ischaemic, the theanine 
did not reduce brain damage in comparison to the control. The explanation of this could be 
that epidemiological studies on green tea and stroke have shown that long term tea 
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consumption is necessary to confer the effects of green tea on stroke (Fraser et al., 2007) and 
that theanine is more effective when it is administered before and after the stroke (Egashira et 
al., 2004). In addition to this, most studies on theanine in ischaemic models involve 
reperfusion for several hours or days. The reperfusion in this model was very brief before 
decapitation took place. Reperfusion allows for an increase in blood flow through the 
penumbra allows for brain cells to recover and regain their functionality (Hossman, 1994). 
Other reasons for the difference in theanine showing little neuroprotection in comparison to 
previous stroke studies could also be because the theanine was administered directly into the 
brain via the lateral ventricle before ischaemia (Kakuda et al., 2000) and that although it 
takes 30 minutes for theanine to be taken up by the brain after intraperitoneal administration 
(Kimura and Murata, 1971), it only reaches peak concentrations in 5 hours (Terashima et al., 
1999) thus by the time the MCA occlusion was carried out, the theanine was still in low 
concentrations in the brain. 
 
Minocycline has been shown to be neuroprotective in several stroke models such as 
intracerebral haemorrhagic stroke (Wasserman and Schlichter, 2007) and focal ischaemia (Xu 
et al., 2004; Li and McCullough, 2009). Yrjänheikki and colleagues (1999) showed that 
minocycline reduces infarct volume by 76 % and by 63 % when it is administered 12 hours 
and 4 hours before the onset of ischaemia respectively. The results of this study (Section 
6.2.3) agree with the previous studies and show that minocycline is neuroprotective in 
ischaemia. Minocycline provides neuroprotection in ischaemia by enhancing neurogenesis, 
reducing NMDA excitotoxicity by inhibiting microglia activity (Tikka and Koistinaho, 2001; 
Koistinaho and Koistinaho, 2007; Liu et al., 2007). Inhibiting microglial activity is an 
important characteristic of minocycline‟s neuroprotection post-ischaemia, as activation of 
microglia contributes to neuronal death. Other ways in which minocycline is neuroprotective 
post-ischaemia is that it protects neurons via an anti-apoptotic mechanism which prevents 
neuronal apoptotic cell death (Matsukawa et al., 2006) and it inhibits the inflammatory 
cascade (Yrjänheikki et al., 1999; Dormercq, 2004). A study by Fagan and colleagues (2004) 
show that absorption after i.p. administration of minocycline is erratic and incomplete and 
that the Tmax levels are reached after 2.5 hours. Minocycline‟s superior neuroprotective 
properties are exhibited in this model of stroke despite documented evidence of poor 
absorption after i.p. administration.  
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Most drugs are found to not be efficacious in the clinical setting after showing great promise 
in experimental models. Theanine administered in doses up to 4000 mg/kg in rats was found 
not to have any adverse effects (Borzelleca et al., 2006). An intravenous dose of 3 mg/kg of 
minocycline is required to obtain serum levels in rats similar to that obtained in humans after 
a standard therapeutic dose of 200 mg of minocycline (Xu et al., 2004). Matsukawa et al., 
(2006) reported that a high dose of minocycline (100 µM) which is approximately 50 mg/kg 
of minocycline is toxic and markedly reduces cell survival. The doses of both theanine and 
minocycline (5 mg/kg) that were administered to the rats are within the non-toxic window of 
both drugs and within the therapeutic window for minocycline. Further studies would have to 
be performed to investigate chronic administration of theanine before and after a stroke in 
order to confirm its potential neuroprotective properties. The results of this study show that 
minocycline is neuroprotective in a clinically appropriate stroke model, within its therapeutic 
range. 
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 CHAPTER 7 
 
OXIDATIVE STRESS 
 
7.1 INTRODUCTION 
 
Oxidative stress occurs when there is an imbalance between radical species produced and the 
endogenous antioxidant defences (Halliwell, 2007). The brain is particularly susceptible to 
oxidative damage as it consumes about 20 % of the O2 inspired despite accounting for only  
2 % of the total body weight. In addition to this, the brain is rich in PUFAs and has relatively 
low levels of antioxidant defences stress (Papa, 1996; Butterfield, 2006). The free radicals 
that are in abundance in a state of oxidative stress are ROS and RNS. The mitochondria is 
responsible for energy production and disturbances to its function due to diseases or injury 
result in the disturbance of mitochondrial function. Diseases that result in mitochondrial 
dysfunction include cancer, heart failure, diabetes, cerebral ischaemia and atherosclerosis, 
among other diseases (Sas et al., 2007).  
 
The results of mitochondrial dysfunction include enhanced radical production, oxidative 
damage resulting from radical production leads to the mtPTPs opening and thus inducing 
apoptosis (Halliwell and Gutteridge, 1989).  In addition to this, there are disturbances of the 
mitochondrial Ca
2+
, decreases in ATP synthesis and ROS metabolism (Brookes et al., 2004). 
The escaping electrons from the respiratory chain interact with O2 to form the O2
•-
 radical. 
The O2
•-
 can also be generated by other means such as the oxidation of xanthine, 
hypoxanthine, NADPH and the auto-oxidation of monoamines (Fridovich, 1999).  The 
mitochondria are sensitive to ONOO
-
 which induces the opening of mtPTPs and activates 
caspase dependent and caspase independent pathways (Sas et al., 2007). The major targets for 
ROS are microglia, neutrophils and macrophages (Sas et al., 2007). The mechanism of cell 
death involves apoptosis and excitotoxicity in which ROS plays a role in both processes (Sas 
et al., 2007). 
 
Neuronal injury leads to the release of glutamic acid into the synaptic space. The excess 
glutamic acid causes an overstimulation of glutamate receptors and ultimately this leads to 
excessive Ca
2+ 
influx into the neuronal cell (Arundine and Tymianski, 2004). Ca
2+
 overload 
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ultimately leads to an increase in the production of ROS and RNS, activation of genetic 
signals leading to apoptosis and mitochondrial dysfunction. Overall, apoptosis is mediated by 
the production of ROS, disturbances in Ca
2+
 homeostasis, caspase activation and 
mitochondrial dysfunction (Mattson et al., 2000). It is not only elevations of extracellular 
glutamic acid that mediate ischaemic brain damage but alteration of glutamate receptor 
functioning has also been implicated as a potential mechanism in the mediation of toxicity to 
neurons (Arundine and Tymianski, 2004). 
 
Free radicals generated as a result of oxidative stress are removed by enzymatic and/or non-
enzymatic means. The main defence systems against radical damage are SOD, GSH, GSH 
peroxidise, CAT, GSH reductase and nutrients such as vitamins E and C (Figure 7.1) (Fang et 
al., 2002). SOD is responsible for the removal of O2
•-
 by a dismutation reaction in which 
H2O2 and O2 are formed (Fridovich, 1975). CAT removes the H2O2 that is produced. GSH 
peroxidise and GSH-S-transferase are enzymes that also remove H2O2 as well as lipid 
peroxides (Halliwell and Gutteridge, 1986). 
 
Aging is characterised by a reduction in the ability of the body to combat environmental 
stress and declined antioxidant defences. There is an increase in the amount of ROS produced 
and because of the reduced ability of an aged body to cope with ROS, there tends to be an 
accumulation of toxic radicals which leads to oxidative damage. Oxidative damage and Ca
2+
 
release is an important factor in neuronal injury that takes place as a result of various 
neurodegenerative disorders. 
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Figure 7.1: The mechanisms by which ROS and RNS are removed from the body. Adenosine diphosphate 
(ADP); arginine (Arg); (6R)-5,6,7,8,-tetrahydro-L-biopterin (BH4); carnosine (Carn); catalase (Cat); citrulline 
(Cit); cytochrome C (Cyt C); L-glutamate (Glu); glycine (Gly); glutamyl-cysteine (Glu-CySH); oxidized 
glutathione, (GS-SG); reduced glutathione (GSH); glutathione peroxidases (GSH-Px); glutathione reductase 
(GSHR);glutathione S-transferase (GSH-T); nitrosylated glutathione (GSNO);oxyhemoglobin (HbO2); heme-
nitric oxide (Heme-NO); histidine, (His); lipid alcohol (LOH); lipid peroxyl radical (LOO.); lipid 
hydroperoxide (LOOH); nitric oxide (.NO); nitrate (NO3-); superoxide anion radical, (O2
-
); pentose cycle (PC); 
radicals (R.); non radicals (R); ribulose 5-phosphate (R5P); superoxide dismutase (SOD); taurine 
(Tau);vitamin C, (Vit C); vitamin C radical, (Vit C•); vitamin E, (Vit E); vitamin E radical, (Vit E•) (Fang et al., 
2002). 
 
RNS and ROS generated intracellularly and extracellularly play a role in the 
neurodegeneration that occurs in AD (Multhaup et al., 1997). Decreased levels of 
antioxidants play a role in neurodegenerative diseases. In PD there are decreased levels of the 
antioxidant GSH in the substantia nigra (Pearce et al., 1997). Oxidative stress also plays a 
role in ischaemia. An ideal stroke model must truly represent the pathophysiological 
consequences of ischaemia such as excitotoxicity and a state of oxidative stress (Figure 7.2). 
The effect of theanine and minocycline were investigated in vitro and in vivo post ischaemia. 
 
Oxidative Stress CHAPTER 7 
 
Page | 125  
 
 
 
Figure 7.2: Diagram showing the multiple processes involved in damaging and killing neuronal cells ischaemia 
or stroke. Involved in these processes are free radicals (Reiter, 1998).  
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7.2 THE COMPARATIVE EFFECTS OF THEANINE AND MINOCYCLINE 
ON CYANIDE-INDUCED ON SUPEROXIDE ANION GENERATION IN 
THE RAT BRAIN IN VITRO 
 
7.2.1 INTRODUCTION 
 
Although the mitochondria converts most of the O2 it consumes to water, about 1-2 % of the 
O2 is reduced to the O2
•-
 (Papa, 1996). The endoplasmic reticulum (ER) in the mitochondria 
is responsible for the storage of Ca
2+
, cell signalling and the folding of newly synthesised 
proteins (Sas et al., 2007). ER dysfunction induces oxidative stress, mitochondrial 
dysfunction and the activation of caspases which leads to apoptosis (Sas et al., 2007).  
 
O2
•-
 is produced by a variety of enzymatic reactions in the tissues or by the auto-oxidation 
reactions of tissue components. Intracellular production of O2
•-
 occurs during processes such 
as the oxidation of PUFAs, auto-oxidation of small molecules, haemoglobin, mitochondrial 
components and oxidative enzymes such as xanthine oxidase and NADPH oxidase in 
phagocytic cells (Kontos, 2001). Equation 7.1 shows how O2 is converted to O2
•-
 (Fridovich, 
1978). 
 
 
 
The enzymatic defence against O2
•-
 is SOD which converts O2
•-
 to H2O2. There are 2 types of 
SOD which lead to the dismutation of O2
•-
 and these are manganese SOD (MnSOD) in the 
mitochondria and copper and zinc SOD (CuZnSOD) in the cytosol (Figure 7.3) (Fridovich, 
1989; Evans et al., 2002). The brain is susceptible to damage by O2
•-
 because it has low levels 
of the antioxidant SOD which scavenges O2
•- 
(Gariballa, 2000). 
 
  
  
   
  
      
          
      
         
     
                                                  Equation 7.1 
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Figure 7.3: The dismutation of O2
•-
 by copper and zinc superoxide dismutase (CuZnSOD) and manganese 
superoxide dismutase (MnSOD) (Szeto, 2006). 
 
The (nitro-blue tetrazolium) NBT assay is a reliable method of assaying O2
•- 
(Das et al., 
1990; Gariballa, 2000). The principle of the assay relies on O2
•- 
generated in the tissues to 
reduce the yellow NBT dye into the water insoluble nitro-blue formazan (NBD) which can be 
extracted by glacial acetic acid (GAA) and quantitatively analysed spectrophotometrically. 
The O2
•-
 in the assay may be generated by chemicals such as potassium cyanide (KCN) or 
QA. Any molecule capable of scavenging O2
•-
 will lead to there being less NBD formed. 
 
Cyanide is a respiratory toxin whose mechanism of action involves the inhibition of 
cytochrome oxidase aa3 which is a terminal oxidative enzyme of the electron transport chain 
(Section 1.2.6) and this later leads to radical-induced neuronal damage. 
 
7.2.2 MATERIALS AND METHODS 
 
7.2.2.1 Animals 
 
Adult male Wistar rats were purchased from the South African Vaccine Producers,   
Johannesburg, South Africa and cared for as described in Section 4.2.2.2. 
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7.2.2.2 Chemicals and reagents 
 
Theanine, minocycline, KCN, NBD and NBT were purchased from Sigma Chemical 
Corporation, St Louis, Missouri, United States of America. Ethanol and GAA were purchased 
from Saarchem, Johannesburg, South Africa.  
 
7.2.2.3 Brain removal 
 
Rats were sacrificed and the brains removed as described in Section 4.2.2.3.  
 
7.2.2.4 Homogenate preparation 
 
The brain homogenate was prepared as described in Section 4.2.2.4. 
 
7.2.2.5 Preparation of the NBD standard curve 
 
NBD was used to prepare the standard curve. A series of NBD standards (0 – 400 nmols/ml) 
were prepared in triplicate using glacial acetic acid as a diluent to give a final volume of 1 ml. 
A standard curve was then generated by measuring the absorbance 560 nm on a Shimadzu 
UV mini 1240 UV/VIS spectrophotometer and plotting these against the molar equivalent 
weight of NBD (Appendix V).  
 
7.2.2.6 Nitro-blue Tetrazolium Assay 
 
A modified method by Das et al., (1990) was used for this assay and is outlined below: 
 
Rat brain homogenate (1 ml) was prepared in triplicate containing 1 mM KCN (250 µL) in 
the absence and presence of increasing concentrations (0 – 2 mM) of either theanine or 
minocycline (250 µL) and 0.4 ml NBT (0.1 % in ethanol and then made up to the required 
volume with milli-Q water). The samples were then incubated in an oscillating water bath for 
1 hour at 37 ºC. Control samples did not contain KCN, theanine or minocycline. 
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The reaction was terminated and the NBD formed was extracted by centrifuging the samples 
for 10 minutes at 2000 x g. The reaction was terminated by the resuspension of the pellets 
with 2 ml of GAA. To remove insoluble debris, the samples were centrifuged for 5 minutes at 
2000 x g. An aliquot of the supernatant (extracted NBD in GAA) was read at 560 nm using a 
Shimadzu UV mini 1240 UV/VIS spectrophotometer. NBD levels were then determined from 
the standard curve generated as described in Section 7.2.2.5. Final results were expressed as 
diformazan (nmol/mg tissue). 
 
7.2.2.7 Statistical Analysis 
 
This was performed as described in Section 2.2.2.3. 
 
7.2.3 RESULTS 
 
Figure 7.4 shows that 1 mM KCN has a significant effect (p < 0.05) in increasing the levels 
of O2
•-
 in vitro in comparison to control. Co-incubation of rat brain with KCN and either 
theanine or minocycline produced no significant change in the levels of O2
•-
 in comparison to 
the brains treated with KCN.  
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Figure 7.4: Effect of theanine and minocycline on the generation of O2
•-
 in rat brain homogenate in vitro. T and 
M represents co-incubation with theanine and minocycline respectively with the concentration of the drug in 
mM next to the letter representing the drug. Each bar represents the mean ± SD; (n= 5).     (p < 0.05) in 
comparison to control; ns (p < 0.01) in comparison to KCN alone; @ (p < 0.001) in comparison to control 
(ANOVA followed by Student Newman-Keuls Multiple Range Test). 
 
7.2.4 DISCUSSION 
 
The results of this study demonstrate that KCN is a potent generator of O2
•-
 in vitro as evident 
from Figure 7.4. As previously mentioned (Section 1.2.6), cyanide inhibits cytochrome 
oxidase aa3 which is a terminal oxidative enzyme of the electron transport chain and 
consequently the homeostatic ATP-dependent Na
+
/K
+
 pumps. This results in an influx of 
Ca
2+
 and elevated levels of Ca
2+
 within the cell which ultimately leads to neuronal death.  
 
There is statistically no significant difference between the O2
•-
 generated by KCN and that by 
both theanine and minocycline co-incubated with KCN. This implies that the KCN generates 
the O2
•-
 and that the drugs have no effect on the generation of O2
•-
 . According to Equation 
7.1, an electron is to be donated to O2 in order to generate O2
•-
. Looking at the chemical 
structure of theanine, it is unable to donate an electron to O2 and thus it is unable to lead to 
the increase in the generation of O2
•-
. From the results, it is clear that theanine is also unable 
to scavenge the O2
•-
.  
ns 
ns 
ns 
ns 
ns 
ns 
ns 
      @ 
      ns 
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The same reasoning that the drug has no effect on the generation of O2
•-
 could possibly apply 
to minocycline. Although the increase in O2
•-
 generation with the combination of minocycline 
and KCN was not statistically significant, minocycline may be able to donate an electron to 
O2 and become resonance stabilised. An increase in the concentration of minocycline 
increases the availability of electrons to donate electrons to O2 and account for the slight 
increase in the generation of O2
•-
. A study by Hu et al. (1996) showed minocycline to be an 
effective O2
•-
 scavenger. The reason for this discrepancy could be because the study carried 
out by Hu and colleagues was in a cell free medium. 
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7.3 THE COMPARATIVE EFFECT OF THEANINE AND MINOCYCLINE 
ON CYANIDE-INDUCED SUPEROXIDE ANION GENERATION IN THE   
RAT BRAIN IN VIVO POST-ISCHAEMIA 
 
7.3.1 INTRODUCTION   
 
Free radicals produced during ischaemia have negative effects on cells. These can cause LP, 
denaturation of proteins, inactivation of enzymes, release of Ca
2+
 from intracellular stores 
(Gariballa, 2000; Kontos, 2001; Ullegaddi et al., 2005). The reactive species formed during 
cardiovascular injury are shown in Figure 7.5. O2
•-
 has effects on cerebral vascular system. 
O2
•-
 causes the dilation of cerebral arterioles by the opening of Ca
2+
-activated K
+
 channels 
(Wei et al., 1996) which means that O2
•-
 has an important role in cerebral blood flow in 
ischaemia. Increases in the levels of O2
•-
 during ischaemic insult have been reported 
(Arundine and Tymianski, 2004) and the levels of O2
•-
 are dependent on the duration of the 
ischaemic insult (Kontos, 2001). 
 
The dramatic increase in the extracellular glutamic acid in the brain following ischaemia 
(Roettger and Lipton, 1996) results in a drastic increase in Ca
2+
 influx into the cell due to 
overstimulation of glutamate receptors by glutamic acid. The generation of ROS due to Ca
2+
 
overload contributes to the disruption of cellular homeostasis and cell death (Camacho and 
Massieu, 2006). Neurotoxicity mediated by NMDA receptor over-stimulation results from 
over-production of NO• and O2
•-
 (Halliwell and Gutteridge, 1989; Arundine and Tymianski, 
2004). Keller and colleagues (1998) proved that O2
•- 
production contributes to neuronal death 
after MCA occlusion model as there was a decrease in the size of infarcts and neuronal 
apoptosis by suppression of peroxynitrite production and mitochondrial dysfunction when the 
animal overproduced SOD.  In ischaemic-reperfusion models, it was found that there was an 
increase in O2
•-
 production due to the accumulation of macrophages in the brain (Saito et al., 
1993). 
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Figure 7.5: Generation of reactive species (Sachidanandam et al., 2005). 
 
Kontos (2001) found that stimulation of AMPA receptors by glutamic acid leads to the 
generation of O2
•-
 which leads to vasodilation of cerebral vasculature. The O2
•-
 generated can 
react with nitric oxide within the cell and produce peroxynitrite which can further lead to 
neuronal damage (Kontos, 2001). O2
•-
 participates in the death of neurons directly and 
indirectly by the formation of reactive species (Section 1.2.2.3).  
 
Although several methods such as inhibiting AMPA receptors have been suggested as a 
preventative measure to reduce the effects of radicals, it is more effective to prevent neuronal 
death by the scavenging of free radicals rather than to target a specific site of radical reaction. 
Scavenging radicals produced is a useful approach in minimising damage in cerebral 
ischaemia (Kontos, 2001). There is an increase in •OH production during ischaemia leading 
to neuronal damage (Negishi et al., 2001). Because the •OH radical is the most reactive ROS 
and thus the most likely to cause a great amount of radical-mediated damage following 
ischaemic insult, it would be practical to target this radical with scavengers (Kontos, 2001). 
However, due to its high reactivity, the •OH would require great amounts of scavenger in 
order to neutralise its effects (Beckman et al., 1990). It would be very impractical to achieve 
such high concentrations of scavengers, thus it would be more worthwhile to target the less 
reactive O2
•-
 (Kontos, 2001) which is responsible for its formation by the Haber-Weiss 
reaction (Equation 1.3).  
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The following study was carried out in order to ascertain whether theanine and minocycline 
are able to scavenge O2
•-
 and thus possess this radical scavenging properties as one of its 
neuroprotective properties. 
 
7.3.2 MATERIALS AND METHODS 
 
7.3.2.1 Animals 
 
Adult male Wistar rats were purchased from the South African Vaccine Producers,   
Johannesburg, South Africa and cared for as described in Section 4.2.2.2. 
 
7.3.2.2 Chemicals and reagents 
 
The drugs used and purchased are the same as the ones described in Section 7.2.2.2. 
 
7.3.2.3 Stroke Study 
 
This was performed as described in Section 6.2.2.4. 
 
7.3.2.4 Brain removal 
 
Rats were sacrificed and the brains removed as described in Section 4.2.2.3 except in this 
case, the cerebellum was removed and the rest of the brain was used for the preparation of the 
homogenate for the assay. The cerebellum was removed based on a study by Saito et al. 
(1993) which showed that there is no significant change in the levels of neurotransmitters in 
the cerebellum post-ischaemia compared to other parts of the brain, namely the cerebral 
cortex, thalamus, striatum and hippocampus. 
 
7.3.2.5 Preparation of tissue 
 
The brain homogenate was prepared as described in Section 4.2.2.4. 
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7.3.2.6 Preparation of the NBD standard curve 
 
The standard curve was prepared as described in Section 7.2.2.5. 
 
7.3.2.7 Nitro-blue Tetrazolium Assay 
 
The assay was carried out as described in Section 7.2.2.6. However, no exogenous theanine 
and minocycline were added to triplicate samples of rat brain homogenate (1 ml). 
 
7.3.2.8 Statistical Analysis 
 
This was performed as described in Section 2.2.2.3. 
 
7.3.3 RESULTS 
 
Administration of minocycline i.p resulted in a statistically significant (p < 0.01) increase in 
O2
•-
 generation in comparison to both control and in the model where stroke alone was 
induced without the pre-treatment with drugs (Figure 7.6). On comparing treatment of the 
animals with and without theanine after inducing a stroke, there was no statistically 
significant change (p > 0.05) in the generation of O2
•-
. 
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Figure 7.6: Effect of pre-treatment with theanine and minocycline on the generation of O2
•-
 in the rat brain 
homogenate in vivo. Stroke + T and Stroke + M represents stroke after pre-treatment with theanine and 
minocycline respectively. Each bar represents the mean ± SD; (n=5). ns (p > 0.05) in comparison to control;  
        (p < 0.01) in comparison to Stroke + M. (ANOVA followed by Student Newman-Keuls Multiple Range 
Test). 
 
7.3.4 DISCUSSION 
 
ROS particularly the O2
•-
 has been shown to cause extensive damage to brain cells (Sections 
1.2.3.3 and 7.2.1). Neuronal damage can also occur due to overstimulation by glutamic acid 
causing excitotoxicity (Section 1.2.3.11).  
 
Drugs must be able to cross the BBB and accumulate in it in order to be considered 
potentially neuroprotective (Zhang et al., 2005). High levels of antioxidants in the blood is 
associated with a reduced risk of ischaemic risk (Gariballa, 2000) which implies that 
antioxidants have an important role in preventing stroke related oxidative damage.  
 
The stroke only model of ischaemia produced no significant increase in O2
•-
 generation in 
comparison to control which does not agree with previous studies which show that ischaemia 
induces the production of O2
•-
 (Halliwell and Gutteridge, 1989; Lipton, 1999). This 
discrepancy may be due to the short period of reperfusion after inducing the stroke followed 
by rapid decapitation. McCord (1985) reported that there is increased generation of O2
•- 
after 
reperfusion when the O2 supply is restored to the tissue. Kontos (2001) reported that the 
ns 
ns 
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concentration of O2
•-
 in the tissues depends on the duration of the preceding ischaemia and 
also on the availability of O2. This ischaemic model had a short duration of ischaemia 
compared to other models of MCA occlusion in which the MCA was occluded for over 1 
hour and tissues reperfused for days (Takagi et al., 1993; Zhang et al., 2005; Xu et al., 2006). 
This implies that with this short duration of ischaemia (3 minutes) and reperfusion may have 
influenced the amount of O2
•-
 generated within the tissues.  
 
In this study, both theanine and minocycline had no free radical scavenging activity. 
Minocycline caused a significant increase in O2
•-
 generation in comparison to control and 
stroke alone. This agrees with the findings in Section 7.2.4 in which minocycline caused a 
significant increase in O2
•-
 levels in a dose dependent manner.  
 
Kontos (2001) studied the effects of effective O2 radical scavengers during ischaemia and 
found that in order to achieve maximal effectiveness of radical scavengers these would have 
to be administered at the time of reperfusion.  Supplementation with antioxidants within 12 
hours post-ischaemia increased the antioxidant capacity of the plasma and reduces oxidative 
damage (Ullegaddi et al., 2005). Minocycline was shown to be an effective radical scavenger 
in vitro (Section 2.3.4), therefore there may be a possibility that on administering it both 
before and after ischaemia that it may be able to scavenge O2
•-
. This may hold true for 
theanine as well, since it was shown to be an effective radical scavenger (Section 2.4) and it 
has been shown by Egashira (2004) that administering it before and after a stroke has proven 
it to be neuroprotective. 
 
Melatonin, an endogenous hormone (Section 1.3.2.5) has poor interaction with O2
•-
, but it 
stimulates the production of SOD (Reiter, 1998; Maharaj et al., 2007). This implies that 
melatonin may lower intracellular levels of O2
•-
 by increasing the levels of the enzyme that 
scavenges it. It can also be hypothesised that the increase in the levels of O2
•- 
in this in vivo 
study could be caused minocycline which shows significant increases in O2
•- 
production, may 
be due to a reduction in the levels of SOD in the brain after pre-treatment. 
 
Irrespective of the mechanism by which increased levels of O2
•-
 are observed, evidence from 
the in vitro and in vivo studies are that theanine and minocycline's neuroprotective properties 
do not include the scavenging of O2
•-
. 
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7.4 THE COMPARATIVE EFFECTS OF THEANINE AND MINOCYCLINE 
ON TOTAL GLUTATHIONE LEVELS IN THE RAT BRAIN IN VIVO 
POST-ISCHAEMIA 
 
7.4.1 INTRODUCTION  
 
The principle antioxidant defence systems in the body include SOD, GSH, reduced GSH, 
CAT, GSH peroxidases and nutrient antioxidants (Section 1.3.2; Figure 7.1). GSH is a thiol 
containing substance found in cells. It is synthesised from glutamic acid, cysteine and glycine 
(Fang et al., 2002). GSH is classified as a free radical scavenger and it acts by donating 
electrons to radical species (Ligumsky et al., 2005). As a component of the intracellular 
antioxidant system, it has the following characteristics:  
 
 GSH is both an exogenous and endogenous antioxidant as it can be partly absorbed 
from the small intestine and synthesised within the body, 
 The GSH radical (GS•) is produced when GSH is oxidised and can react with another 
GS• to form GS-SG which can be reduced by GSH, 
 GSH is able to react with various xenobiotic electrophilic compounds in the catalytic 
reaction of GSH-S-transferase, 
 GSH  acts as a free radical scavenger of ROS, 
 NO reacts with GSH forming the S-nitroso-GSH adduct which is then cleaved by 
thioredoxin system to re-generate NO and GSH and 
 GSH indirectly plays a role in the regulation of cellular redox homeostasis by 
interacting with thioredoxin and glutaredoxin (Fang et al., 2002). 
 
GSH is a substrate of GSH peroxidase which removes H2O2 and converts GSH to GSSG 
(Section 1.3.2.2). Damage to DNA usually occurs with a decrease in the GSH: GSSH ratio 
(Halliwell and Gutteridge, 1989). Astrocytes are more resistant than neurons to damage by 
ONOO- due to their high GSH content which is able to neutralise the effects of the ONOO- 
(Sas et al., 2007). 
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GSH levels can be determined spectrophotometrically. The principle on which the assay 
depends is the reduction of 5‟ 5‟ di-thiobis-(2-nitrobenzoic acid) (DTNB) by SH groups into 
the yellow coloured 2-nitro-5-mercaptobenzoic acid. 
 
In Sections 7.2.4 and 7.3.4 theanine showed no significant change in O2
•-
 and minocycline 
was shown to increase levels of O2
•-
 in vitro and post ischaemia. It was therefore decided to 
investigate how minocycline mediates its neuroprotective property in stroke (Section 6.2.4) 
by investigating whether it changes the levels of GSH and if theanine is able to have 
neuroprotective properties by increasing GSH levels after a stroke. 
 
7.4.2 MATERIALS AND METHODS 
 
7.4.2.1 Animals 
 
Adult male Wistar rats were purchased from the South African Vaccine Producers,   
Johannesburg, South Africa and cared for as described in Section 4.2.2.2. 
 
7.4.2.2 Chemicals and reagents 
 
Theanine, minocycline, reduced GSH and DTNB were purchased from Sigma Chemical 
Corporation, St Louis, Missouri, United States of America. Methanol was purchased from 
Saarchem, Johannesburg, South Africa. Tris hydroxymethyl amino methane (tris-HCl) was 
purchased from Merck, Darmstadt, Germany. 
 
7.4.2.3 Stroke Study 
 
This was performed as described in Section 6.2.2.4. 
 
7.4.2.4 Brain removal 
 
Rats were sacrificed and the brains removed as described in Section 4.2.2.3 and the 
cerebellum was removed and the rest of the brain used for homogenate preparation for 
reasons stated in Section 7.3.2.4. 
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7.4.2.5 Preparation of tissue 
 
The brain homogenate was prepared as described in Section 4.2.2.4. 
 
7.4.2.6 Preparation of the GSH standard curve 
 
Reduced GSH was used to prepare the standard curve. A series of GSH standards  
(0-10 nmols/ml) were prepared in triplicate using PBS (pH 7.4) as the diluents to give a total 
volume of 0.5 ml. To this, 1.5 ml of 0.2 M tris-HCl buffer (pH 8.2) and 0.1 ml of 0.01 M 
DTNB were added to the test tubes. The mixture was then made up to 10 ml by the addition 
of 7.9 ml of methanol and then left to stand in the dark for 30 minutes.  A standard curve was 
then generated by measuring the absorbance at 412 nm on a Shimadzu UV mini 1240 
UV/VIS spectrophotometer and plotting these against the molar equivalent weight of GSH 
(Appendix VI).  
 
7.4.2.7 Glutathione Assay 
 
The levels of GSH were estimated using a modified method of Sedlak and Lindsay (1968) 
and is described below: 
 
To precipitate the proteins, 0.5 ml of TCA (25 % in milli-Q water) was added to rat brain 
homogenate (1 ml). In so doing, the protein-bound thiol containing compounds were 
separated from the non-protein bound thiol-containing compounds (Sedlak and Lindsay). The 
samples were then centrifuged at 2000 x g for 15 minutes. Aliquots of the supernatant were 
transferred to a clean set of test tubes to which 1.5 ml of 0.2 M of tris-HCl (pH 8.2) and 0.1 
ml DTNB (0.01 M in methanol) were added and made up to 10 ml by adding methanol. The 
samples were incubated at room temperature for 30 minutes. The incubation mixture was 
then centrifuged at 2000 x g for 15 minutes and the supernatant was read at 412 nm using a 
Shimadzu UV mini 1240 UV/VIS spectrophotometer. The levels of GSH were determined 
using the GSH standard curve generated (Section 7.4.2.6). Final results were expressed as 
GSH (nmol/mg tissue). 
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7.4.2.8 Statistical Analysis 
 
This was performed as described in Section 2.2.2.3. 
 
7.4.3 RESULTS 
 
Figure 7.7 illustrates that there was no statistically significant (p > 0.05) change in the levels 
of GSH after the stroke was induced in comparison to control. There was also no statistically 
significant change in the levels of GSH in the rats that were pre-treated with theanine and 
minocycline, in comparison to both control and stroke alone. 
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Figure 7.7: Effect of pre-treatment with theanine and minocycline on GSH levels in rat brain homogenate in 
vivo. Stroke + T and Stroke + M represents stroke after pre-treatment with theanine and minocycline 
respectively. Each bar represents the mean ± SD; (n=5). ns (p > 0.05) in comparison to control; ns
1 
(p > 0.05) in 
comparison to Stroke (ANOVA followed by Student Newman-Keuls Multiple Range Test). 
 
7.4.4 DISCUSSION 
 
The brain contains low concentrations of GSH peroxidase (Halliwell and Gutteridge, 1985) 
which implies that there are also low levels of its substrate GSH. The low levels of protective 
antioxidant enzymes is one of the reasons that the brain is extremely vulnerable to injury after 
ischaemia.  
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ns ns 
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The results of this study show that neither stroke nor pre-treatment with theanine and 
minocycline influenced the levels of GSH in the brain. This implies that both drugs do not 
stimulate the production of GSH and thus allow for the GSH to mediate in the removal of 
H2O2. 
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 CHAPTER 8 
 
SUMMARY OF RESULTS AND GENERAL CONCLUSIONS 
 
8.1 SUMMARY OF RESULTS 
 
The experiments that were conducted in this study shed light on the neuroprotective 
properties of both theanine and minocycline and the mechanisms in which they act. Oxidative 
stress that arises after a stroke leads to neuronal damage. Agents that will limit free radical 
damage will cause and enhance the endogenous capacity of the body to combat neuronal 
death and will prove to be of therapeutic potential.  
 
During oxidative stress the antioxidant system within the body is unable to cope with free 
radicals generated during a tissue injury. The free radicals cause extensive damage to 
biomolecules and thus it is important that a potentially neuroprotective drug possesses 
antiradical properties. Chapter 2 explored the potential of each drug in scavenging the DPPH 
radical in vitro in comparison to vitamin C, a known radical scavenger with rapid reaction 
kinetics. The results showed that minocycline was a highly effective radical scavenger with 
intermediate reaction kinetics whose scavenging activity was comparable to that of vitamin 
C. Theanine on the other hand has slow reaction kinetics and its scavenging activity was 
found to be very low compared to both minocycline and vitamin C. Minocycline is thought to 
be a highly effective radical scavenger due to its ability to donate a hydrogen to the DPPH• 
and thus it may prevent chain initiation and propagation reactions in radical-mediated 
membrane damage. 
 
Iron is an essential element in the body and it is abundant in the brain. When damage occurs 
in the brain, excess iron is released from intracellular „pools‟ and catalyses the Fenton and 
Haber-Weiss reactions (Equations 1.1, 1.2 and 1.3) in which ROS are generated. The purpose 
of Chapter 3 was to investigate the iron binding properties of both drugs. UV/VIS 
spectroscopy, electrochemical analysis, ferrozine and ferritin assays were employed to assess 
the iron binding properties of the drugs. A UV/VIS spectrum was not generated by theanine 
due to the lack of delocalised electrons within its structure, however minocycline was able to 
as it has several delocalised electrons in its structure. Further UV/VIS studies confirmed that 
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minocycline interacts with Fe
2+
 and Fe
3+
 as exhibited by the decrease in the absorptive 
intensity of the minocycline spectrum when both ions were added to it. Further 
electrochemical analysis using AdSV and cyclic voltammetry demonstrated that both 
theanine and minocycline formed complexes with Fe
3+
. This complexing ability implies that 
these drugs would prevent the reduction of Fe
3+
 to Fe
2+
 by forming a complex with it.  
 
As chelation therapy has been regarded a suitable approach to the removal of toxic iron 
(Goyer, 1995), the chelating ability of theanine and minocycline was further investigated by 
assessing their inhibition of the formation of the Fe
2+
-ferrozine complex. Ferrozine is a strong 
chelator of Fe
2+
 and EDTA was used as a positive control as it is a powerful inhibitor of the 
formation of the Fe
2+-
ferrozine complex. Both test compounds showed poor inhibition of the 
formation of the complex and this shows that the complexes they form with iron may be 
disrupted easily in the presence of a strong chelator. The iron binding properties of the drugs 
was further investigated using ferritin, the storage protein of iron, to assess whether they are 
able to complex with the Fe
2+
 released from its core. This experiment was conducted as 
increased levels of ferritin in the blood have been associated with the severity of a stroke 
(Erdemoglu and Ozbakir, 2002). In this experiment, EDTA was again used as a positive 
control. Minocycline exhibited the ability to complex with the released Fe
2+
 whilst theanine 
was unable to do so. This chapter shows that minocycline is able to bind to both forms of iron 
whereas theanine does not. 
 
LP is one of the undesirable effects of a stroke and the reperfusion of blood into hypoxic 
tissues after a stroke. LP is initiated by free radicals and its rate increases with an increase in 
iron in the tissues (Zaleska and Floyd, 1985). Previous studies have shown that antioxidants 
that prevent radical-mediated damage to lipids and chelators of metals are able to prevent LP 
(Halliwell and Gutteridge, 1989). Theanine has shown poor free radical scavenging and iron 
binding properties in comparison to minocycline. The objective of Chapter 4 was to explore 
the extent of theanine and minocycline‟s protection against QA-induced LP. Minocycline‟s 
ability to significantly reduce LP in vitro was speculated to be due to its iron binding ability. 
Theanine displayed poor inhibition of LP in vitro but on further in vivo studies in which the 
rats were treated with theanine for 5 and for 10 days, theanine significantly reduced LP. It 
was hypothesised that theanine‟s neuroprotective effects are improved when it is 
administered chronically and thus its radical scavenging and iron binding characteristics were 
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improved making it effective in protecting the brain against LP. Theanine has been shown to 
increase levels of SOD (Wang et al., 2008) and therefore theanine may mediate its protective 
property against LP by decreasing the levels of O2
•-
 in the brain. The effects of both theanine 
and minocycline on O2
•-
 levels was investigated in chapter 7. 
 
QA is released by activated microglia and macrophages in response to injury and its levels 
increase during a cerebral ischaemic episode (Halliwell and Gutteridge, 1989). The liver 
enzyme TDO is important in the catalysis of TRP to QA. In vitro studies demonstrated that 
co-incubation of liver homogenates with minocycline at a concentration 100 µM produces an 
increase in the holoenzyme and total enzyme activity. This effect was speculated to be due to 
minocycline either reducing the inactive form of the holoenzyme to the active form or 
reducing O2 to O2
•-
. Theanine demonstrated no effect on co-incubation with liver 
homogenates in vitro. However, pre-treatment with theanine for 10 days exhibited an 
inhibitory effect on the total enzymatic activity. This effect was postulated to be due to either 
theanine affecting the way in which TRP binds to the enzyme or to it preventing the reduction 
of O2 to O2
•-
.  
 
Focal ischaemia is a result of the occlusion of a cerebral blood vessel, is the most clinically 
encountered stroke and an animal model of this type of stroke was studied. Ischaemia results 
in oxidative stress which leads to tissue injury. Thus far minocycline has shown the most 
promise as a neuroprotective agent as it decreases LP, chelates iron and scavenges free 
radicals. Theanine has shown improved neuroprotection on pre-treatment.  The purpose of 
Chapter 6 was to investigate whether these agents are able to reduce the size of the infarct in 
the hippocampus after the occlusion of the MCA when administered 1 hour before the stroke. 
It was shown that the stroke model resulted in 39 % expansion of the hippocampus in the side 
of occlusion. Treatment before the stroke resulted in a 44 % and 7 % increase in hippocampal 
size with theanine and minocycline respectively. Thus theanine was not as effective as 
minocycline in decreasing the size of the infarct.  
 
The conclusions in Chapters 4 and 5 found that the reduction of O2 into O2
•-
 played a role in 
the mechanisms of action of the drugs. Since O2
•-
 has a role in LP and both the Fenton and 
Haber-Weiss reactions, it was decided to investigate the effects of both drugs on cyanide-
induced O2
•-
 generation. The drugs showed no significant effect on O2
•-
 levels generated by 
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the toxic KCN. Their effects on O2
•-
 generation after ischaemia were also investigated. It was 
found that stroke and treating the rat with theanine before inducing the stroke caused no 
significant effect in the generation of O2
•-
 in comparison to the control brain. However, 
minocycline significantly reduced O2
•-
 generation in the brain.  
 
According to Equation 1.3, the Haber-Weiss reaction depends on a metal catalyst to drive the 
formation of •OH from H2O2 and O2
•-
. This means that in ischaemic models, the release of 
iron together with the ischaemia-induced increase in O2
•-
 and H2O2, the Haber Weiss reaction 
must be considerably favoured. However, minocycline is a chelator of iron and although it 
may result in an increase in the levels of O2
•-
 will probably not facilitate the fast progression 
of the Haber-Weiss reaction and thus less •OH is formed. Since •OH is more toxic than the 
molecules that form it, a reduction in its formation could mean that this could possibly be one 
of the ways in which minocycline protects the brain after a stroke. 
 
Finally, the effects of theanine and minocycline on brain GSH levels were investigated and 
neither of these agents caused a significant alteration. 
 
8.2 CONCLUSIONS 
 
Traumatic brain injury resulting from ischaemic insult leads to neuronal degeneration that 
involves free radical-induced damage, LP, the activation of neutrophils and the biosynthesis 
of endogenous toxins such as QA (Gariballa, 2000). The molecular pathways of ischaemic 
cell death involve a rise in cytosolic Na
+
, a fall in ATP and a drastic increase in Ca
2+
 influx 
into the cells (Onténiente et al., 2003). Free radicals however have a major role in the 
initiation of neuronal cell death after ischaemia therefore antioxidants are important role in 
limiting the oxidative stress that arises as a result of ischaemic injury. This is a popularly 
studied area in the search of therapeutic agents that may potentially reduce neuronal death 
and reducing the severity of stroke.  
 
Minocycline and theanine were chosen in this study to investigate their potential 
neuroprotective properties in the events that lead to neuronal death and in a model of 
ischaemia.  Theanine was shown to have the ability to inhibit LP in vitro after 5 and 10 days 
of treatment and to reduce the total enzymatic activity of TDO holoenzyme after 10 days of 
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treatment. It showed poor in vitro results for the scavenging of free radicals, iron binding, LP, 
changing the levels of O2
•-
 and GSH and on reducing the swelling in the hippocampus 
induced by MCA occlusion. It was postulated that the effects of theanine as a radical 
scavenger and iron chelator were improved on treating the animals for 5 and 10 days.  
 
Minocycline showed superior neuroprotective potential in that it attenuated LP in vitro, 
showed effective in vitro free radical scavenging properties and iron binding and reducing the 
post-ischaemic swelling in the hippocampus. These properties contributed to its 
neuroprotective properties. However it did exhibit some potential untoward effects such as 
the increasing of holoenzyme activity in vitro which may contribute to the biosynthesis of 
QA and increase the generation of O2
•-
 when co-incubated with KCN in comparison to 
control brains. Treatment with both theanine and minocycline had no effect on GSH levels 
after the induction of ischaemia. Most drugs are studied at doses that are much higher than 
those used in a clinical setting but in this study the minocycline was used in concentrations 
that were lower than their usual clinical doses.  
 
From the preceding evidence that these agents have potential neuroprotective properties and 
the mechanisms by which they act are outline. This study has shown various ways in which 
both drugs may interfere in the biochemical pathways which are important during a clinical 
relevant model of ischaemia.  
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 CHAPTER 9 
 
FUTURE RECOMMENDATIONS 
 
Further analytical work to probe other neuroprotective properties and mechanisms of 
theanine and minocycline is necessary. These recommendations are outlined in this chapter. 
 
Chapter 4 showed theanine as useful in inhibiting QA-induced LP after pre-treatment of 5 
and 10 days which was completely different from the in vitro results.  QA is an endogenous 
neurotoxin that is able to induce the Ca
2+
 overload intracellularly via interaction with the 
glutamate receptors and thus lead to the progression of excitotoxicity. Since both theanine (as 
an antagonist) and QA (as an agonist) are able to bind to NMDA receptors, it would be 
interesting to investigate the effects of QA alone and in combination with theanine on 
glutamic acid release in hippocampal synaptosomes. Such a study would prove to be useful in 
determining the interaction of theanine and QA at a receptor level. This study revealed that 
both theanine and minocycline prevented QA-induced LP. Further studies on whether these 
agents are able to reduce LP after ischaemia need to be conducted. 
 
Ottino and Duncan (1996) hypothesised that any increase in COX activity could result in an 
increase in MDA production. The MDA produced can be determined by the TBA assay and 
linked to LP. Further studies of the effects of theanine and minocycline on COX activity 
would have to be conducted to determine other ways in which they may offer protection 
against LP. 
 
TDO is an important enzyme in the KP and in the biosynthesis of QA. Levels of KP 
metabolites have an impact on the Ca
2+
 influxes and thus neuronal damage due to their 
interaction with glutamate receptors. Drugs that target KP or that change the balance between 
KYN (which is neuroprotective) and the toxic QA could prove to be potentially 
neuroprotective (Stone and Addae, 2002). Further studies on the drugs‟ effects on IDO and 
how these affect the levels of brain indoles would be beneficial for determining the overall 
effect that theanine and minocycline have on the KP. 
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Another area for further research would be a further investigation of the MCA occlusion 
stroke model. The areas in which the results of this experiment can be made more clinically 
relevant is to have a longer period of occlusion and reperfusion  and using rats between the 
ages 2 – 3 years because this age range would mimic that of humans above the age of 50 
years in which stroke usually occurs (Gupta and Briyal, 2004). The use of spontaneously 
hypertensive rats in stroke would be another clinically relevant study on the effects of these 
drugs on stroke.  
 
Studies have shown that administration of the drug before and after ischaemia was induced, 
proved to be neuroprotective (Yrjänheikki et al., 1999; Egashira, 2004; Cimino et al., 2005). 
It would be worthwhile to investigate the potential neuroprotective effects of both drugs if 
administered before and after the stroke to determine the neuroprotective effects of theanine 
and minocycline. It would also be recommended that further studies would have to be carried 
out to investigate chronic administration of theanine and minocycline before a stroke in order 
to confirm its potential neuroprotective properties.  
 
Theanine and minocycline have shown to be neuroprotective in stroke by various methods 
investigated in this study. It would be of great benefit if more studies were conducted on 
these drugs and their effects on stroke. Due to their wide use in the beverage industry 
(theanine in green tea) and as an antibiotic (minocycline), these drugs could prove to be a 
worthwhile investment into research towards neuroprotective agents in stroke.  
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APPENDICES 
 
APPENDIX I 
 
 
Abstract for the 19
th
 International Brain Research Organisation (IBRO) Schools 
Conference (24-30
th
 August 2009) 
 
Stroke (cerebral ischaemia) is the third leading cause for mortality and the leading cause of 
disability in the United States (Yasuhara et al., 2008). Thus there is a dire need to develop or 
screen agents that have the ability to protect the brain against injury during stroke. A number 
of neurotransmitters are released during stroke. For example, the glutamic acid concentration 
rises in the brain when there is cerebral ischemia. This excess glutamate causes further 
damage due to the glutamic acid binding to receptors such as the NMDA receptors. This 
causes an influx of calcium into the cell resulting in neuronal death (Yashura et al., 2008). 
There is also an increase in the generation of free radicals as a result of ischaemic injury 
which may lead to neuronal damage. In our search for agents which could protect the brain, 
an agent found in green tea, viz theanine has been shown to inhibit lipid peroxidation and that 
it is neuroprotective in cerebral ischaemia (Tsuge et al., 2003).  It has been shown that 
ischemia-induced neuronal death in hippocampal region is significantly prevented in a dose-
dependent manner after the administration of theanine (Kakuda et al., 2002). These findings 
indicate that theanine may be clinically useful in preventing ischemic neuronal damage. The 
antioxidant activity of theanine was investigated in vitro and it was found to be a less 
effective radical scavenger of the 2, 2-diphenyl-1-picryl-hydrazyl (DPPH
●
) radical in 
comparison to vitamin C. These results show that theanine may be neuroprotective in free 
radical-mediated neuronal death after ischaemia and contributes to the antiradical properties 
of green tea 
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APPENDIX II 
 
Abstract for the 43
rd
 Annual Congress 2009 of the South African Society for  Basic and 
Clinical Pharmacology (SASBCP) (23-26
th
 September 2009) 
 
ANTIRADICAL AND ANTIOXIDANT ACTIVITY OF THEANINE 
 
Authors: Tariro Mpofu, Santy Daya* 
*Corresponding author. Faculty of Pharmacy, Department of Pharmacology, Rhodes 
University, Grahamstown, South Africa. Email Address: s.daya@ru.ac.za 
 
Introduction 
Free radicals that are generated in vivo result in damage of DNA, small molecules and lipids 
(Halliwell et al, 1995). Lipid peroxidation results from free radicals attacking membrane 
lipids which leads to the destruction of the cell membrane, cell integrity and the proper 
functioning of membrane bound enzymes and receptors. Free radicals have also been shown 
to play a role in cardio vascular diseases (Dorman et al., 2003). Importance of an antioxidant 
in vivo cannot be emphasized enough as these agents protect the human body against damage 
by ROS. Thus in the search for agents that have antioxidant activity, theanine which is a 
natural component of green tea was studied as it has been shown to prevent lipid peroxidation 
(Tsuge et al., 2003). 
 
The free radical scavenging activity of a potential antioxidant is evaluated in vitro by its 
ability to scavenge the stable 2, 2-diphenyl-1-picryl-hydrazyl (DPPH
●
) radical which acts as 
both an oxidizable substrate and as a reaction indicator molecule (Dorman et al, 2003).  
 
Method 
 
A modified method of free radical scavenging of Brand-Williams et al., (1995) was used to 
measure the free radical scavenging ability of theanine and melatonin. Vitamin C was used as 
a positive control (Brand-Williams et al., 1995; du Toit et al., 2001).  
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Results  
 
Theanine scavenges 32 % of the radicals on average over the entire concentration range 
tested which is significantly lower than the free radical scavenging ability of vitamin C which 
is 95 %. Flavonoids in tea account for most of the antioxidant activity in tea and thus the 
presence of Theanine in green tea also increases the antioxidant capacity of tea.  
 
Conclusion 
 
Theanine can be an antioxidant in vitro due to it antiradical activity. 
 
Keywords: Theanine, DPPH, antiradical, antioxidant, green tea  
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APPENDIX III 
 
 
 
Appendix III: Malondialdehyde (MDA) standard curve. 
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APPENDIX IV 
 
 
 
Appendix IV: Protein standard curve. 
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APPENDIX V 
 
 
 
Appendix V: NBD standard curve. 
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APPENDIX VI 
 
 
 
Appendix VI: Gluthathione standard curve. 
